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DEVELOPMENT OF MASS SPECTROMETRY TECHNIQUES FOR ANALYSIS OF 
BIOMEDICAL SYSTEMS 
 
The advances of modern mass spectrometry (MS) have allowed MS to become one of the 
essential analytical tools for biological and biomedical research. Mass spectrometry’s ability to 
provide rapid and sensitive analysis of many types of analytes made it an excellent candidate to 
study the polysaccharide dextran, biodegradable poly(organophosphazene) and polyester derived 
polymers, as well as interfering species in commonly used cell viability studies. Electrospray 
ionization time-of-flight mass spectrometry (ESI-TOF MS) was used to analyze the polysaccharide 
dextran. Polysaccharides, including dextran, are difficult to ionize due to their inherent neutrality. 
Ionization efficiency is poor in negative polarity ESI because they lack acidic groups typically 
needed for proton abstraction, and ionization efficiency in positive polarity ESI is poor because 
polysaccharides have low proton affinity. In efforts to circumvent the issue of low ionization 
efficiency, dextran was derivatized to try mimicking protein-like ionization. Dextran was 
derivatized using a one-pot derivatization procedure with ethylenediamine, thus, giving dextran 
free terminal amine groups. The derivatization procedure attached up to four ethylenediamine 
groups and allowed dextran to have up to four protonations (or positive charges). The ability to 
carry up to four charges shifted the molecular weight of dextran to a lower m/z, similar to protein 
supercharging ionization. Mass spectrometric analysis was successfully applied to identify 
potential degradation products during the catalytic release of nitric oxide (NO) from S-
nitrosoglutathione (GSNO) when it was exposed to metal-organic frameworks (MOFs) embedded 
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onto chitosan polymer support systems. Oxidized glutathione (GSSG) was confirmed to be the 
reaction byproduct of the release of NO from GSNO, and glucosamine and N-acetylglucosamine 
were identified as the degradation products from the chitosan polymer support system. In a similar 
use of MS, potential interferences in the commonly used CellTiter Blue and MTT cell viability 
assays were studied. When the UV-vis spectroscopic assays suggested interferences or produced 
inconclusive results, mass spectrometric analyses accurately determined whether selected small 
molecules were responsible for conversion of resazurin to resorufin, MTT to formazan, or if they 
were responsible for severe signal suppression on the UV-vis spectroscopic assays. MS was also 
successfully used to study the biodegradable poly(phosphazene), polyester polymers and their 
nitrosated analogues. The purpose of the studies was to investigate the potential degradation 
products from the degradation of these polymers. In-depth understanding of the degradation 
products from these polymers may aid in determining potential unwanted side effects that may 
render the polymeric devices unusable. A combination of direct flow injection MS, liquid 
chromatography mass spectrometry (LC-MS), and tandem mass spectrometry (LC-MS/MS) were 
successfully applied to identify the degradation products from each polymer system investigated. 
Identification of each degradation product from these polymers strongly suggests the 
implementation of LC-MS/MS when biodegradable polymers are developed for biomedical 
applications. Particularly because these methods can be used when a device intended for medical 
use undergoes the ISO 10993 series Biological Evaluation of Medical Devices. Additionally, in a 
highly collaborative effort, a chiral metal-organic framework (MOF) was used as a chiral 
stationary phase (CSP) for chiral resolution. The chiral-MOF (TAMOF-1) was packed in-house 
into an empty HPLC column and successfully used to resolve chiral compounds efficiently using 
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1.1 Mass Spectrometry 
 Mass spectrometry is an analytical technique used to determine the mass of molecules of 
interest1. By determining the mass of a molecule, the molecular formula can be calculated to 
confirm the identity of the molecule of interest or to identify an unknown molecule2. Mass 
spectrometry takes place in a mass spectrometer, an instrument made up of an ion source, a mass 
analyzer, a detector and a computer system2–4. For analysis using mass spectrometry to take place, 
the molecule of interest must first be ionized in the ion source, then transported into the mass 
analyzer to measure its mass, detected, and recorded in a data form in a computer system (Figure 
1.1)1–4.  
 
Figure 1.1 Block diagram of a mass spectrometer 
 
1.1.1 Ion Sources/Methods of Ionization  
The ionization stage has the function of generating ions that will be transferred into the 
mass analyzer. Multiple ionization techniques have been developed over time, but their purpose is 
the same: generate ions by addition of energy (electrons, electric fields, photons) or additives 
(adducted cations or anions)5. Ions can be formed in vacuo inside the mass spectrometer or outside 
at atmospheric pressure. Examples of ionization under vacuum are electron ionization (EI)6, 
chemical ionization (CI), and matrix-assisted laser desorption/ionization (MALDI)7. Examples of 
atmospheric pressure ionization (API) include electrospray ionization (ESI)8, atmospheric pressure 
chemical ionization (APCI)9 and desorption electrospray ionization (DESI)10.  
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Each method of ionization has advantages and disadvantages when used to generate ions. 
These will depend on the polarity and size of the analyte, and the amount of energy applied to the 
analyte. Depending on the amount of energy added during the ionization process, the structure of 
the analyte molecule ion generated will either remain intact or fragment into smaller ions. For 
example, EI is the most energetic type of ionization and ions will most likely fragment making EI 
an example of hard ionization6,11. An example of soft ionization is ESI8,12,13, which will typically 
preserve the analyte intact. The order of the amount of energy applied from most to least is  
EI > CI ≈ APCI ≈ APPI > MALDI ≈ ESI 
A similar order applies to the size and polarity of molecules. Small molecules and non-
polar molecules are typically ionized using EI, whereas ESI ionizes efficiently only polar 
compounds and imparts minimal energy to the analyte. Both ESI and MALDI are the preferred 
ionization methods to ionize large molecules. These relationships are shown in Figures 1.2 and 1.3 
and for the work presented in this dissertation, ESI was the main ionization method used14.  
 
Figure 1.2 Ionization methods according to polarity of analytes 
 
 
Figure 1.3 Mass ranges for each type of ionization  
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Electrospray ionization is a method by which analytes present in solution are transferred to 
into the gas phase as ions. ESI can ionize analytes such as polymers, nucleic acids, and proteins 
that may have very high molecular mass up to megadaltons for proteins15–17. The analytes in 
solution may be present as ions (dissociated metal ions Mn+, protonated amines, deprotonated 
carboxylic acids, sulfates, alcohols, dissociated halides Xn-, and so on). Analytes of interest may 
also be neutral in solution, which are charged as they are sprayed by adduct formation12,18.   
Ionization by ESI takes place following three major steps: (1) charged droplets are 
produced at the ES tip; (2) the charged droplets shrink by evaporating the solvent leading to very 
small highly charged droplets; (3) production of the gas-phase ions ejected from the highly charged 
droplets13,14,19. The process is driven by an imposed electric field into the liquid being sprayed 
which creates a Taylor cone and a jet charged by excess of positive or negative ions. The jet splits 
into droplets charged with an excess of positive or negative ions, and as the solvent evaporates, 
the shrinking of the droplets brings the charges closer together. The increasing Coulombic 
repulsion destabilizes the droplets leading them to emit smaller daughter droplets until free gas-
phase ions form (Figure 1.4)19.  
 
Figure 1.4 Electrospray ionization source. (1) the nebulizer delivers the analyte(s) of interest 
(Liquid flow) which produces charged droplets at the nebulizer tip; (2) the charged droplets shrink 
by evaporation of the solvent (done by drying gas and in some cases a sheath gas); (3) ions are 





1.1.2 Mass Analyzers 
Following the formation of ions, the ions are separated according to their m/z ratios using 
a mass analyzer. There are several types of mass analyzers (Table 1.1) including the quadrupole 
(Q), quadrupole ion traps (QIT, LIT)20,21, Fourier transform ion cyclotron resonance (FT-ICR)22, 
orbitrap23 and time-of-flight (TOF)24,25. Of all these mass analyzers, TOF was the mass analyzer 
used for the bulk of the work presented in this dissertation.  
Table 1.1 Types of mass analyzers 
Analyzer Type Resolution m/z range Mass Accuracy (ppm) 
Quadrupole Up to 2000 4000 50 - 100 
Time of Flight Up to 30000 Unlimited 2 - 50 
Orbitrap Up to 150000 6000 2 - 5 
FT-ICR Up to 1000000 6000 < 2 
                   14 
 
Time of flight mass analyzers determine the mass of analytes by measuring the time it takes 
the ions of interest to arrive from a starting position, the ion pulser, to a detector (Figure 1.5). The 
mass can be determined because the flight time for each mass is unique. This process starts when 
a high voltage pulse is applied to the ions of interest at the ion pulser, the ions travel through the 
time of flight tube, and the ions strike the detector (Figure 1.5). The flight time (t) is determined 
by the energy (E) to which an ion is accelerated, the distance (d) it travels and its mass, specifically 
its mass to charge ratio (m/z)24,25.  
Two main equations apply to time-of-flight mass analysis. The first one is the formula for 
kinetic energy: 𝐸 = 12𝑚𝑣2     Eq. 1 
in which E stands for kinetic energy, m for mass and v for velocity and when it is solved 
for mass (m): 𝑚 = 2𝐸𝑣2      Eq. 2 
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and further solved for velocity (v): 
𝑣 = √2𝐸𝑚       Eq. 3 
By solving the equation for kinetic energy, it is observable that smaller masses will have 
larger velocities, and larger masses will have smaller velocities. This phenomenon is observed in 
the time-of-flight mass spectrometer, ions with lower masses arrive at the detector earlier, and ions 
with higher masses arrive at the detector later (Figure 1.5)25. Since time-of-flight is what is 
measured, the second equation is: 𝑣 = 𝑑𝑡        Eq. 4 
in which v stands for velocity, d for distance and t for time. When equations 2 and 4 are 
combined the following equation is obtained: 𝑚 = (2𝐸𝑑2) 𝑡2     Eq. 5 
With equation 5, a basic time-of-flight relationship is established. For any given energy (E) 
and distance (d), the mass is proportional to the square of the flight time of the ion. In the final 
design of a time-of-flight tube, the energy applied and traveled distance of the ions is kept constant, 
so that the measurement of flight time is measured accurately to give an accurate mass value. Since 
the terms are kept constant, energy and distance are combined into a single variable giving equation 
6, which is the generalized equation used to measure the mass (m/z) of ions of interest26. 𝑚 = 𝐴𝑡2      Eq. 6 
 Most current TOF tubes are designed with an ion mirror or reflectron as shown in Figure 
1.5. The purpose of using a reflectron is to mitigate potential problems caused by different initial 
kinetic energies after ions are accelerated by the ion pulser11,14. Ions with higher kinetic energy 
penetrate more deeply than ions with lower kinetic energy before leaving the reflectron. Total 
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flight time corrections occur using the reflectron because ions with higher energy of a given m/z 
enter sooner, penetrate more deeply, spend more time in the mirror and exit later than the lower 
energy ions of the same m/z. Ion reflection takes place because there is a potential hill in the ion 
mirror leading to a time shift as the ions enter the mirror, are decelerated, turn around at an angle, 
and are accelerated in the opposite direction toward the detector11,26–28 . The correction can be seen 
in the Ion Mirror inset in Figure 1.5. Implementation of ion mirrors lead to high resolving power 
since it allows all ions of the same m/z to arrive at the detector at exactly the same time25,27,28.  
 
Figure 1.5 Schematic of time of flight mass analyzer. As the ions arrive to the TOF tube, an ion 
pulser pushes the ions towards the ion mirror and eventually the detector.  
 
1.1.3 Tandem mass spectrometry 
 While efficient ionization and accurate mass measurements of analytes of interest can be 
readily achieved, no structural information is provided. When structural information is also 
desired, particularly when an unknown analyte is being analyzed, tandem mass spectrometry 
(MS/MS) is performed22. Combinations of quadrupole, ion trap, and TOF analyzers are MS/MS 
systems that are used. In MS/MS systems, the first analyzer usually selects an ion of interest that 
is then passed, with or without fragmentation, into a second analyzer. Between the first and second 
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analyzers, there is a collision cell that can be used to induce fragmentation. Once a selected ion is 
fragmented, the fragment ions can be used to determine the structure of an unknown to confirm its 
identity29.  
1.2 Mass Spectrometry Application to Polysaccharides 
1.2.1 Polysaccharides  
Carbohydrates are central players in several biological processes and play both a functional 
and structural role in nature. Usually classified as monosaccharides, oligosaccharides or 
polysaccharides (Figure 1.6), they are involved in molecular recognition, cellular signaling, cell 
adhesion, energy generation as well as being structural components30.  
 
Figure 1.6 Examples of a monosaccharide (glucose), oligosaccharide (maltotriose) and 
polysaccharide (pullulan).  
 
In contrast with nucleic acids and proteins, the biosynthesis of carbohydrates is not 
template-driven, leading polysaccharides to exist in nature as heterogeneous mixtures, often of 
high complexity with up to millions of monosaccharide units31. The possibility of substitution at 
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different positions in the monosaccharide units makes the primary structure of carbohydrates more 
complex than proteins, that have well-defined amide bond forming a linear structure31–33. 
Additionally, increased complexity arises from the possibility of α- or β-configuration at the 
anomeric carbon of the monosaccharide units. For example, amylose in starch consists of α-1,4-
linked glucose residues while cellulose in plants consists of β-1,4-linked glucose residues (Figure 
1.7)34.  
 
Figure 1.7 Amylose and cellulose representations of α-1,4- and β-1,4-glucose linkage 
configurations. 
 
The different stereochemistry of the glycosidic linkages give amylose and cellulose very 
different properties. Additionally, due to the possibility of substitution at any of the positions of 
glucose monosaccharides, the monomer units can be linked to more than two other units, giving 
the possibility for polysaccharides to be branched (Figure 1.8)31,35,36. 
 




1.2.2 Mass Spectrometric Analysis of Polysaccharides 
Compared to advances in protein analysis, progress in the application of mass spectrometry 
to carbohydrates has evolved somewhat slowly, mostly because carbohydrates are a more 
challenging set of analytes for structural characterization. Unlike proteins, there is no database 
containing an extensive set of sequences representing all possible carbohydrate structures31,33. 
Therefore, characterization of carbohydrates relies upon obtaining the full details of structure from 
a collected mass spectrum31.  
 A fundamental flaw that limits mass spectrometric analysis of polysaccharides is their poor 
ionization due to their neutrality. Nevertheless, MALDI and ESI are still the predominant methods 
of ionization for polysaccharides. Unfortunately, the absence of basic sites in neutral 
polysaccharides inhibits protonation in MALDI and ESI mass spectrometry. Instead, 
polysaccharides most often ionize by adduction of metal ion, usually sodium cation, with 
comparatively low efficiency30,36,37. Additionally, the absence of acidic sites in neutral 
polysaccharides inhibits deprotonation in MALDI and ESI mass spectrometry. To date, the 
majority of polysaccharide studies have focused on the positive-ion mode, done by metal cation 
adduction33,38.  
 Despite the limitations in both MALDI and ESI, work has been done to analyze native 
oligosaccharides and polysaccharides and their derivatives. Mock39 and coworkers reported the 
measurement of underivatized mannose oligosaccharides with MALDI-TOF MS with molecular 
mass of up to 2395 Da as [M+Na]+ cations. Stahl40 and coworkers also reported the measurement 
of the underivatized oligosaccharides maltodextrin and dextran using MALDI-TOF MS with 
molecular mass measurements of up to 3500 and 7000 Da respectively. Hsu41 and coworkers 
reported the molecular weight measurement of dextran up to 8000 Da using MALDI-TOF MS. 
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Using ESI-TOF MS, Ghiulai36 and coworkers reported the analysis of underivatized dextrans with 
molecular mass of up to 5500 Da.  
 Despite the successful analysis of polysaccharides with molecular mass of up to 8000 Da, 
dextran, a polysaccharide with clinical and pharmaceutical applications requires a high molecular 
mass of between 40 and 70 kDa to have antithrombic effects. Interest in molecular mass and 
structural information for dextran 40 – 70 is therefore not attainable with the current MALDI-TOF 
and ESI-TOF techniques. Derivatization treatment of polysaccharides and glycans such as 
permethylation can improve MS sensitivity and the range of measurement to approximately 15 
kDa36.  
 These limitations contrast with the highly successful analysis of protein by both MALDI-
TOF and ESI-TOF MS. Proteins can routinely be analyzed using both techniques and largest 
protein reported by Bahr42 and coworkers was the trimer of urease at 272000 Da. This substantial 
mass range is possible due to the ability of proteins to get multiply charged. For example, if a 
hypothetical protein has a molecular mass of 40 kDa, the hypothetical mass spectrum shown in 
Figure 1.9 shows the effects of multiple charges.  
 
Figure 1.9 Multiple charging of a hypothetical 40 kDa protein.  
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 This molecular mass measurement extends beyond typical TOF mass spectrometers. For 
example, the Agilent 6224 TOF operates at the 100 – 3200 m/z range in high accuracy mode and 
at the 100 – 20000 m/z range in extended mass mode. If the protein was to be analyzed by single 
charging, it would not be measurable in either mode. However, due to multiple charging14,43, the 
protein should be accurately measured in the high accuracy mode that covers the 100 – 3200 m/z 
range. When an MS pattern like that shown in Figure 1.9 is obtained, and it is suspected that 
multiple charging is occurring, the spectra can be deconvoluted to obtain the actual mass of the 
protein using the following equations:  
  𝑧 = (𝑚 𝑧⁄ )1−𝑥(𝑚 𝑧⁄ )2−(𝑚 𝑧⁄ )1     Eq. 7 
  𝑀 = 𝑧((𝑚 𝑧⁄ )2 − 𝑥)     Eq. 8  
where m/z is the mass of each peak on the mass spectrum and x is the mass of the adduct. In the 
case of proteins, the adduct is typically a proton with the exact mass of 1.0073. 
Equation 7 is used to determine the number of charges found by using two adjacent peaks. 
For example, using the peaks 1334.33 and 1380.31 the number of charges for the peak at 1380.31 
can be calculated: 
𝑧 = (𝑚 𝑧⁄ )1 − 𝑥(𝑚 𝑧⁄ )2 − (𝑚 𝑧⁄ )1 = 1334.33 − 1.00731380.31 − 1334.33 = 28.99 
Therefore, the number of protonations (charges) on the ion found at 1334.33 is 29. The next step 
is to deconvolute the actual mass of the protein, using equation 8: 𝑀 = 𝑧((𝑚 𝑧⁄ )2 − 𝑥) = 29 × (1380.31 − 1.0073) = 39999.78 
The same process is performed for all the peaks found in the mass spectrum until all the charges 
are found and the masses deconvoluted.  
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The ability of proteins to hold multiple charges is of great interest since applying this 
concept to polysaccharides would greatly extend their measurable range using mass spectrometry. 
Multiple charging of polysaccharides should in theory, shift the large molecular mass of 
polysaccharides toward a lower m/z range for accurate mass spectrometric analysis. 
1.3 Mass Spectrometry Application to Biodegradable Polymers 
1.3.1 Biodegradable Polymers 
 Biodegradable polymers are defined as degradable materials for which the degradation is 
a result from the action of microorganisms and ultimately the polymer is converted to water, carbon 
dioxide (aerobic degradation) and/or methane (anaerobic degradation)44–46. Biodegradable 
polymers include polysaccharides and other biopolymers, polyesters produced by microorganisms, 
synthetic polyesters, among others47. The majority of biodegradable polymers belong to the 
polyester group (Figure 1.10).  
 
Figure 1.10 Polyester general structural features. 
Polyesters can be easily broken down by hydrolysis, making them excellent candidates to 
be used to develop biomedical devices48,49. Biodegradable polyesters can be used to developed 
devices capable of drug delivery, for tissue engineering and wound dressings.50,51 
1.3.2 Characterization of Biodegradable Polymers 
 Current techniques used to determine the biodegradation of a device over time are 
gravimetric analysis, Fourier transform infrared spectroscopy (FT-IR), nuclear magnetic 
resonance spectroscopy (NMR), scanning electron microscopy (SEM), high-performance liquid 
chromatography (HPLC) and mass spectrometry (MS). For example, the degradation mechanism 
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of acrylate-derivatized poly(ethylene glycol) (PEGDA) hydrogels was determined by tracking the 
cleavage of networked groups that result in a reduced crosslink density over time. The changes in 
crosslink density were monitored by measuring the swelling ratio and/or modulus of the 
hydrogel52. Another example follows the oxidative degradation of poly(carbonate urethanes) 
(PCU) that was tracked using FT-IR by monitoring selected functional groups over time. 
Additionally, SEM was used to track surface damage of the PCUs over time53. A different study 
developed an HPLC method to track the degradation of implanted medical devices by determining 
acrylic monomers and degradation products54. The degradation of poly(5-hydroxy-trimethylene 
carbonate) in aqueous environment was monitored using 1H-NMR and the main degradation 
products were identified with electrospray ionization mass spectrometry (ESI-MS)55. 
 The advantages of soft ionization mass spectrometry have further advanced the routine use 
of mass spectrometry  for characterization of biodegradable polymers beginning with their design 
and synthesis all the way to investigation of their degradation products15,56–58. Accurate knowledge 
of the degradation products of biodegradable polymers is highly desirable when they are used to 
develop biomedical devices. The importance of mass spectrometric implementation toward 
analysis of biopolymer degradation is highlighted when a biodegradable device must undergo 
biological evaluation for release as a medical device. While mass spectrometric identification of 
biodegradation products cannot determine the whole extent of a device’s biological compatibility, 
it is an important addition for the fulfillment of the widely accepted standards for device evaluation 
under the ISO 10993 series (Biological Evaluation of Medical Devices).  
1.4 Metal Organic Frameworks 
 Metal-organic frameworks (MOFs) are an extensive class of crystalline materials with 
ultrahigh porosity (up to 90% free volume) and ultrahigh surface areas, exceeding 6000 m2g-1 59. 
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These hybrid inorganic-organic materials are constructed by joining metal-containing units with 
organic linkers to form open crystalline structures with permanent porosity60,61. The flexibility 
with which the metal-containing units and organic linkers can be varied has led to many MOFs 
being prepared for highly specific applications. Potential applications include gas storage, 
separations, catalysis and biomedical applications62–64. The extraordinary degree of variability for 
both the organic and inorganic components, as well as the synthetic procedure can have a strong 
influence on the formation of the MOF and the pore size59,65. An example is the design of MOFs 
with applications as antibacterial agents, drug delivery systems, and for catalytic release of 
therapeutic gases such as nitric oxide (NO)64,66–68. MOFs designed for separations include gas-
phase adsorptive separations, liquid-phase adsorptive separations and membrane-based 
separations63,69. A particularly interesting type of separation falls under liquid-phase separations is 
the ability for MOFs to be designed for enantio-separation70–73.  
1.4.1 Metal-Organic Frameworks as Chiral Stationary Phases (CSP) 
 Enantio-separation continues to be a substantial challenge in the modern pharmaceutical 
industry. Most of the produced drugs and natural products exhibit chirality, however, in most cases 
only one of the enantiomers has the desired specific biological activity and the other enantiomer 
has the potential for undesired effects. Since it is possible for one of the enantiomers to have 
undesirable effects, chiral drug molecules require stereoselective syntheses or challenging 
separations to purify one single enantiomer74. Despite the crucial requirement of chiral separations 
in the pharmaceutical industry, it remains an expensive and complex challenge. Current chiral 
separations are performed using chiral chromatography which primarily depends on 
polysaccharide and cyclodextrin based chiral stationary phases (CSPs) with some chiral 
separations performed using protein, ligand, ion exchange and macrocyclic antibiotic CSPs75. 
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Typically, these CSPs are poorly robust, expensive to manufacture and often to specific, lacking 
desirable versatility across multiple different chiral analytes75,76. To circumvent these 
shortcomings, the use of MOFs is gaining attention for their potential use as CSPs. Examples of 
chiral MOFs have been synthesized using enantiopure organic linkers and have been used for 
chiral separations or asymmetric catalysis. 
1.5 Dissertation Outline 
 The dissertation presented herein utilizes mass spectrometry as an analytical tool in a 
variety of systems to help answer a series of analytical questions: 
Chapter 2. Derivatization techniques are investigated with the purpose of inducing ionization of 
dextran by means of multiple charges. Most polysaccharides, including dextran, are difficult to 
ionize due to their inherent neutrality. Ionization efficiency is poor in negative mode ESI because 
they lack acidic groups typically needed for proton abstraction, and ionization efficiency in 
positive mode ESI because they have low proton affinity. The goal for this project was to find a 
derivatization technique that would allow dextran to carry multiple charges. If successful, more 
charges would allow the molecular mass of dextran to be measured in a lover m/z region, similar 
to the supercharging of proteins with large molecular mass that allows them to be are measured. 
To encourage ionization of dextran by means of multiple proton adducts for ESI-TOF MS 
analysis, a one pot derivatization technique using ethylenediamine was used. We were able 
to successfully attach up to four ethylenediamine groups onto dextran allowing for up to four 
protonations. The ability of derivatized dextran to hold up to 4 charges by means of 
protonation is the first time a polysaccharide has been multiply charged by multiple 
protonations. The progress made suggests that derivatization can allow for large and otherwise 
neutral polysaccharides be measured using mass spectrometry.  
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Chapter 3. The third chapter of this dissertation focuses the application of mass spectrometry to 
answer a series of analytical questions: to confirm the hypothesized reaction byproducts produced 
during the catalytic release of nitric oxide (NO) from S-nitrosoglutathione (GSNO) when exposed 
to metal-organic frameworks (MOFs) embedded onto chitosan polymer support systems. 
Simultaneously, the degradation products from the chitosan-MOF composite were studied to probe 
for the potential decomposition of the MOF by searching for the starting ligand. With the use of 
mass spectrometry, oxidized glutathione (GSSG) was confirmed to be the reaction byproduct 
of the release of NO form GSNO. Additionally, the hydrolytic degradation of chitosan 
produced the anticipated glucosamine and N-acetylglucosamine as the degradation products. 
But most importantly, within the same mass spectrometric analyses, H3BTTri, the ligand 
used to synthesize the MOF was not detected, indicating no decomposition of the MOF over 
time.  
 In a second application of mass spectrometry, my colleague Bella H. Neufeld raised 
awareness regarding the potential chemical transformation of cell viability assays in the absence 
of cells. To investigate potential interferences and their effects, the CellTiter Blue (resazurin → 
resorufin) and MTT (MTT → formazan) cell viability assays were tested against selected small 
molecules. When the UV-vis spectroscopic assays suggested interferences or produced 
inconclusive results, mass spectrometric analysis allowed for the accurate determination of 
resazurin/formazan or MTT/formazan presence and whether the selected small molecule 
was responsible for false positives/negatives or severe signal suppression. Our findings 
strongly suggest that whenever the CellTiter Blue or MTT assays are used, the selected therapeutic 
should always first be tested for its effects on the assay first and the best way to do this is to run 
the assays in the absence of cells and confirm whether transformation has occurred using mass 
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spectrometry. This proved to be of great importance since even when appropriate control studies 
are performed, the typical user of this assays does not perform a thorough examination of the full 
UV-vis spectroscopic measurements which may still lead to inconclusive results regarding 
potential interferences.  
Chapter 4. The importance of using mass spectrometry coupled with a pre-separation step is 
emphasized in Chapter 4 for analysis of polymer degradation products. Polymer systems based on 
poly(phosphazene) and polyester structures synthesized in our lab were degraded over time by 
hydrolytic degradation. The implementation of routine direct flow injection mass spectrometric 
analysis helped with the identification of the major degradation products from each polymer. 
However, a polyester based polymer with promising properties for biomedical applications was 
further studied for its decomposition over time to assess potential toxicity concerns that may arise 
during degradation. In addition to direct flow injection mass spectrometry, a chromatographic 
separation step with a C18 column allowed for additional details including structural isomerism of 
the degradation products. And finally, tandem mass spectrometry (MS/MS) was critical for 
accurate structural determination of each degradation product. The degradation products from 
each polymer system were characterized using TOF-MS to complement full characterization 
of the polymers, particularly during the degradation process. One of our main concerns was 
to address whether the polyesters would degrade into individual monomers, with the 
potential of increasing localized acidity. Fortunately, our results show that the degradation 
products were primarily esters, as dimers and beyond, rather that the starting acidic 
monomers. The results presented in this chapter should pave the way for the future 
development of biodegradable polymers intended for biomedical applications. Particularly 
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since the methodology presented can be used when a device intended to be for medical use 
undergoes the ISO 10993 series Biological Evaluation of Medical Devices.  
Chapter 5. The fifth chapter represents the work performed in an international collaborative effort 
to use a new chiral metal-organic framework (MOF) as a chiral stationary phase (CSP) for chiral 
resolution. A chiral MOF designed and synthesized by Prof. Galán-Mascarós’ group was provided 
to the Reynolds group to investigate potential applications. The chiral-MOF (called TAMOF-1) 
was packed in-house into an empty HPLC column with the primary objective of achieving chiral 
resolution of chiral compounds. The results presented in this chapter strongly suggest that 
chiral-MOFs can and should be used for chiral chromatograph since efficient chiral 
resolution was observed using solvent systems that range from normal to reversed phase. 
The ability of TAMOF-1 to be used as a CSP is very promising since to this day, chiral resolution 
continues to be an expensive, tie consuming and complex analytical challenge.  
Summarizing remarks. This dissertation presents studies emphasizing the benefits of incorporating 
mass spectrometric analyses to a variety of biomedically oriented projects. While it is an expensive 
technique and not available to every research group/industry, appropriate mass spectrometric 
methods can answer questions difficult to explore otherwise. Difficulties in mass spectrometric 
analysis of polysaccharides were addressed by exploring derivatization of dextran to mimic 
protein-like ionization. Byproducts of catalytic reactions and potential interferences in cell 
viability assays were confirmed using mass spectrometric analyses. The degradation products from 
poly(phosphazene) and polyester based polymers intended for biomedical applications were 
identified, in aims to provide information necessary and of importance for biological evaluation of 
medical devices. Finally, an international collaborative effort presented the opportunity to 
investigate the potential of a chiral-MOF CSP intended to advance chiral chromatography. 
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Collectively, the projects and findings outlined in this dissertation advance the field of 
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DERIVATIZATION OF DEXTRAN TO IMPROVE ELECTROSPRAY IONIZATION TIME-
OF-FLIGHT MASS SPECTROMETRIC ANALYSIS OF POLYSACCHARIDES 
 
2.1 Background 
 The use of NO-releasing materials for biomedical applications have been extensible studied 
in Prof. Melissa M. Reynolds group to combat bacterial infections and device biofouling. The 
incorporation of stable NO moieties onto polymer substrates such as dextran continues to be a 
critical part of NO materials development. The work described in this study was originally 
intended to design a mass spectrometric method to track the degradation of NO-releasing dextran 
(approx. molecular mass of 40 kDa) as a function of time in the presence of dextranase as NO was 
released. The hypothesis was that tracking the change in molecular weight could eventually be 
correlated to the decay of NO-releasing dextran after it is administered intravenously. Preliminary 
studies revealed that the dextran’s molecular mass was too large for the instrument’s measurement 
range, leading to severe changes of the initial hypothesis. The project became a more fundamental 
study regarding ionization of underivatized dextran and a derivatization study aimed at improving 
ionization and mass spectrometric measurement of dextran and its derivatives. The initial 
hypothesis evolved to shift focus to develop an appropriate derivatization procedure for dextran to 
improve ionization. For this purpose, the goal was to attempt mimicking protein-like ionization 
for mass spectrometric analysis. Due to the highly available terminal amines found in proteins 
(such as the basic amino acids arginine, histidine and lysine), proteins with very large molecular 
weights (up to megadalton range) are ionizable by supercharging them with multiple protonations. 
This supercharging phenomenon shifts the molecular weight of proteins toward a lower m/z range, 
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therefore making them measurable within the limits of typical mass spectrometers. Our approach 
was to find a way to attach the compound ethylenediamine (H2NCH2CH2NH2) to the dextran in a 
manner that would leave one of the terminal amine groups freely available. If successful, multiple 
ethylenediamine attachments would take place allowing for ionization of dextran by means of 
multiple protonations. The results were promising (as will be shown in this chapter) in that we 
found a one-pot derivatization technique that allowed ethylenediamine-derivatized dextran to 
ionize by means of multiple charges, similar to the behavior of proteins when analyzed by MS. 
This work was originally published in the Journal of The American Society of Mass Spectrometry 
(Tapia, J. B.; Hibbard, H. A. J.; Reynolds, M. M. Derivatization of Dextran for Multiply Charged 
Ion Formation and Electrospray Ionization Time-of-Flight Mass Spectrometric Analysis. J. Am. 
Soc. Mass Spectrom. 2017, 28 (10), 2201–2208). The work has been reprinted with permission 
from the American Chemical Society (Copyright 2017). The synthetic procedure was designed by 
Hailey A. J. Hibbard. Characterization of the reactants and products using ATR-IR, H-NMR and 
MS was done by Jesus B. Tapia. Prof. Melissa M. Reynolds acted as the advisor on this project. 
2.2 Introduction 
Molecular weight and structural analysis of polysaccharides by mass spectrometry (MS) 
continues to be a challenging task. Compared to the rate of advances in method development for 
protein analysis, progress in the use of MS for polysaccharide analysis continues to evolve 
relatively slowly1. The most widely used ionization methods for large biomolecules, including 
polysaccharides, are matrix-assisted laser desorption ionization (MALDI) and electrospray 
ionization (ESI) coupled with time-of-flight (TOF) mass analyzers2,3. These ionization techniques 
are commonly used for the analysis of large proteins2 and nucleic acids4, but both methods have 
had little success when applied to polysaccharides5. The limited success in mass spectrometric 
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analysis of polysaccharides can be primarily attributed to ionization limitations. Ionization 
efficiency is low for negative mode ESI because polysaccharides lack the acidic groups typically 
needed for efficient proton abstraction. Also, for positive mode, ionization efficiency is weak with 
ESI because polysaccharides have low proton affinity, leading to the more commonly observed 
metal cation adduct formation6–8.  
Even though both MALDI and ESI have been used for ionization of polysaccharides, 
MALDI has been the preferred method9–12. Unfortunately, MALDI is susceptible to lack of 
reproducibility due to limited control during the crystallization process, which leads to the 
formation of “sweet spots” (inhomogeneous distribution of analyte in the matrix, leading to 
localized high analyte signal intensities), as well as higher likelihood of in-source fragmentation13–
15. Although ESI is typically considered poorly suited for analyzing polysaccharides because it is 
less effective for ionization of neutral molecules, and sensitivity decreases as the weight of the 
molecule increases, it does not suffer from the same drawbacks of using MALDI ionization7,14,16,17.  
To increase ionization efficiency, derivatization processes that may allow for 
polysaccharides to carry multiple charges can be used. This would allow for mass spectrometric 
measurements of multiply-charged polysaccharides. While multiple charges using ESI can be 
detrimental when complex mixtures are analyzed, this feature could allow high molecular weight 
polysaccharides to be observed in a low m/z region13. To date however, there is limited literature 
regarding the use of derivatization techniques to enhance ionization of polysaccharides with ESI 
by means of multiple charges.  
2.2.1 Dextran 
 An early study of dextran was performed by Pasteur in which it was proven that dextran 
formation in wine was caused by microbial activity18. The term “dextran” was coined after 
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Scheibler19 determined that dextran was a carbohydrate of the empirical formula (C6H10O6)n 
having a positive optical rotation. The dextran-forming bacterium Leuconostoc mesenteroides was 
identified by Van Tieghem20 and further investigated by Beijerinck21 and Hehre22. Historically, 
scientific interest in dextran was stimulated by studies suggesting its use as a blood plasma volume 
expander (BPE)23. 
 Dextran is defined as a homopolysaccharide of glucose that exhibits primarily consecutive 
α-1,6-glycosidic linkages in the major chain (Figure 2.1)15,24–27. These α-D-glucan can also possess 
side chains stemming from α-1,2-, α-1,3-, or α-1,4- branch linkages. The exact structure, branching 
type and degree of branching depends on its specific microbial strain of origin. Dextran from the 
lactic acid bacteria strain Leuconostoc mesenteroides NRRL B-512F are the most widely used due 
to the presence of ~95% linear α-1,6-linkages15,28,29. 
 
Figure 2.1 Structure of dextran. Dextran is a homopolysaccharide of glucose primarily composed 
of α-1,6-glycosidic linkages. 
 
 Dextran is biosynthesized by the enzyme dextransucrase which catalyzes the production of 
dextran from sucrose. The majority of dextrans in nature are secreted mainly by Leuconostoc, 
Streptococcus and Lactobacillus bacterial species. Leuconostoc mesenteroides NRRL B512F 
dextransucrase has received the most attention and it is utilized to produce dextran commercially 
due to its linearity. Dextransucrase is an extracellular glucosyltransferase (GTF), which catalyzes 
the transfer of D-glucose residues from sucrose to dextran, releasing fructose as a byproduct 




Figure 2.2 Synthesis of dextran. Dextranase adds glucose monomers to the growing dextran chain 
by attaching a new glucose unit to the reducing end and giving fructose as the byproduct.  
 
2.2.2 Dextran Uses and Applications 
 As a naturally occurring polysaccharide, there has been interest in the development of 
useful applications for native dextran, partially degraded dextran, and its derivatives (summarized 
in Table 2.1). At the end of 1942, considerable effort was put at the time to the freeze-drying of 
blood plasma for military medicine. Within a few months, the idea of using a hydrolyzed dextran 
as a plasma substitute was discovered15,25,30. After a series of studies, a Swedish pharmaceutical 
company adopted the project in 1943. The dextran used at the time was derived from Leuconostoc 
mesenteroides 7E, from which the use of a 6% dextran (fraction) solution was approved for clinical 
use in Sweden, and shortly thereafter, in the UK15,26. Eventually, the dextran utilized was 
optimized and designated Dextran 70 (70 kDa). The production of clinical dextran has since grown 
throughout the world and Dextran 70 is generally marketed as a 6% solution in normal saline and 
continues to be the plasma volume expander of choice. This clinical dextran is recommended for 
the treatment of shock or impending shock due, for example, to hemorrhage, severe burns, surgery 









Improves freshness, mouthfeel, softness, crumb texture, loaf volume, and 
shelf life 
 
Ice Cream, Frozen and Dried foods 15,32 
Cryoprotectant and protection from oxidation and chemical changes and 
preservation in texture and flavor 
 
Cheese Making 33 
Improves water binding and increases moisture in nonfat cheese 
 
Blood Plasma Expander 15,24,32,34 
 Therapeutic agent in restoring blood plasma volume  
 
Anemia Treatment 35 




Purification/separation of proteins, nucleic acids and polysaccharides 
 
 
2.2.3 Current Methods for Dextran Analysis 
 Size exclusion chromatography (SEC) has been and continues to be the major choice to 
obtain molecular mass information of polysaccharides14, along with other techniques including 
field-flow fractionation (FFF)36. Dextran studies have been monitored by analyzing the 
polysaccharide primarily by coupling SEC with refractive index (RI) and/or light scattering 
detection (LS)14,36. To obtain molecular mass measurements of dextran, a calibration curve is 
obtained by utilizing a set of dextran standards with known molecular masses that correlate 
molecular mass with retention time/volume36. Unfortunately, the use of SEC with RI and or/LS 
detection generally provides results with poor resolution that only allow for an estimate of the 
molecular mass. This is an issue when we need to observe single monomer changes in molecular 
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weight due to degradation over time. Under typical SEC conditions, it is not easily possible to 
measure such small changes in molecular weight of polysaccharides/polymers. If the goal is to 
perform real time measurements, time sensitive measurements, or time-point degradation 
measurements, single monomer unit changes would not be observed. Therefore, MS detection 
would be able to detect subtle changes in MW from the starting polymer while simultaneously 
detecting increase(s) in abundance of the monomer units. 
2.2.4 Derivatization Method for Dextran to Achieve Improved Ionization Efficiency 
In this study, we investigated the use of a derivatization technique to impart charged 
functional moieties onto dextran to enhance its ability to ionize in a TOF MS.  Dextran was chosen 
because it is a difficult polysaccharide to ionize due to the lack of acidic groups for proton 
abstraction and its low proton affinity for proton adduction. To encourage ionization of dextran by 
means of multiple proton adducts for ESI-TOF MS analysis, we used a one-pot derivatization 
procedure with ethylenediamine that has been previously utilized as the first step to produce water 
soluble Dextran-Taxol conjugates 37. We selected dextran-T1 (approximately 1 kDa) because its 
molecular weight allowed us to track the mass changes and determine the number of 
ethylenediamine attachments from underivatized to derivatized dextran T1 (EDA-dex-T1). With 
the attached groups, we took advantage of multiply charged ions typical of ESI to observe a shift 
of the molecular weight distribution toward the low m/z region in the form of ions with multiple 
charges, depending on the number of successful attachments. To the best of our knowledge, this 
is the first report of successful use of multiple charges via ESI to analyze the polysaccharide 





1,1′-Carbonyldiimidazole (CDI) was obtained from Sigma (St Louis, MO, USA). Dextran 
T1 (average Mr ~ 1100) was obtained from Pharmacosmos (Holbaek, Denmark). Spectra/Por 
dialysis membranes with a molecular weight cutoff of 100–500 Da were obtained from Spectrum 
Labs (Rancho Domingues, CA, USA). Ethylenediamine (Alfa Aesar), dimethyl sulfoxide 
(DMSO), liquid chromatography–MS grade methanol, liquid chromatography–MS grade water, 
herein referred to as methanol and water, were obtained from VWR (Denver, CO, USA). All 
chemicals were used as received without further purification. 
2.3.2 Derivatization Procedure 
The derivatization of dextran was performed on a half-gram scale, following an 
established procedure37 (Figure 2.3) in which 0.5 g dextran was dissolved in 6 mL DMSO, to 
which a solution of 0.2 g 1,1′-carbonyldiimidazole dissolved in 2 mL DMSO was added, and the 
reaction was allowed to proceed for 15 min at 60 °C to activate the dextran. Following the 
activation step, 1 mL ethylenediamine was added and the resulting mixture was allowed to react 
for 18 h at 60 °C. After the reaction reached completion, the mixture was allowed to reach room 
temperature, and the EDA-dex-T1 was precipitated out of the DMSO with use of excess methanol. 
The precipitate was then filtered by vacuum filtration and washed with methanol to remove any 
DMSO still present and impurities soluble in methanol. The solid was then re-dissolved in 
Millipore water and dialyzed for 24 h in 0.5% w/v NaCl solution and then for an additional 24 h 
in 0.01% v/v acetic acid solution. The dialyzed product was then lyophilized for 4 days to recover 




Figure 2.3 Derivatization of dextran. This one-pot derivatization produced EDA-dex with the 
purpose of giving dextran free terminal amine groups.  
 
2.3.3 General Characterization Techniques 
NMR spectra were obtained with a Varian Inova 400-MHz Fourier transform NMR 
spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA). 1H NMR spectra were 
referenced relative to the solvent (DMSO) and tetramethylsilane (TMS). Attenuated total 
reflectance (ATR) Fourier transform infrared (FT-IR) spectra were collected between 650 and 
4000 cm-1 with a Nicolet 6700 FT-IR spectrometer (Thermo Electron Corp., Madison, WI, USA) 
fitted with a Smart iTR ATR sampling accessory and a ZnSe crystal plate. 
2.3.4 Mass Spectrometry 
ESI-TOF MS. All experiments were performed with a 6224 TOF mass spectrometer 
(Agilent, Palo Alto, CA, USA) equipped with a dual electrospray ion source operated in positive 
mode. EDA-dex-T1 solutions were prepared at a concentration of 1 mg/mL in 0.1% acetic acid 
solution. The solutions were directly injected into the ion source (without a pre-separation step) 
at a flow rate of 0.15 mL/min with use of the autosampler on a 1260 Infinity high-performance 
liquid chromatograph (Agilent, Palo Alto, CA, USA) with an isocratic mobile phase consisting 
of 90% water and 10% methanol, both with 0.1% acetic acid. The ion source conditions were as 
follows: 4.0-kV capillary voltage, 80-V fragmentor voltage, 75-V skimmer voltage, 650-V 
octopole voltage, 12.5 L/min gas flow (N2), and 45-psi nebulizer pressure. The detection range 
was set at 100–3200 m/z. 
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ESI-MS/MS. All MS/MS experiments were performed with a Thermo Finnigan linear trap 
quadrupole (LTQ) equipped with an ESI probe operated in positive mode. Underivatized dextran 
T1 solutions were prepared at a concentration of 1 mg/mL in a methanol–water (40:60, v/v), and 
the EDA-dex-T1 solutions were prepared at a concentration of 1 mg/mL in 0.1% acetic acid 
solution. The solutions were directly injected into the ion source by syringe infusion at a flow rate 
of 15 μL/min. The following instrument conditions were automatically optimized: electrospray 
voltage, heated capillary temperature (voltage), tube lens voltage, capillary voltage, sheath gas 
flow rate, auxiliary gas flow rate and sweep gas flow rate (N2). The conditions were automatically 
adjusted with use of the automatic tune function optimizing on ion m/z 689 for dextan T1 (m/z of 
689 corresponds to a four-glucose monomer dextran with a sodium adduct) and on ion m/z 753 
for EDA-dex-T1 (m/z 753 corresponds to a four-glucose monomer dextran with one 
ethylenediamine attachment and a proton adduct). For the fragmentation studies, the collision-
induced dissociation (CID) energy was set as 30 V. 
2.3.5 Data Analysis 
Data were reported from a minimum of triplicate measurements, unless otherwise noted, 
and all data were analyzed with Agilent MassHunter Qualitative Analysis B.07.00 (ESI-TOF 
data) and Thermo Xcalibur Qual Browser 2.2 SP1.48 (ESI-MS/MS data). 
2.4 Results and Discussion 
2.4.1 Initial derivatization techniques for dextran 
2.4.1.1 Carboxymethylation of dextran 
 Carboxymethylation of dextran to produce carboxymethylated dextran (CM-dextran) was 
the first derivatization attempted to improve ionization of dextran (Figure 2.4). The purpose of this 
derivatization was to attach free terminal carboxylic acid groups with to improve ionization in 
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negative polarity. The derivatization procedure was performed as follows, following a previously 
established procedure38: dextran-6 (6 kDa, 5 g) and sodium hydroxide (5 g) were mixed together 
in 125 mL 80% isopropanol (IPA) solution in Millipore water and stirred at 60 °C until a clear 
solution was obtained. A solution of chloroacetic acid (5.62 g) in 40 mL 80% IPA solution was 
prepared separately and slowly charged to the reaction using a pressure equilibrium addition funnel 
over a period of 30 min. The reaction was maintained at 60 °C for 5 h and after 5 h, the reaction 
was cooled to room temperature and the pH was adjusted to 5 by adding glacial acetic acid. The 
CM-dextran was precipitated into excess methanol and the crude product was isolated by filtration, 
washed with methanol and dried under vacuum. The CM-dextran was redissolved in 25 mL 
Millipore water and dialyzed against Millipore water using dialysis membranes for one week with 
multiple changes per day.  
 
Figure 2.4 Carboxymethylation of dextran. This derivatization produced CM-dextran with the 
purpose of giving dextran terminal acidic groups. 
 
 The obtained CM-dextran was analyzed using ESI-TOF MS with the main purpose of 
multiply charging dextran in negative mode. The carboxylic acid moieties were excellent 
candidates for deprotonation that would lead to multiple negative charges, therefore moving the 
mass of CM-dextran to a lower m/z range. The production of CM-dextran however, did not 
improve ionization as originally intended and a new derivatization was performed. This was 
determined by not finding CM-dextran within the 100 – 3200 m/z range of the instrument. 
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Additionally, using dextran-6 did not give promising results prior to derivatization since the mass 
was outside the instrument limits.  
2.4.1.2 Carbodiimide coupling of ethylenediamine to CM-dextran 
 While the synthesis of CM-dextran did not improve ionization, CM-dextran was previously 
shown to be further derivatized38 by using carbodiimide coupling chemistry to form amide bonds 
between the terminal carboxylic acid and free amines (Figure 2.5).  
 
Figure 2.5 Carbodiimide coupling of ethylenediamine to CM-dextran. CM-dextran synthesis: (1) 
MCA, NaOH, 80% IPA; (ii) acetic acid (see section 2.4.1.1). CM-dextran was used to attach 
ethylenediamine and give dextran free terminal amine functional groups.  
 
The dextran-ethylenediamine (CM-EDA-dextran) was prepared by first derivatizing 
dextran using the procedure in section 2.4.1.1 to produce CM-dextran. CM-dextran (1 g) was first 
pre-activated by reacting with N-hydroxysuccinimide (1.5 g) and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC·HCl, 2.5 g) in Millipore water. To this solution, 3.5 g of 
ethylenediamine were charged. The solution was stirred at 25 °C for 5 h. The produced CM-EDA-
dextran was dialyzed against Millipore water using dialysis membranes for one week with multiple 
changes per day.  
The obtained CM-EDA-dextran was analyzed using ESI-TOF MS with the main purpose 
of multiply charging dextran in positive mode. The free terminal amine moieties were excellent 
candidates for protonation that would lead to multiple positive charges, therefore moving the mass 
of CM-EDA-dextran to a lower m/z range. The production of CM-EDA-dextran however, did not 
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improve ionization as originally intended and a new derivatization was performed. The corrections 
that had to be made were: use dextran with a lower MW that is well within the limits of the 
instrument to confirm the presence of dextran, and to be able to track the mass changes observed 
when dextran is derivatized.  
2.4.1.3 Final derivatization procedure to synthesize EDA-dextran 
 The final and successful derivatization procedure, as described in the experimental section 
(2.3.2 Derivatization Procedure) allowed for a direct attachment of ethylenediamine to dextran. 
Direct coupling of ethylenediamine to dextran was ideal because the use of harsh conditions to 
make CM-dextran were avoided, limiting potential degradation of dextran. For this specific 
reaction procedure, dextran-T1 (Technical grade, 1 kDa) was first characterized to confirm that it 
was measurable using our instrument (see following sections). Following characterization, dextran 
was derivatized and characterized using NMR, IR and the developed ESI-TOF MS methodology 
presented in sections 2.3.3 (General Characterization Techniques) and 2.3.4 (Mass Spectrometry) 
and explained in the following sections.  
2.4.2 Characterization of dextran and EDA-dextran 
Derivatization of dextran T1 with ethylenediamine resulted in the attachment of –
(C=O)NH(CH2)2NH2 moieties through the formation of carbamate linkages to the polysaccharide 
as depicted in Figure 2.3. We found the 1H NMR spectrum of EDA-dex-T1 (Figure 2.6c) to be 
largely consistent with that of dextran T1 (Figure 2.6b) with broadened features appearing 
between 3.71 and 2.88 ppm corresponding to the C2–C6 protons. The major feature change 
between dextran T1 and EDA-dex-T1 was the appearance of two proton shifts at 3.01 and 1.87 
ppm, corresponding to the methylene groups from –(C=O)NH(CH2)2NH2 attachments. Compared 
with the spectrum for ethylenediamine (Figure 2.6a), we expected this peak to split into two 
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different peaks and shift downfield because of the carbamate linkage formation. Infrared 
spectroscopy (ATR FT-IR) was also performed on dextran T1 and EDA-dex-T1 (Figure 2.7), 
from which we observed the formation of the carbonyl stretch at 1705 cm-1. This corresponds to 
the carbonyl on the carbamate linkage formed from derivatization of EDA-dex-T1, further 
confirming the desired product. 
 
Figure 2.6 1H NMR (400 MHz, DMSO, solvent peak δ 2.50 ppm) spectrum of (a) 
ethylenediamine, δ 1.28 ppm, (b) dextran-T1, δ 3.71 – 2.88 ppm C2 – C6 protons, and (c) δ 3.71 – 



























Figure 2.7 Top: ATR-IR spectrum of EDA-dex-T1. IR: Appearance of stretch at 1705 cm-1 after 
derivatization. Bottom: ATR-IR spectrum of dextran-T1.  
 
2.4.3 ESI-TOF MS Analysis of dextran T1 and EDA-dex-T1 
We quantified the efficiency of derivatization by counting the number of ethylenediamine 
attachments and comparing the starting mass spectrum of dextran T1 with the spectrum of EDA-
dex-T1. In the ESI mass spectrum shown in Figure 2.8, we observed dextran T1 to range from 
two to nine repeating glucose residues, corresponding to neutral masses ranging from 342 to 1476 
Da as either [M + NH4]+ ions or [M + Na]+ ions, with peak differences of 162 Da that account for 
one repeating glucose residue. The collected mass spectrum is similar to previously observed 
distributions for dextran obtained with ESI in which the observed peaks are primarily a product 
of Na+ ion adduct formation7. 
 
Figure 2.8 Electrospray ionization (ESI) mass spectrum of dextran T1. The observed mass 
distribution corresponds to two to nine repeating glucose residue chains with the m/z range 360 
to 1494 as [M + NH4]+ ions and the m/z range from 365 to 1499 as [M + Na]+ ions. gluc. glucose 
 
The ESI mass spectrum generated from EDA-dex-T1 is shown in Figure 2.9. We found 



























































































































































gain of 86 Da, indicating successful derivatization due to –(C=O)NH(CH2)2NH2 attachment. We 
observed ionization to have occurred through the formation of H+ adducts rather than Na+ or NH4+ 
adducts, one of the intended purposes of derivatizing dextran. The new observed distribution 
ranged from m/z 429 to m/z 1563 in the form of [M + 86 + H]+, which corresponds to a single 
ethylenediamine attachment onto the dextran. 
 
Figure 2.9 ESI mass spectrum for ethylenediamine-derivatized dextran T1 (EDA-dex-T1). The 
two to nine glucose residue distribution is shown with an m/z range from 429 to 1563 with a mass 
offset of 86 Da from the dextran T1 distribution. This 86-Da mass increase indicates attachment 
of a single ethylenediamine to each dextran chain. gluc. glucose 
 
On further investigation of each ion, we found that some dextran chains had more than 
one ethylenediamine attachment. A second distribution that ranged from m/z 258 to m/z 825 
corresponded to the same two to nine glucose residue chains, but with two ethylenediamine 
attachments and two charges (two H+ adducts). The extracted mass distributions are shown in 
Figure 2.10, in which the same results for triple attachments/charges (255 to 579 Da) and 
quadruple attachments/charges (253 to 455 Da) for the two to nine glucose residue chains are 








































to show that a polysaccharide can be ionized by means of multiple H+ adducts. This is remarkably 
important since we achieved multiple charges on a polysaccharide and shifted the mass 
distribution toward the lower m/z region, the first step toward reducing the problem of low 
ionization efficiency for polysaccharides. 
 
Figure 2.10 Extracted mass distributions showing single attachment/charge to quadruple 
attachments/charges. For single attachment/charge, we saw the 162 Da mass increments 
corresponding to a single repeating glucose residue. We observed similar distribution for double 
attachments/charges, triple attachments/charges, and quadruple attachments/charges with mass 
increments of 81, 54, and 40 Da respectively, each corresponding to the mass of a single glucose 
residue (162 Da) divided by the corresponding number of charges 
 
After further investigation of the ion peaks, we found protein-like charge distributions for 
EDA-dex-T1. For example, in Figure 2.11 we show the charge distribution observed for a four-
glucose-unit chain with four ethylenediamine attachments. The three ion peaks correspond to m/z 
253, 337, and 506 as 4+, 3+, and 2+ ions respectively, all corresponding to the formula 
C36H66N8O25 with a deconvoluted mass of 1010 Da. We determined that these ions were multiply 
charged from the spectrum as indicated by the 0.25-Da interval for the quadruply charged ion, 









































ion shown in the insets in Figure 2.11. The remainder of the combinations of ethylenediamine 
attachments, charges, and charge distributions are shown in Table 2.2. 
 
Figure 2.11 Extracted charge distribution showing the peaks 253, 337, and 506 as 4+, 3+, and 2+ 
respectively. The deconvoluted mass corresponds to C36H66N8O25, or the four-glucose chain with 
four ethylenediamine attachments with a mass of 1010 Da. The 0.25-, 0.33-, and 0.50-Da intervals 
for the quadruply, triply and doubly charged ions are shown in the insets. Note that the 507.2034 
peak exhibited severe peak overlap 
 
Also, we determined that there is also no evidence that EDA-dex-T1 degraded in the 
sample derivatization, preparation, or ionization as we did not find the m/z 162 or m/z 249 ion 
peaks that would correspond to a single repeating glucose residue or single-attachment glucose 












































































































Formula # of glucose 
units 
# of attachments 
429.1730 +1, H+ 428.1652 C15H28N2O12 2 1 
258.1146 +2, H+ 514.2136 C18H34N4O13 2 2 
591.2256 +1, H+ 590.2178 C21H38N2O17 3 1 
339.1413 +2, H+ 676.2670 C24H44N4O18 3 2 
677.2693 +1, H+ 676.2615 C24H44N4O18 3 2 
255.1129 +3, H+ 762.3153 C27H50N6O19 3 3 
382.1639 +2, H+ 762.3122 C27H50N6O19 3 3 
753.2787 +1, H+ 752.2709 C27H48N2O22 4 1 
420.1676 +2, H+ 838.3196 C30H54N4O23 4 2 
839.3229 +1, H+ 838.3151 C30H54N4O23 4 2 
309.1313 +3, H+ 924.3705* C33H60N6O24 4 3 
463.1909 +2, H+ 924.3662 C33H60N6O24 4 3 
253.6122 +4, H+ 1010.4176 C36H66N8O25 4 4 
337.8128 +3, H+ 1010.4150 C36H66N8O25 4 4 
506.2108 +2, H+ 1010.4060 C36H66N8O25 4 4 
915.3306 +1, H+ 914.3228 C33H58N2O27 5 1 
501.1942 +2, H+ 1000.3728 C36H64N4O28 5 2 
1001.3760 +1, H+ 1000.3682 C36H64N4O28 5 2 
363.1484 +3, H+ 1086.4218 C39H70N6O29 5 3 
544.2170 +2, H+ 1086.4184 C39H70N6O29 5 3 
1087.4209 +1, H+ 1086.4131* C39H70N6O29 5 3 
294.1300** +4, H+ 1172.4888* C42H76N8O30 5 4 
391.8306 +3, H+ 1172.4684 C42H76N8O30 5 4 
1077.3825 +1, H+ 1076.3747 C39H68N2O32 6 1 
582.2204 +2, H+ 1162.4252 C42H74N4O33 6 2 
1163.4277 +1, H+ 1162.4199 C42H74N4O33 6 2 
417.1667 +3, H+ 1248.4767 C45H80N6O34 6 3 
625.2437 +2, H+ 1248.4718 C45H80N6O34 6 3 
334.6389 +4, H+ 1334.5244 C48H86N8O35 6 4 
445.8480 +3, H+ 1334.5206 C48H86N8O35 6 4 
668.2636 +2, H+ 1334.5116* C48H86N8O35 6 4 
1239.4347 +1, H+ 1238.4269 C45H78N2O37 7 1 
663.2468 +2, H+ 1324.4780 C48H84N4O38 7 2 
1325.4801 +1, H+ 1324.4723 C48H84N4O38 7 2 
471.1899 +3, H+ 1410.5463 C51H90N6O39 7 3 
706.2701 +2, H+ 1410.5246 C51H90N6O39 7 3 
375.1567** +4, H+ 1496.5956 C54H96N8O40 7 4 
499.8653** +3, H+ 1496.5725 C54H96N8O40 7 4 
749.2900** +2, H+ 1496.5644 C54H96N8O40 7 4 
1401.4879 +1, H+ 1400.4801 C51H88N2O42 8 1 
744.2731 +2, H+ 1486.5306 C54H94N4O43 8 2 
1487.5321 +1, H+ 1486.5243 C54H94N4O43 8 2 
525.2026 +3, H+ 1572.5844 C57H100N6O44 8 3 
787.2975 +2, H+ 1572.5794 C57H100N6O44 8 3 
415.6656 +4, H+ 1658.6312 C60H106N8O45 8 4 
1563.5349 +1, H+ 1562.5271 C57H98N2O47 9 1 
579.2191 +3, H+ 1734.6339 C63H110N6O49 9 3 
868.3222 +2, H+ 1734.6288 C63H110N6O49 9 3 
456.1802 +4, H+ 1820.6896 C66H116N8O50 9 4 




2.4.4 ESI-MS/MS of dextran T1 and EDA-dex-T1 Trisaccharides 
To further investigate the properties of our derivatized dextran, we collected MS/MS data 
to determine where the ethylenediamine attachments occurred. We collected fragmentation for a 
dextran T1 trisaccharide, and then compared this with that of an EDA-dex-T1 trisaccharide with 
single, double, and triple ethylenediamine attachments. The MS/MS spectrum for the dextran T1 
trisaccharide is shown in Figure 2.12. We assigned the molecular ions and fragment ions using 
the nomenclature of Domon and Costello39. We observed fragment ions that correspond to 
glycosidic bond cleavages, such as C1 (m/z 203), B2 (m/z 347), and C2 (m/z 365), and cross-ring 
cleavage fragment ions, 0,2A, 0,3A, and 0,4A, which correspond to the second and third residues 
from the nonreducing end. All the ions we observed in Figure 2.12 we found to be largely 
consistent with the literature40. 
 
Figure 2.12 Tandem mass spectrometry (MS/MS) spectrum of dextran T1 trisaccharide 
 
The MS/MS spectrum for the EDA-dex-T1 trisaccharide with a single ethylenediamine 
attachment is shown in Figure 2.13. We observed the fragment ions that correspond to glycosidic 
bond cleavages such as Z1 (m/z 249), Y1 (m/z 267), Z2 (m/z 411), and Y2 (m/z 429). We also 
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identified cross-ring cleavage fragment ions such as 0,2X1 (m/z 309), 0,2X2 (m/z 471), and 1,5A3 
(m/z 544), which suggested the location of attachment to be at the C-2 position of the reducing-
end glucose monomer. Determination of the exact location of attachment further confirms that 
ethylenediamine was attached to the dextran trisaccharide and supports our finding that ionization 
occurred in the form of a proton adduct. 
 
Figure 2.13 MS/MS spectrum of EDA-dex-T1 trisaccharide with a single attachment as indicated 
by m/z 591. R denotes the ethylenediamine attachment (–(C=O)NH(CH2)2NH2), which our data 
suggest to be at the C-2 position of the reducing-end glucose monomer 
 
The MS/MS spectra for the EDA-dex-T1 trisaccharide with double and triple 
ethylenediamine attachments are shown in Figure 2.14. For EDA-dex-T1 with two attachments 
(Figure 2.14a), we observed the fragment ions that correspond to glycosidic bond cleavages: C1 
(m/z 353) and C2 (m/z 515). The ions m/z 353 and m/z 515 indicate that two attachments occurred 
on the glucose at the nonreducing end, as well as the ions Z1 (m/z 249), Y1 (m/z 411), and m/z 
573, which suggests that one attachment occurred at the glucose on the reducing end and a second 




































































suggests attachment to be a random occurrence when more than one ethylenediamine is attached 
to dextran. 
 
Figure 2.14 MS/MS spectra of EDA-dex-T1 trisaccharide with double and triple ethylenediamine 
attachments. a EDA-dex-T1 with double ethylenediamine attachments as indicated by m/z 677. 
The fragment ions Z1, Z2, and Y2 in blue are indicative of one attachment at the reducing end and 
one at the nonreducing end. The fragment ions C1 and C2 in red are indicative of two attachments 
at the glucose at the nonreducing end and the fragment ion C1 in purple is indicative of one 
attachment at the middle glucose and a second attachment at the reducing-end glucose. b EDA-
dex-T1 with triple ethylenediamine attachments as indicated by m/z 763. The fragment ion Z1 in 
pink is indicative of a single attachment at the reducing end and the fragment ions C1 and C2 in 
green are indicative of three attachments at the glucose at the nonreducing end. The fragment ions 
C1 and C2 in gray are indicative of two attachments at the glucose at the nonreducing end and the 
third attachment at the reducing-end glucose 
 
For EDA-dex-T1 with three attachments (Figure 2.14b) we also observed fragment ions 
that correspond to glycosidic bond cleavages, such as C1 (m/z 353 and 439) and C2 (m/z 515 and 
601). The C1 (m/z 439) ion was further indicative of random ethylenediamine attachment since it 
corresponds to all three attachments occurring at the glucose at the nonreducing end. This further 
suggests that attachment of multiple ethylenediamine groups to dextran occurs at random 










































































dextran appears to be random, our goal of achieving multiple proton adducts was not diminished 
by this phenomenon as we show in Figures 2.9 and 2.10 and Table 2.2. 
2.5 Conclusions 
 This is the first report of a simple, one-pot derivatization of a polysaccharide that allows 
for multiple charge ionization, typical of proteins and glycoproteins, but not previously shown for 
polysaccharides. ESI-MS is capable of detecting derivatized dextran by allowing for multiple 
charging and thus shifting detection of the polysaccharide toward lower m/z ratios. The one-pot 
derivatization reaction was ideal to attach ethylenediamine groups via carbamate bonds to the 
polysaccharide resulting in EDA-dex-T1. Evidence of single attachment/charge to quadruple 
attachment/charge was shown, as well as protein-like charge distributions with ionization taking 
place as proton adducts due to the terminal amine groups present in EDA-dex-T1, rather than the 
more common metal cation adducts seen with underivatized dextran. Our MS/MS studies indicate 
that multiple attachments to dextran after the derivatization step occur at random locations on the 
polysaccharide. This did not limit EDA-dex-T1’s ability to carry multiple charges and differences 
in exact location of the attachments did not impair our primary goal of attaching ethylenediamine 
groups to encourage ionization to take place by proton adduct formation and achieve multiple 
charges on a polysaccharide. Collectively, the data obtained from this work show that EDA-dex-
T1 is capable of ionizing with multiple proton adducts, thereby shifting the molecular weight 
distribution to the lower m/z ratio detection range. Based on our findings, the derivatization may 
be adaptable for use with larger molecular weight dextran. For example, with the assumption that 
only a maximum of four ethylenediamine attachments are possible, theoretically, we could detect 
dextran with a maximum molecular weight of upwards of 12 kDa resulting in a measured m/z of 
3000 Da with four charges using our current derivatization method and instrument settings.  
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DEVELOPMENT OF MASS SPECTROMETRIC METHODS TO IDENTIFY UNKNOWN 
COMPOUNDS AND REACTION PRODUCTS IN COMPLEX SYSTEMS 
 
3.1 Background 
Accurate mass spectrometric measurements using high resolution mass spectrometers is a 
reasonable approach to characterize and identify known/unknown compounds of interest. This is 
particularly important during the discovery phase of research projects in which every possible 
outcome of a process/reaction and the potential for unwanted interferences have not been fully 
identified. One example is the application of metal–organic frameworks (MOFs) embedded into 
polymer substrates to induce catalytic release of nitric oxide (NO) from S-nitrosothiols (RSNOs). 
The MOF, Cu-BTTri, used in this project has been widely studied in the Reynolds group because 
of its water stability. Multiple reports have demonstrated the NO generation capabilities of the 
CuBTTri MOF alone as well as the MOF-polymer composites materials. While others have 
extensively studied NO release from these MOF materials, no studies have performed that to 
determine the other products/byproducts formed from the MOF-catalyzed decomposition of 
RSNOs to form NO. Originally, it had been hypothesized that the release of NO from S-
nitrosoglutathione (GSNO) would lead to the formation of glutathione disulfide (GSSG) using our 
MOF-chitosan films, however, this had not been confirmed experimentally. Additionally, interest 
in identifying any potential hydrolytic degradation products of the MOF itself would add to full 
characterization of the system. To test the hypothesis that the decomposition of GSNO via Cu-
BBTri would produce NO + GSSH as shown in equation (3.1), samples from the media collected 
after the NO-release experiments were analyzed using accurate mass MS. 
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A second example of the power of accurate mass MS is to identify potential chemical 
interferences in common cell assays. In particular, a MS study was employed to identify interfering 
compounds in the commonly used, commercially available CellTiter Blue and MTT assays.  The 
purpose of these assays is to assess cell viability spectroscopically by measuring the number of 
metabolically active cells. Previous studies found that these spectroscopy assays produced false 
positives or negatives, depending on whether the therapeutic of interest interferes with the cell 
viability assay1. For example, colleagues noted that the addition of non-nitrosated, reduced 
glutathione to a solution of the MTT starting reagent caused the solution to change from yellow to 
purple, suggesting a chemical transformation. This observation was a critical indicator that the 
assays typically used to test for viable cells may be susceptible to false positives or negatives in 
the absence of cells. The possibility for false positives or negatives led to an in-depth study of 
several small molecules effect on the CellTiter Blue and MTT assays using mass spectrometry. 
The main question addressed in these interference experiments was whether it would be possible 
to use accurate mass MS to track the transformation of resazurin to resorufin and MTT to MTT-
formazan while in the absence of cells. To do so, the cell viability assays were performed in the 
presence of compounds suspected of interference while in the absence of cells. 
Altogether, this chapter describes mass spectrometric methods were developed to perform the 
following analyses: 
1. To confirm that after NO is released from GSNO in the presence of chitosan-CuBTTri 
films, the byproduct is oxidized glutathione (GSSG); 
2. To probe for the presence of H3BTTri during the reaction mentioned previously (1), which 
if present, would indicate MOF decomposition from within chitosan-MOF matrix; 
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3. To identify interferent species that would lead to false positives or false negative during 
the use of the cell viability assays CellTiter Blue and MTT in vitro cytotoxicity methods. 
Alec Lutzke performed the synthesis of the MOF and fabricated the MOF-polymer films. 
Megan J. Neufeld performed the NO-release studies and provided the sample aliquots used for the 
MS studies. Jesus B. Tapia performed the MS studies to investigate the catalytic products and 
potential degradation products. The MS work regarding the MOF-polymer composites was 
published in ACS Applied Materials and Interfaces (Neufeld, M. J.; Lutzke, A.; Tapia, J. B.; 
Reynolds, M. M. Metal – Organic Framework/Chitosan Hybrid Materials Promote Nitric Oxide 
Release from S-nitrosoglutathione. ACS Appl. Mater. Interfaces 2017, 9(6), 5139–5148). Alec 
Lutzke provided guidance and support for the in vitro cytotoxicity assays, including identifying 
the molecules to be tested. Bella H. Neufeld provided the in vitro assay samples used to perform 
the MS experiments. Jesus B. Tapia performed the MS studies to track the chemical transformation 
of the in vitro assays. The MS work regarding the investigation for in vitro assay interferences was 
published in ACS Analytical Chemistry (Neufeld, B. H.; Tapia, J. B.; Lutzke, A.; Reynolds, M. M. 
Small Molecule Interferences in Resazurin and MTT-Based Metabolic Assays in the Absence of 
Cells. Anal. Chem. 2018, 90 (11), 6867–6876). The work has been reprinted for both manuscripts 
with permission from the American Chemical Society (Copyright 2017 and 2018).  
3.2 Introduction  
 The usefulness of applying mass spectrometry to complex systems is shown in two 
different systems: a chitosan-MOF composite system (section 3.2.1) used to induce catalytic 
release of NO, and in two cell viability assays (section 3.2.2) that were suspected to be negatively 
affected by interferences. In the case of the chitosan-MOF composites, their main purpose of 
inducing catalytic release of nitric oxide (NO) from S-nitrosoglutathione (GSNO) was successfully 
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characterized, therefore making the composites great candidates for the purpose of catalyzing 
release of NO. However, as with many devices, their implementation is not only reliant on success 
of their primary purpose, but also knowledge of byproducts and potential degradation of the 
devices that may lead to toxicity concerns or product degradation. As will be shown in this chapter, 
mass spectrometry was used to address those potential concerns.  
Specific to cell viability studies, well-established and widely used techniques for 
cytotoxicity studies have the potential for negative interfering effects from compounds to be used 
as therapeutics that may lead to false positives or false negatives. As described in this chapter, the 
uncertainties that may arise from interfering species in the UV-vis stereoscopic measurements used 
for CellTiter Blue/MTT cell viability assays were identified using mass spectrometry. With the 
use of mass spectrometry, it was possible to determine the identity of the interfering species and 
to assign whether the uncertainty regarding false positives, false negatives, or spectroscopic 
suppression was the reason for any inconclusive results from the assays.  
3.2.1 Chitosan-MOF composites  
 Metal-organic frameworks (MOFs) are crystalline structures that consist of organic linkers 
bound to metal centers2 characterized by ultrahigh porosity (up to 90% free volume) and ultrahigh 
surface areas, exceeding 6000 m2/g 3. MOFs have been frequently used in gas storage and 
heterogeneous catalysis, among other applications4–7. It has been previously reported that copper-
based MOFs may be capable of inducing decomposition of S-nitrosothiols (RSNOs)8,9.  
 Nitric oxide (NO) is endogenously produced in the body to contribute to the immune 
response, neurotransmission and regulation of vascular tone10. Additionally, since NO has been 
determined to be essential to the wound-healing process, exogenous NO supplementation has been 
shown to promote accelerated wound healing11,12. To take advantage of endogenously present 
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NO13,14, the copper-based MOF CuBTTri was investigated for its application to induce the release 
NO from the physiologically present S-nitrosoglutathione (GSNO).  
 Incorporation of MOFs capable of inducing release of NO onto polymer support systems 
is highly desirable, particularly when designing extracorporeal systems that are blood-contacting 
devices. The MOF-polymer materials investigated were developed by incorporating CuBTTri onto 
the polysaccharide chitosan. Chitosan is a naturally derived polysaccharide that consists of β-1,4-
linked glucosamine and N-acetylglucosamine, generally regarded as nontoxic15,16. Chitosan was 
the ideal candidate because it has been used as an antimicrobial material in the form of chitosan-
based wound dressings that can significantly accelerate the wound healing process17–19.  
 The incorporation of CuBTTri onto chitosan led to successful release of NO from GSNO 
and supported the potential use of the hybrid materials in extracorporeal systems. In addition to 
investigating the capability of NO release form GSNO using the hybrid materials, mass 
spectrometric methodology was developed to confirm the production of oxidized glutathione 
(GSSG) and to investigate the degradation of the polymer support system and to probe for the 
decomposition of the MOF. The compounds of interest from chitosan were glucosamine and N-
acetylglucosamine, and to screen for MOF decomposition, the compound of interest was the 
H3BTTri ligand.  
3.2.2 Cell viability studies 
 In vitro assays are very important for pharmaceutical and therapeutic agents due to their 
ability to rapidly and efficiently evaluate cytotoxicity of compounds without the need for in vivo 
testing20,21. These assays are frequently used because they rely on the ability of metabolically 
active cells to transform the starting assay compound to a final compound22. The most common in 
vitro cytotoxicity assays are the resazurin → resorufin dyes (commercially available as CellTiter 
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Blue and Alamar Blue)1 and the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-siphenyl-
tetrazolium bromide)23. These assays work by cellular conversion of the starting dye (either 
resazurin of MTT) to the final compound (resorufin or MTT formazan). The transformations 
resazurin → resorufin and MTT → MTT formazan shown in Figure 3.1 are determined 
spectroscopically by monitoring the absorbance values associated with the formation of resorufin 
or MTT formazan over time1,23.  
 
Figure 3.1 Commonly used in vitro cytotoxicity assays. Resazurin is converted to resorufin in the 
presence of metabolically active cells and MTT is converted to formazan in the presence of 
metabolically active cells. 
 
These chemical transformations expected from metabolically active cells have been shown 
to also be induced by functional groups and moieties that may be present within a therapeutic agent 
of interest causing interferences1,22,24,25. These interferences negatively lead to false positives or 
negatives that can inappropriately classify the use of therapeutics. A false positive occurs when 
for example (as will be demonstrated in this chapter) glutathione interacts with resazurin (CellTiter 
Blue assay), converting it to resorufin in the absence of metabolically active cells. Using the typical 
UV-vis spectroscopic detection for the assay, the presence of resorufin and the absence of resazurin 
would inaccurately indicate metabolically active cells. A false negative could occur for example 
(as will be demonstrated in this chapter), severe ion suppression from oxidized glutathione (GSSG) 
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indicates the absence of resorufin (CellTiter Blue assay), therefore inaccurately indicating the 
absence of metabolically active cells.  
To study whether interferences would lead to false positives/negatives, mass spectrometry 
was an ideal addition to the spectroscopic studies performed by Bella H. Neufeld because mass 
spectrometric analyses were not affected by the interferences studied. Any studies that would 
produce inconclusive results using spectroscopic measurements were determined using mass 
spectrometry because the m/z’s of resazurin, resorufin, MTT and MTT-formazan were accurately 
identified regardless of the selected interference. To emphasize this, the exact masses of resazurin 
and resorufin are 229.0375 (230.0448 m/z as [M-H]-) and 213.0426 (212.0353 m/z as [M-H]-) 
respectively. If the assay suffers from severe signal suppression using the UV-vis spectroscopic 
detection (GSSG for example), complementing the studies with mass spectrometry would 
accurately indicate whether resazurin or resorufin are present or both. This is possible because the 
exact mass of GSSG is 612.1520 (611.1447 m/z as [M-H]-) which does not interfere in the mass 
spectrometric method’s ability to detect the presence of resazurin/resorufin and if GSSG has 
effectively converted any of the resazurin to resorufin over time. Therefore, the complementary 
use of mass spectrometry for the cell viability assays can help accurately determine, when not 
possible by UV-vis spectroscopic measurements, whether compounds of interest interfere with the 
assays.  
3.2.3 Goals for this chapter 
 The experiments presented in this chapter show the successful use of mass spectrometry to 
determine/identify analytes of interest such as reaction byproducts, biodegradation products and 
interfering species in complex systems. Two research questions will be addressed: 
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1) Is GSSG the reaction byproduct MOF-catalytized release of NO from GSNO in MOF-
chitosan materials?  
2) From the MOF-chitosan material, what are the degradation products resulting from the 
chitosan support system?  
3) What are the identities of the interferences in the cell-titre blue assay? Do these interfering 
species give a false positive or false negative outcome?    
3.3 Experimental 
3.3.1 Materials and Methods 
3.3.1.1 Chitosan-MOF membranes Materials 
 LC-MS grade acetonitrile, water and formic acid were purchased from VWR (Solon, OH, 
USA). Glutathione (98%) was purchased from AMRESCO (Solon, OH, USA). Deionized water 
(18.2 MΩ·cm) was obtained from a Millipore Direct-Q water purification system (EMD Millipore, 
Billerica, MA, USA). Chitosan-CuBTTri membranes and GSNO were provided by Alec Lutzke 
and Megan Neufeld. 
3.3.1.2 Chitosan-MOF membranes Methods 
The products formed following exposure of CuBTTri membrane to GSNO were 
determined by suspension of approximately 20 mg of chitosan-CuBTTri membrane in a 1 mM 
solution of GSNO. The experiment was protected from light and maintained at 37 °C until the 
characteristic pink color of GSNO disappeared in solution. A control experiment was conducted 
in a similar manner using a chitosan membrane without the CuBTTri MOF intended to reflect the 
thermal decomposition of GSNO. A second control experiment was performed by exposing GSNO 
only to 365 nm UV light to encourage UV decomposition of GSNO.  
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The collected solutions were analyzed using an Agilent 6224 TOF LC/MS. The instrument 
was equipped with an Agilent multimode (MMI) ion source capable of electrospray ionization 
(ESI) and atmospheric pressure chemical ionization (APCI). For all the analyses, ESI in positive 
polarity was used. The sample solutions were introduced into the ion source by direct flow 
injection using an Agilent 1260 Infinity at a flow rate of 0.220 mL/min via the ESI nebulizer using 
a mobile phase consisting of 80/20/0.1 water/acetonitrile/formic acid. The mass spectrometer 
conditions were as follows: 3000 V capillary voltage, 200 V fragmentor voltage, 60 V skimmer 
voltage, 310 °C drying gas (N2) temperature, 10 l/min drying gas flow rate, and 45 psi nebulizer 
pressure. All data were processed with Agilent MassHunter Qualitative Analysis B.07.00. 
3.3.1.3 Cell viability studies Materials 
Glutathione, MTT cell viability assay and LC-MS grade methanol were purchased from 
VWR (Solon, OH, USA). Dimethyl sulfoxide, oxidized glutathione, D-penicillamine, and N-
acetyl-D-penicillamine were purchased from Sigma Aldrich (St. Louis, MO, USA). L-cysteine and 
mercaptosuccinic acid were purchased from Alfa Aesar (Ward Hill, MA, USA). CellTiter Blue 
(resazurin-resorufin) was purchased from Promega (Madison, WI, USA). Deionized water (18.2 
MΩ·cm) was obtained from a Millipore Direct-Q water purification system (MilliporeSigma, 
Billerica, MA, USA). 
3.3.1.4 Cell viability studies Methods 
 All MS analyses were performed on an Agilent 6224 TOF LC/MS. The instrument was 
equipped with an Agilent multimode ion (MMI) source capable of electrospray ionization (ESI) 
and atmospheric pressure chemical ionization (APCI). For the assays, mixed-mode ionization was 
used. The sample solutions were introduced to the ion source by direct flow injection using an 
Agilent 1260 Infinity at a flow rate of 0.220 mL/min via the ESI nebulizer with methanol as the 
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mobile phase. The mass spectrometer conditions were as follows: 2500 V capillary voltage, 120 
V fragmentor voltage, 60 V skimmer voltage, 2000 V corona charging voltage, 310 °C drying gas 
(N2) temperature, 10 l/min drying gas flow rate, and 45 psi nebulizer pressure. All data were 
processed with Agilent MassHunter Qualitative Analysis B.07.00.  
 The samples for the resazurin → resorufin assay were prepared by Bella H. Neufeld using 
Millipore water to minimize potential interfering ions and ion suppression in the mass spectrometer 
and the analyses were performed in negative polarity. The samples for the MTT → MTT formazan 
assay were prepared by Bella H. Neufeld using a solvent mixture containing PBS and DMSO that 
were diluted in ethanol (to 0.1%) to facilitate dissolution before injection into the mass 
spectrometer. All analyses were performed in positive polarity for the MTT → MTT-formazan 
assay.  
3.4 Results 
3.4.1 Chitosan-MOF membranes 
 The main purpose of the MS studies regarding the chitosan-CuBTTri membranes was to 
determine the reaction products as GSNO decomposed in the presence of Cu-BTTri to produce 
NO and other products (Figure 3.2). Additionally, since the CuBTTri was embedded into a 
chitosan support, it was important to track the degradation of chitosan as well as any potential 
degradation of the CuBTTri MOF. GSNO products other than NO were determined by probing for 
the presence of the H3BTTri (Figure 3.2b) precursor ligand which would indicate CuBTTri 
degradation. Secondly, in the case of the chitosan support system, degradation was probed by 




Figure 3.2 Compounds investigated using MS. (a) the production of GSSG from release of NO 
from GSSG. (b) H3BTTri ligand, building block from the CuBTTri MOF. (c) glucosamine and (d) 
N-acetylglucosamine, building blocks (monomers) form chitosan. 
  
3.4.1.1 Identification of GSNO decomposition products, chitosan degradation products and 
screening for H3BTTri ligand 
 
Upon exposure of GSNO to the chitosan-CuBTTri composite films, the GSNO was 
expected to be decomposed as NO was released as has been previously demonstrated8. As part of 
additional investigative studies, as shown in Figure 3.3, GSSG was accurately identified by ESI-
TOF MS as the [M+H]+ ion at 613.1598 m/z. Additionally, dehydrated glucosamine, glucosamine 
and dehydrated N-acetyl glucosamine were found as the [M+H]+ ions at 162.0767, 180.0868, and 
204.0875 m/z, respectively. These monomers should appear as hydrolytic degradation of the 
chitosan support system takes place over time. The last component of the investigative process 
was to probe for the potential decomposition of the CuBTTri MOF. To do so, in the mass 
spectrometric analyses, the ligand H3BTTri (C12H9N9) was searched for, which if present, would 
appear as the [M+H]+ ion at 280.1054 m/z. The absence of the H3BTTri ligand suggests no 




Figure 3.3 Mass spectrum of the investigative analysis of potential degradation of chitosan-
CuBTTri hybrid materials. Glucosamine and N-acetylglucosamine are a product of hydrolytic 
degradation of chitosan and GSSG was confirmed to be the product of NO release form GSNO 
when exposed to the hybrid materials. 
 
3.4.2 Cell viability studies 
 Both cell viability assays work by reduction of resazurin and MTT to their counterparts 
(resorufin and formazan) in the presence of metabolically active cells (Figure 3.1). Therefore, the 
relative conversion of resazurin and MTT to resorufin and formazan is directly correlated to the 
number of healthy cells1,23. While the exact mechanistic pathways for both assays are not entirely 
understood, it is suggested that resazurin is reduced either in chemically reduced media produced 
by cellular growth or enzymatic reduction within the mitochondria, while MTT reduction is likely 
to occur exclusively intracellularly by mitochondrial enzymes1,22–25.  
 After careful investigation, the resazurin assay was studied for potential interferences from 
glutathione, oxidized glutathione, D-penicillamine, and mercaptosuccinic acid (Figure 3.4). The 
selection included a primary thiol (glutathione), a secondary thiol (mercaptosuccinic acid), a 
tertiary thiol (D-penicillamine) and a disulfide (oxidized glutathione) that are also of biological 
relevance. In the case of the MTT assay, the potential interferences investigated were glutathione 
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(primary thiol), D-penicillamine (tertiary thiol), L-cysteine (primary thiol), mercaptosuccinic acid 
(secondary thiol) and N-acetyl-D-penicillamine (tertiary thiol).  
 
Figure 3.4 Selected compounds to probe for interference in the resazurin and MTT metabolic 
assays. (a) glutathione, (b) mercaptosuccinic acid, (c) N-acetyl-D-penicillamine, (d) D-
penicillamine, (e) L-cysteine, (f) oxidized glutathione. Resazurin was investigated for potential 
interferences from (a), (b), (d) and (f). MTT was investigated for potential interferences from (a), 
(b), (c), (d) and (e).   
 
 A typical spectroscopic assay performed with resazurin looks like that shown in Figure 3.5 
in which E. coli was incubated with resazurin. The trace in black corresponds to 0 h of cell 
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incubation where no reduction of resazurin to resorufin is expected as shown by the λmax at ~600 
nm which corresponds to resazurin. After 1 hour of incubation, and until the 4 hour incubation 
mark (colored traces), the spectroscopic results indicate the effective conversion of resazurin to 
resorufin expected from metabolically active cells since the λmax at ~570 nm corresponds to 
resorufin.  
 
Figure 3.5 Typical spectroscopic traces from the resazurin assay performed on E. coli cells by 
Bella H. Neufeld. The transformation of resazurin to resorufin is visible by the transition from 600 
nm (resazurin) to 570 nm (resorufin). 
 
 In Figure 3.6, a typical MTT assay in the presence of E. coli cells is shown. The trace in 
black corresponds to 0 h of the cell incubation process in the presence of MTT where no reduction 
of MTT to formazan was expected as shown by the λmax at ~380 nm which corresponds to MTT. 
After 1 hour of incubation, and until the 4-hour incubation mark (colored traces), the spectroscopic 
results indicate the effective conversion of MTT to formazan expected from metabolically active 




Figure 3.6 Typical spectroscopic results from the resazurin assay performed on E. coli cells by 
Bella H. Neufeld. The transformation of MTT to formazan is visible by the transition from 380 
nm (MTT) to 550 nm (formazan). 
 
 To study the interference effects of glutathione, mercaptosuccinic acid, D-penicillamine 
and oxidized glutathione on the resazurin assay, each interference was incubated for 4-hours in the 
absence of cells. In the case of glutathione, the spectroscopic results collected by Bella H. Neufeld 
suggested full conversion of resazurin to resorufin over the incubation period as indicated by the 
disappearance of the ~600 nm absorption band and the appearance of the ~570 nm absorption 
bands. The conversion of resazurin to resorufin in the absence of cells would indicate a false 
positive when the assay is performed in the presence of glutathione. To confirm that indeed 
resazurin was converted to resorufin, MS analysis was performed. As shown in Figure 3.7, after 
only 1 hour of incubation, resazurin appears to be largely converted to resorufin and by the time 
the incubation is complete (4 h), the majority of resazurin has been converted to resorufin. The 
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mass spectra collected confirms the spectroscopic results that glutathione induces conversion in 
the absence of cells and therefore a false positive.  
 
Figure 3.7 Mass spectra of the incubation of resazurin with glutathione in the absence of cells. As 
indicated by the black spectrum, conversion of resazurin began after 1 hour. By the 4-hour period, 
the resazurin appears to be mostly converted to resorufin. 
 
 The spectroscopic results collected by Bella H. Neufeld suggested that D-penicillamine 
also induces the conversion of resazurin to resorufin. Over the course of the incubation period, the 
~600 nm absorption band for resazurin disappeared and the ~570 nm band for resorufin bands 
were more prominent. After performing MS analysis (Figure 3.8) during the incubation process, 
D-penicillamine was only shown to induce a small amount of conversion to resorufin. This 
indicates that a small amount of resorufin may lead to a substantial false positive since 
spectroscopic measurements suggest full conversion of resazurin after the 4-hour incubation 
period. The mass spectra collected confirms the spectroscopic findings that D-penicillamine are a 





Figure 3.8 Mass spectra of the incubation of resazurin with D-penicillamine in the absence of 
cells. As indicated by all spectra, only a minor fraction of resazurin was converted to resorufin 
during the entire incubation process.  
 
 The third interference investigated was mercaptosuccinic acid. The collected spectroscopic 
data showed substantial suppression of both absorbances indicative of resazurin or resorufin. In 
this case it was difficult to label mercaptosuccinic acid as a false positive or negative since neither 
absorbance bands were present. However, the mass spectra collected (Figure 3.9) show that after 
the first hour of incubation the majority of resazurin had been converted to resorufin. The 
interference of mercaptosuccinic acid was not expected to be this severe since there was no 
absorbance band indicative of resorufin. In this case, if the assay is performed by only monitoring 




Figure 3.9 Mass spectra of the incubation of resazurin with mercaptosuccinic acid in the absence 
of cells. As indicated by the black spectrum, conversion of resazurin appears to be complete after 
1 hour.  
 
 The fourth interference investigated for the resazurin assay was oxidized glutathione or 
GSSG. The spectroscopic data collected by Bella H. Neufeld labeled GSSG’s interference as 
neither a false positive nor negative. GSSG produced inconclusive spectroscopic results because 
it appears to induce severe suppression from both resazurin and resorufin signals making it difficult 
to decide whether there are viable cells. This may not be considered an actual problem since the 
MS results (Figure 3.10) show that GSSG did not induce any conversion from resazurin to 
resorufin during the entirety of the study. However, when cells are being treated with, for example, 
S-nitrosated glutathione (GSNO), the byproduct of GSNO release is GSSG which may lead to 




Figure 3.10 Mass spectra of the incubation of resazurin with GSSG in the absence of cells. As 
indicated by all spectra, no conversion of resazurin to resorufin was observed.  
 
 To study the interference effects of glutathione, D-penicillamine, L-cysteine, 
mercaptosuccinic acid and N-acetyl-D-penicillamine on the MTT assay, each interference was 
incubated for 4-hours in the absence of cells. In the case of glutathione, D-penicillamine and L-
cysteine, the spectroscopic results collected by Bella H. Neufeld suggested that MTT had been 
converted to formazan since the absorption band at ~380 nm corresponding to MTT was no longer 
visible and the absorption band at ~550 nm corresponding to formazan was very prominent. It is 
possible that the features indicative of MTT were hidden under the absorbance features from 
formazan, and to test whether glutathione, D-penicillamine and L-cysteine were responsible for 
conversion of MTT to formazan, ESI-TOF MS was also performed. The MS results from 
interference studies by glutathione, D-penicillamine and L-cysteine are shown in Figures 3.11, 
3.12 and 3.13. As shown in Figure 3.11, it appears that incubation of MTT with glutathione induces 
conversion of MTT to formazan starting at hour 1 of incubation. The conversion appears to be 
mostly steady until hour 4 in which there appears to be a slight excess of formazan, but overall, 




Figure 3.11 Mass spectra of the incubation of MTT with glutathione in the absence of cells. As 
indicated by the black spectrum, conversion of MTT begins after 1 hour. 
 
 As shown in Figure 3.12, MTT appears to be fully converted to formazan after the first 
hour of incubation with D-penicillamine. This results directly confirm the spectroscopic results 
obtained by Bella H. Neufeld that show full conversion and this results strongly indicate that D-
penicillamine can be responsible for a false positive in the assay.  
 
Figure 3.12 Mass spectra of the incubation of MTT with D-penicillamine in the absence of cells. 
As indicated by the black spectrum, full conversion of MTT to formazan is evident after 1 hour.  
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 As shown in Figure 3.13, MTT appears to be fully converted to formazan after the first 
hour of incubation with L-cysteine. This MS results directly confirm the spectroscopic results 
obtained by Bella H. Neufeld that show full conversion of MTT to formazan and strongly indicates 
that L-cysteine can be responsible for a false positive in the assay.  
 
Figure 3.13 Mass spectra of the incubation of MTT with L-cysteine in the absence of cells. As 
indicated by the black spectrum, full conversion of MTT to formazan is evident after 1 hour. 
 
In the case of mercaptosuccinic acid and N-acetyl-D-penicillamine, the spectroscopic 
results obtained by Bella H. Neufeld suggested no conversion of MTT to formazan during the 
incubation period. To confirm the findings on whether mercaptosuccinic acid and N-acetyl-D-
penicillamine do not interfere and are not responsible for conversion of MTT to formazan, ESI-
TOF MS was also performed. The MS results from interference studies by mercaptosuccinic acid 
and N-acetyl-D-penicillamine are shown in Figures 3.14 and 3.15. As shown in Figure 3.14, it 
appears that incubation of MTT with mercaptosuccinic acid does not induce significant conversion 
of MTT to formazan. In this case, both spectroscopic and mass spectrometric analyses suggest that 




Figure 3.14 Mass spectra of the incubation of MTT with mercaptosuccinic acid in the absence of 
cells. Mercaptosuccinic acid does not induce significant conversion of MTT to formazan over the 
entire incubation period.  
 
 As shown in Figure 3.15, it also appears that the incubation of MTT with N-acetyl-D-
penicillamine does not induce significant conversion of MTT to formazan. Also in this case, both 
spectroscopic and mass spectrometric analyses suggest that N-acetyl-D-penicillamine will result 




Figure 3.15 Mass spectra of incubation of MTT with N-acetyl-D-penicillamine in the absence of 
cells. N-acetyl-D-penicillamine does not induce significant conversion of MTT to formazan over 
the entire incubation period. 
 
3.4 Conclusions 
 The collaborative efforts presented in this chapter show the importance and benefit of 
incorporating mass spectrometry to complex systems to identify reaction byproducts, potential 
degradation products and to further investigate inconclusive results provided by well-established 
analytical methods. In the case of the chitosan-MOF hybrid materials, the formation of GSSG from 
exposing GSNO to the hybrid materials was confirmed. Additionally, mass spectrometry was used 
to provide evidence that the MOF did not decompose over time during the use of the material and 
that any gravimetrically measured loss of material can primarily be attributed to degradation of the 
chitosan polymer support system. 
 Regarding the cell viability studies, the addition of mass spectrometric analyses strongly 
emphasized the importance of clearly identifying whether potentially selected therapeutics would 
lead to false positives/negatives in the absence of cells. This is of high importance because the 
resazurin and MTT assays are both widely used for in vitro studies aimed at making preliminary 
decisions regarding use of therapeutics. The results obtained suggest that without proper control 
studies, the data collected can lead to a significant number of false positives/negatives that 
minimize the reliability of the studies performed. Even when appropriate control studies are 
performed, the full UV-vis spectroscopic scans are not usually examined which may still lead to 
inconclusive results regarding potential interferences. This is particularly important for the cases 
in which the interference studied caused severe signal suppression that may lead to false negatives 
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MASS SPECTROMETRIC METHODS FOR ANALYSIS OF DEGRADATION PRODUCTS 
FROM POLYPHOSPHAZENE AND POLYESTER BIODEGRADABLE POLYMERS  
 
4.1 Background 
 The development of polymeric materials with the intended purpose of becoming 
biomedical devices is extensively studied in Prof. Melissa M. Reynolds research group. The bulk 
of the materials consist of a polymer that is biodegradable and is capable of release NO over time. 
Part of the characterization performed on said polymers is to assess their ability to release NO 
during extended periods of time, have the correct mechanical properties, and hold structural 
integrity over the life of the material. A crucial part of the characterization process is to determine 
what biodegradable polymers decompose into as they degrade. This is of high importance if the 
material developed can be used as a biomedical device because it must undergo biological 
evaluation, typically the International Standards ISO-10993 series. To identify the degradation 
products of biodegradable polymers, a tertiary S-nitrosothiol-based polyphosphazene and a series 
of polyester derived polymers were used. The underlying question was whether we could identify 
the degradation products of our polymer systems and specific to the polyester polymers, our main 
concern was to address whether the polymer systems would degrade into the individual monomers, 
with the potential of increasing localized acidity. Ideally, the smallest degradation products would 
be at least a dimer of the starting monomers, thereby reducing the risk of diacids lowering the local 
pH. With the use of MS, LC-MS and LC-MS/MS it was possible to identify the degradation 
products from each polymer, and for a selected set of polymers, structural identification was 
accomplished using LC-MS and LC-MS/MS. The MS work done for the polyphosphazene 
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polymer was originally published in ACS Applied Materials and Interfaces (Lutzke, A.; Tapia, J. 
B.; Neufeld, M. J.; Reynolds, M. M. Sustained Nitric Oxide Release from a Tertiary S-
Nitrosothiol-based Polyphosphazene Coating. ACS Appl. Mater. Interfaces 2017, 9(3), 2104–
2113) and has been reprinted with permission from the American Chemical Society (Copyright 
2017). Alec Lutzke synthesized the polyphosphazene polymers. Jesus B. Tapia performed all MS 
studies. The MS work done for the polyester polymers was published in the Journal of Materials 
Chemistry B (Yapor, J. P.; Neufeld, B. H.; Tapia, J. B.; Reynolds, M. M. Biodegradable 
crosslinked polyesters derived from thiomalic acid and S-nitrosothiol analogues for nitric oxide 
release. J. Mater. Chem. B 2018, 6 (24), 4071–4081) and has been adapted with permission from 
the Royal Society of Chemistry. Janet P. Yapor synthesized the polyester polymers and performed 
the initial polymer degradation studies. Jesus B. Tapia performed all MS studies. The MS, LC-MS 
and LC-MS/MS work performed on two selected polyester polymers was published in the Journal 
of Polymer Degradation and Stability (Tapia, J. B.; Haines, J.; Yapor, J. P.; Reynolds, M. M. 
Identification of the degradation products of a crosslinked polyester using LC-MS. Polym. Degrad. 
Stabil. 2019, 168, 108948) and has been adapted with permission from Elsevier. Janet P. Yapor 
provided the polymers for the subsequent degradation studies. Jason Haines performed the LC-
MS/MS studies. Jesus B. Tapia performed all MS and LC-MS studies. Prof. Melissa M. Reynolds 
acted as the advisor on this project.  
4.2 Introduction 
 The importance of the use of nitric oxide (NO) as a biotherapeutic agent is can be 
emphasized by its incorporation onto NO-releasing materials1–3. NO is a naturally-occurring 
molecule with physiological functions in the cardiovascular and immune systems4. Endogenously 
produced NO by endothelial cells regulates vascular tone and inhibits platelet adhesion and 
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aggregation5. NO is used by phagocytes as an antimicrobial agent during immune response6. 
Additionally, NO’s ability to exert antithrombic, wound healing, and broad-spectrum 
antimicrobial effects has led to the incorporation of NO onto polymeric substrates for biointerfacial 
applications7. The purpose of incorporating NO onto polymeric devices is primarily to have the 
device slowly release NO over time. This is important for devices that are meant to be 
thromboresistant, blood-contacting medical devices such as stents and catheters8. Biodegradable 
polymeric devices can also offer the benefits of NO-release in addition to their many application 
that include drug delivery, tissue engineering and wound dressings. These materials have been 
extensively studied for their hydrolytic degradation and potential to match application-oriented 
moduli2,9–12. After matching the desired moduli for the intended application of a device, the device 
must undergo biological evaluation before it is cleared for use. The most widely accepted standard 
for device evaluation is the ISO 10993 series (Biological Evaluation of Medical Devices). Part of 
the biological evaluation includes determination of the biodegradation products of the device, 
which falls under ISO 10993-9, “biological evaluation of medical devices – part 9: framework for 
identification and quantification of potential degradation products.” Identification of the 
degradation products can help determine potential side effects that could render a device as toxic 
either during or after its intended use. Addressing potential toxicity concerns falls under ISO 
10993-1, “biological evaluation of medical devices – part 1: evaluation and testing within a risk 
management process.” 
Current techniques used to determine the biodegradation of a device over time are 
gravimetric analysis, Fourier transform infrared spectroscopy (FT-IR), nuclear magnetic 
resonance spectroscopy (NMR), scanning electron microscopy (SEM), high-performance liquid 
chromatography (HPLC) and mass spectrometry (MS). For example, the degradation mechanism 
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of acrylate-derivatized poly(ethylene glycol) (PEGDA) hydrogels was determined by tracking the 
cleavage of networked groups that result in a reduced crosslink density over time. The changes in 
crosslink density were monitored by measuring the swelling ratio and/or modulus of the 
hydrogel13. Another example follows the oxidative degradation of poly(carbonate urethanes) 
(PCU) that was tracked using FT-IR by monitoring selected functional groups over time. 
Additionally, SEM was used to track surface damage of the PCUs over time14. A different study 
developed an HPLC method to track the degradation of implanted medical devices by determining 
acrylic monomers and degradation products15. The degradation of poly(5-hydroxy-trimethylene 
carbonate) in aqueous environment was monitored using 1H-NMR and the main degradation 
products were identified with electrospray ionization mass spectrometry (ESI-MS)16. The 
combination of these techniques facilitates exceptionally accurate determination of the 
biodegradation mechanism of polymeric devices, and as we show from the work performed, the 
combination of LC-MS and LC-MS/MS provide additional structural information regarding the 
complexity of the degradation process. 
To develop mass spectrometric methods to identify the degradation products of polymer 
devices intended for biomedical applications, four polymer systems and their nitrosated analogues 
were used (Figure 4.1). The polyphosphazene (POP) polymer POP-Gly-MMB, which contained a 
tertiary free thiol, was subsequently nitrosated to produce the S-nitrosated analogue POP-Gly-
MMB-NO. Additionally, the polyester polymers designed for implantable meshes composed of 
combinations of 1,8-octanediol, maleic acid, citric acid and thiomalic acid (Poly(thiomalic-co-
maleic acid-co-1,8-octanediol) or PTMO, poly(thiomalic-co-citric acid-co-1,8-octanediol) or 
PTCO and poly(thiomalic acid-co-1,8-octanediol or PTO), as well as the S-nitrosated analogues 
(PTMO-NO, PTCO-NO and PTO-NO) were used to investigate the degradation products as the 
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polymers are hydrolytically degraded. POP-Gly-MMB-NO was developed to evaluate its ability 
to release NO as a tertiary RSNO and the purpose of developing the polyester polymer systems 
was to mitigate limitations regarding mismatch of mechanical properties and adverse reactions that 
typically limit polymeric devices’ use as biomaterials.  
Figure 4.1 Polymer systems used to develop mass spectrometric methods to identify hydrolytic 
degradation products.  
 
 Herein we report mass spectrometric and liquid chromatography mass spectrometric 
methodology to separate and identify each component of the degradation of biodegradable POPs, 
polyesters and their nitrosated analogues, potential candidates for use in biomedical devices. This 
study sought to provide structural elucidation of each component found during the degradation of 
these polymers, which will aid in the deduction of the degradation mechanisms and for elucidation 
of potential toxicity concerns of a biomedical device. The goals for each polymer system were as 
follows: 
• POPs polymer system: determine the products formed due to hydrolytic degradation 
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• Polyester polymer systems: determine the products formed due to hydrolytic degradation 
for each system (PTO, PTCO, PTMO and their S-nitrosated analogues) 
• PTMO and PTMO-NO: expand upon the determination of products of hydrolytic 
degradation by developing LC-MS and LC-MS/MS methodology for structural elucidation 
4.3 Experimental 
4.3.1 Polyphosphazene Degradation 
4.3.1.1 Materials  
 LC-MS grade methanol and water were purchased from VWR (Solon, OH, USA). Media 
from POP-Gly-MMB and POP-Gly-MMB-NO were provided by Alec Lutzke. A Millipore Direct-
Q water purification system was used to produce 18.2 MΩ water for the polymer degradation 
studies (MilliporeSigma). All degradation experiments were performed in Millipore water instead 
of using the PBS buffer system due to phosphate buffers detrimental effects on mass spectrometric 
detectors, leading to severe ion suppression and unreliable analyses.  
4.3.1.2 Mass Spectrometry Methods 
Degradation of POP-Gly-MMB and POP-Gly-MMB-NO 
 To identify the potential hydrolytic degradation products from POP-Gly-MMB and POP-
Gly-MMB-NO, samples from each polymer were hydrolyzed in Millipore water at 37 °C under 
ambient atmosphere for 2 weeks. The media were subsequently analyzed by time-of-flight (TOF) 
mass spectrometry (TOF-MS). All mass spectrometric analyses were performed on an Agilent 
6224 TOF LC/MS. The instrument was equipped with an Agilent multimode ionization (MMI) 
source capable of electrospray ionization (ESI) and atmospheric pressure chemical ionization 
(APCI). For all experiments, mixed-mode ionization in both positive and negative polarity was 
employed with the mass range set to 70–3200 m/z. The sample solutions were introduced by flow 
89 
 
injection at a flow rate of 0.200 mL/min via the ESI nebulizer using methanol as the mobile phase. 
The MS conditions were as follows: capillary voltage, 2500 V; fragmentor voltage, 120 V; 
skimmer voltage, 60 V; charging voltage, 2000 V; drying gas (N2) flow rate, 10 l/min; drying gas 
temperature 310 °C; and nebulizer pressure, 45 psi. All data were processed using Agilent 
MassHunter Qualitative Analysis B.07.00. 
4.3.2 Biodegradable Polyester Degradation 
4.3.2.1 Materials 
 LC-MS grade methanol and water were purchased from VWR (Solon, OH, USA). The 
polymer films PTO, PTMO, PTCO and their nitrosated analogues PTO-NO, PTMO-NO and 
PTCO-NO were provided by Janet P. Yapor2. Ammonium acetate (≥98%) was obtained from 
MilliporeSigma (St. Louis, MO, USA). A Millipore Direct-Q water purification system was used 
to produce 18.2 MΩ water for the polymer degradation studies (MilliporeSigma). All 
degradation experiments were performed in Millipore water instead of using the PBS buffer 
system due to phosphate buffers detrimental effects on mass spectrometric detectors, leading to 
severe ion suppression and unreliable analyses. 
4.3.2.2 Methods 
Degradation of PTO, PTMO, PTCO and their S-nitrosated analogues 
 The hydrolytic degradation potential of the polymers was assessed by immersing samples 
(n=3) of PTO, PTO-NO, PTCO, PTCO-NO, PTMO, and PTMO-NO in Millipore water at 37 °C 
in the absence of light for up to 6 weeks. Samples were collected every 7 days (n=3), washed with 
Millipore water, and lyophilized for 24 h. Since the samples were incubated longer than 1 week, 
the water was replaced at the end of each week.  
Degradation of PTMO and PTMO-NO for LC-MS and LC-MS/MS 
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Three 100-mg samples from each polymer were incubated in 10-mL Millipore water at 37 
°C for up to 10 weeks. Samples were collected during weeks 1, 3, 6 and 10 (100 µL, n = 3) and 
immediately analyzed using direct flow injection mass spectrometry to complete a 10-week study. 
After direct flow injection MS analysis, the samples were stored at -20 °C for LC-MS and LC-
MS/MS analysis. 
Chromatographic and Mass Spectrometric Methods 
The products from the polymer degradation studies were identified using an Agilent 6224 
TOF LC/MS. The instrument was equipped with a dual electrospray ion (dual ESI) source. For the 
experiments, ionization was performed in negative polarity. The sample solutions were introduced 
to the ion source by direct flow injection using an Agilent 1260 Infinity at a flow rate of 0.200 
mL/min via the ESI nebulizer with methanol as the mobile phase. The mass spectrometer 
conditions were as follows: 4000 V capillary voltage, 120 V fragmentor voltage, 60 V skimmer 
voltage, 310 °C drying gas (N2) temperature, 10 l/min drying gas flow rate, and 25 psi nebulizer 
pressure. All data were processed with Agilent MassHunter Qualitative Analysis B.07.00.  
 The LC-MS analyses were performed on the Agilent 6224 TOF LC/MS with use of the 
Agilent 1260 Infinity chromatograph for chromatographic separations. A Zorbax SB-C18, (150  
4.6, 3.5 μm, Agilent) rapid resolution column, kept at 40 °C was used for all chromatographic 
separations. The mobile phase was composed of water with 10 mM ammonium acetate designated 
as solvent A, and methanol with 10 mM ammonium acetate designated as solvent B. A linear 
gradient was used from 15% to 100% B from 0 to 30 min, kept isocratic at 100% B from 30 to 40 
min, and returned to 15% B using a linear gradient from 40 to 50 min at 0.250 mL/min. Since a 
gradient was utilized, to re-equilibrate the column to the starting conditions, approximately 10 
column volumes were used at the end of each run.  
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 The LC-MS/MS analyses were performed on a Bruker maXis UHT-QTOF MS (Bellirica, 
MA, USA) coupled with a Waters ACQUITY-H UPLC (Milford, MA, USA). The instrument was 
equipped with an electrospray ion source. For the LC-MS/MS experiments, the mass spectrometer 
settings were as follows: 2400 V capillary voltage, 500 V end plate offset, 300 °C drying gas (N2) 
temperature, 10 l/min drying gas flow rate, and 3.0 bar nebulizer pressure. All fragmentations were 
performed with a collision energy of 35 eV. 
 Data analysis for MS only and LC-MS analyses were reported from a minimum of triplicate 
measurements, unless otherwise noted, and all data were analyzed with Agilent MassHunter 
Qualitative Analysis B.07.00. Data for LC-MS/MS analyses were reported from a single run for a 
PTMO sample and a single run for PTMO-NO sample. All data were analyzed with Bruker 
Compass DataAnalysis 4.4.  
4.4 Results 
4.4.1 Mass Spectrometric Identification of Degradation Products 
4.4.1.1 Method to Identify the Degradation Products of the POPs Polymers: 
 The first step for the development the MS method for analysis of POPs degradation 
products was to look at the synthetic procedure followed to synthesize the polymers. From the 
synthetic procedure, the identified building blocks for the polymer were a poly(phosphazene) 
backbone, glycine, and 3-mercapto-3-methylbutanol. Glycine (Figure 4.4) can be ionized in either 
positive mode (-NH2 moiety) or negative mode (-COOH), with positive mode as the preferred 
polarity for ionization. 3-mercapto-3-methylbutanol (Figure 4.4) is more likely to be ionized in 
negative mode due to the potential to deprotonate the thiol group. Knowledge of the synthetic 
building blocks and their potential polarity of ionization led to analyzing the samples twice: first 
in positive mode and then in negative mode as will be shown in the next sections.  The parameters 
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presented in section 4.2.1 were determined using recommendations from CSU’s central instrument 
facility and recommendations when methanol is the mobile phase17.  
4.4.1.2 Degradation and Direct Injection MS analysis of POPs polymers.   
 The general synthetic procedures for the POP-Gly-MMB-NO polymer have been reported 
previously3 and are shown in Figure 4.2.  
 
Figure 4.2 Synthesis of POP-Gly-MMB-NO 
 Based on the connectivity between glycine, 3-mercapto-3-methylbutanol, and the 
poly(phosphazene) backbone, we suspected to find glycine (Gly), 3-mercapto-3-methylbutanol 
(MMB), the combination of the two (Gly-MMB) and during the NO-release from the S-nitrosated 




Figure 4.3 Hydrolytic degradation and disulfide bond formation. (a) possible degradation products 
of hydrolytic degradation. (b) disulfide bond formation after release of NO. 
 
Based on the predicted degradation products, glycine, Gly-MMB and Gly-MMB disulfide were 
more likely to be successfully ionized in positive mode, while MMB and MMB disulfide were 
more likely to be ionized successfully in negative mode. Therefore, the solutions provided by Alec 
were ran twice, in positive and negative mode.  
 
Figure 4.4 Potential degradation products from POP-Gly-MMB and POP-Gly-MMB-NO  
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 The primary identifiable degradation products common to both POP-Gly-MMB and POP-
Gly-MMB-NO were glycine, MMB and the Gly-MMB dimer. This is consistent with the 
anticipated degradation of the amine-substituted POPs polymer backbone. In Figure 4.5, glycine 
is shown at m/z 76.0398 and Gly-MMB is shown at m/z 178.0889. Both ions are consistent with 
the masses of glycine and Gly-MMB forming as [M+H]+ ions. To find MMB, ionization was 
performed in negative mode as shown in Figure 4.6. Based on the structure of MMB, ionization in 
positive mode was unlikely due to the lack of basic sites. However, both the free thiol and alcohol 
would allow for removal of a proton leading to the ion at m/z 119.0543 which corresponds to MMB 
as [M-H]- ion.  
 
Figure 4.5 Positive ionization of degradation products from POP-Gly-MMB. Glycine and Gly-
MMB were found at m/z 76 and 178 respectively.  
 
 In the case of the S-nitrosated POP-Gly-MMB-NO, the ions corresponding to glycine, 
MMB and gly-MMB were found, with the addition of the ions that correspond to 3-[(4-hydroxy-
2-methylbutan-2-yl)disulfanyl]-3-methylbut-1-yl glycinate (C12H25NO3S2) and 3-[(4-glycyloxy-
2-methylbutan-2-yl)disulfanyl]-3-methylbut-1-yl 2-hydroxyacetate (C14H27NO5S2). Both 
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molecules are likely to represent disulfide-bond degradation products that formed during the 
decomposition of the POP-Gly-MMB-NO S-nitrosothiol (Figure 4.7).  
 
Figure 4.6 Negative ionization of degradation products from POP-Gly-MMB. 3-mercapto-3-
methylbutanol was found at m/z 119. 
 
 
Figure 4.7 Positive ionization of degradation products from POP-Gly-MMN-NO. The ions found 
at m/z 296 and 354 were found only as products from the S-nitrosated polymer.  
 
 Mass spectrometric analysis of the degradation products from POP-Gly-MMB and POP-
Gly-MMB-NO allowed for the development of a preliminary analytical model that aids in the 
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appropriate screening of biodegradable polymer degradation products. This analytical model 
paved the way to develop mass spectrometric methods to identify the degradation products from 
PTO, PTCO, PTMO and their S-nitrosated analogues.  
4.4.1.3 Method to Measure the Degradation Products of Polyesters 
 Similar to the development of mass spectrometric methods for analysis of degradation 
products of the POPs polymers, the first step was to examine the synthetic procedure for each of 
the polyesters to be studied. The building blocks for the polymers were a combination of thiomalic 
acid, maleic acid, citric acid and 1,8-octanediol. For all cases, it was determined that ionization in 
negative mode would be most appropriate due to the -COOH moieties present in thiomalic, maleic 
and citric acid and the -OH moieties in 1,8-octanediol. As will be shown for each polymer system, 
ionization in negative polarity was appropriate to identify each degradation product.  
4.4.1.4 Degradation and Direct Injection MS Analysis of Polyester Polymers 
The synthesis of poly(thiomalic acid-co-1,8-octanediol) or PTO and the S-nitrosated 
analogue is shown in Figure 4.8. Based on the polycondensation reaction and S-nitrosation, the 




Figure 4.8 Synthesis of PTO and PTO-NO. (I) Polycondensation to synthesize PTO. (II) S-
nitrosation of PTO.   
 
 As shown in Figure 4.8, PTO was prepared via melt-phase polycondensation using 
thiomalic acid and 1,8-octanediol. The polycondensation took place at 140 °C for 17 h under 
nitrogen to obtain a viscous polymer. To reduce the amount of disulfide bonds formed during the 
polycondensation reaction, the crude polymer was dissolved in ethyl ether anhydrous and treated 
with DL-dithiothreitol (DTT) and triethyl amine (TEA). S-nitrosation was subsequently performed 
by stirring PTO in ethanol with tert-butyl nitrite (t-BuONO) to make PTO-NO. The degradation 
product from PTO is shown in Figure 4.9 in which the major product identified is a dimer of 




Figure 4.9 Degradation product from PTO. The dimer corresponds to the combination of the 
starting monomers thiomalic acid and 1,8-octanediol. 
 
The degradation products from PTO-NO are shown in Figure 4.10. The same dimer shown 
in Figure 4.9 was found as well as the ions m/z 391 and 521 also shown in Figure 4.10. The 
structures shown in Figure 4.10 were products only found from degradation of the nitrosated PTO 
polymer.  
 




The synthesis of poly(thiomalic-co-citric acid-co-1,8-octanediol) or PTCO and the S-
nitrosated analogue is shown in Figure 4.11. Based on the polycondensation reaction and S-
nitrosation, the monomers were initially predicted to be found during the degradation process 
(Figure 4.11).  
 
Figure 4.11 Synthesis of PTCO and PTCO-NO. (I) Polycondensation to synthesize PTCO. (II) S-
nitrosation of PTCO. 
 
As shown in Figure 4.11, PTCO also was prepared via melt-phase polycondensation using 
thiomalic acid, citric acid, and 1,8-octanediol. The polycondensation took place at 140 °C for 1 h 
under nitrogen to obtain a viscous polymer. To reduce the amount of disulfide bonds formed during 
the polycondensation reaction, the crude polymer was dissolved in absolute ethanol and treated 
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with DTT and TEA. S-nitrosation was subsequently performed by stirring PTCO in ethanol with 
t-BuONO to make PTCO-NO. The resulting mass spectrum for PTCO is shown in Figure 4.12 and 
the structural candidates are shown in Figure 4.13.  
 
Figure 4.12 Mass spectrum from the degradation of PTCO.  
 As shown in Figure 4.12, more ions were found from PTCO than from PTO and PTO-NO. 
This can be attributed to the addition of citric acid to the starting maleic acid and 1,8-octanediol 
monomers for the polycondensation reaction. All the potential degradation products are shown in 
Figure 4.13 where thiomalic acid was the only monomer found and the majority of the remaining 




Figure 4.13 Potential structures for the ions found during the degradation of PTCO.  
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The resulting mass spectrum for PTCO-NO is shown in Figure 4.14 and the structural 
candidates are the same as m/z 149, 243, 277 and 319.  
 
Figure 4.14 Mass spectrum of the degradation products from PTCO-NO.  
The synthesis of poly(thiomalic-co-maleic acid-co-1,8-octanediol) or PTMO and the S-
nitrosated analogue is shown in Figure 4.15. Based on the polycondensation reaction and S-
nitrosation, the monomers were initially predicted to be found during the degradation process 




Figure 4.15 Synthesis of PTMO and PTMO-NO. (I) Polycondensation to synthesize PTMO. (II) 
S-nitrosation of PTMO. 
 
As shown in Figure 4.15, PTMO also was prepared via melt-phase polycondensation using 
thiomalic acid, maleic acid, and 1,8-octanediol. The polycondensation took place at 140 °C for 38 
min under nitrogen to obtain a viscous polymer. To reduce the amount of disulfide bonds formed 
during the polycondensation reaction, the crude polymer was dissolved in absolute ethanol and 
treated with DTT and TEA. S-nitrosation was subsequently performed by stirring PTMO in ethanol 
with t-BuONO to make PTMO-NO. The collected mass spectrum from the degradation products 




Figure 4.16 Mass spectrum of the degradation products from PTMO. 
 The candidate structures of the degradation products from PTMO are shown in Figure 4.17. 
The ions m/z 243 and 277 are the dimers composed of maleic acid – 1,8-octanediol and thiomalic 
acid – 1,8-octanediol. The ions m/z 393 and 521 were later identified as the four major structures 




Figure 4.17 Potential structures of the degradation products from PTMO.  
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 The degradation products from PTMO-NO are shown in the mass spectrum in Figure 4.18. 
As shown in the mass spectrum, the same ions found from PTMO were also found in PTMO-NO 
with the exception of m/z 277.  
 
Figure 4.18 Mass spectrum of the degradation products from PTMO-NO.  
 
 The degradation products were expected due to the connectivity between the monomers 
used for each polycondensation reaction. Based on the ions shown in each Figure showing the 
degradation products, the m/z ions remained questionable. After J. Pamela Yapor determined 
PTMO and PTMO-NO to be the best candidate for use as a biodegradable polymer with the 
desirable properties for potential biological applications, the next step was to include a 
chromatographic separation to further isolate the components from degradation and perform 
fragmentation studies (LC-MS and LC-MS/MS) to obtain accurate structural information. 
4.4.2 Liquid Chromatography-Mass Spectrometric Analysis 
 Following the recommendation from J. Pamela Yapor, PTMO and PTMO-NO were 
selected for further studies. PTMO and PTMO-NO demonstrated the most efficient hydrolytic 
degradation of the three sets of polymers which may be of interest for development of 
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biodegradable devices. A new set of PTMO and PTMO-NO were provided by J. Pamela Yapor to 
perform a 10-week study of the hydrolytic degradation products. As shown in Figure 4.19 and 
Figure 4.20, both PTMO and PTMO-NO degraded into the same three ions (m/z 243, 393, 521) 
during the 10-week period. As described previously (Figure 4.17), only the maleic acid-1,8-
octanediol dimer was successfully identified. However, it was still hypothesized that the 
unidentified ions were a combination of the starting monomers from the synthetic procedure.  
 
Figure 4.19 Mass spectrum of PTMO products during the degradation process. All three ions 





Figure 4.20 Mass spectrum of PTMO-NO products during the degradation process. All three 
ions continued to be present during the 10-week period. 
 
 The initial target was to isolate the three major ions found during the degradation process. 
To do so, a series of chromatographic separations were performed using a Zorbax SB-C18, 4.6  
150 mm, 3.5-micron rapid resolution column using the collected media from PTMO and PTMO-
NO degradation that eventually led to the method established in section 4.2. The main challenge 
that had to be addressed was not having a complete knowledge of each individual degradation 
product’s structure. This led to multiple sample injections keeping the chromatography isocratic 
at different solvent compositions that ranged from 90:10 aqueous/organic to 0:100 
aqueous/organic with 10% changes in solvent composition. Contrary to the initially expected three 
major ions (Figures 4.19 and 4.20), the 10 chromatographic analyses at each solvent composition 
revealed the presence of components not previously detected by flow injection MS only, and the 
presence of structural isomers (Figure 4.21). With these series of isocratic chromatographic 




Figure 4.21 Representative chromatogram from PTMO-NO degradation products.  
 
After the initial MS screenings (Figures 4.19, 4.20), the optimized LC-MS method 
described in the methodology section allowed for separation (Figure 4.21) and identification of 7 
major chromatographic peaks. From each chromatogram, the mass spectrometric data was 
extracted to identify the ions found under each peak. The peak at 5.07 min corresponds to the ion 
m/z 265, the broad peak at 12.39 min and the peak at 15.85 min correspond to identical ions m/z 
393, the peak at 24.67 min corresponds to the ion m/z 243 and the peaks at 26.59 and 28.08 min 
correspond to identical ions m/z 521. Triplicates for weeks 1, 3, 6 and 10 for PTMO-NO are found 
in Appendix A1.  
4.4.3 LC-MS/MS Structural Elucidation of Degradation Products 
 Following the chromatographic separation of each peak, fragmentation data was obtained 
using the LC-MS/MS method described in the methodology section, in combination with the use 
of the program CFM-ID18 to determine the structure of each identified peak (Figure 4.21). Based 
on the starting monomers and polymerization reaction (Figure 4.15), the ion found at 5.07 min 
(m/z 265) corresponds to the structure shown in Figure 4.22a, matching the formula C8H10O8S as 
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[M-H]-. The structure is feasible based on the expected connectivity of the monomers after the 
polymerization reaction and is confirmed by LC-MS/MS (Figure A1.5). The peak at 6.26 min 
corresponds to the sodium acetate + acetate ions clusters that arise from the ammonium acetate 
mobile phase (Figure A1.6) used during the LC-MS analyses. 
The ions found at 12.39 and 15.85 min (m/z 393) correspond to the structures shown in 
Figure 4.22b-c, matching the formula C16H26O9S as [M-H]-. These ions were of interest due to 
suspected structural isomerism from the MS only data and the presence of two peaks with the same 
m/z during the LC-MS analyses. The structure of each isomer was identified by LC-MS/MS as 
shown in Figures A1.7 and A1.8. The ion found at 24.67 min corresponds to the structure shown 
in Figure 4.22d and Figure A1.9 matching the formula C12H20O5 as [M-H]-. The formula and 
structure of this ion was previously identified to be the combination of 1,8-octanediol and maleic 
acid2. 
Lastly, the ions found at 26.59 and 28.08 min correspond to the structures shown in Figure 
4.22e-f, matching the formula C24H42O10S as [M-H]-. These ions were also of high interest due to 
the suspected structural isomerism from the MS only data and the presence of two peaks with the 
same m/z during the LC-MS analyses. The structure of each isomer was identified by LC-MS/MS 




Figure 4.22 Structures of each component found during the degradation process.  
 
Previous studies utilizing matrix-assisted laser desorption ionization (MALDI-MS) and 
ESI-MS have illustrated that PLGA polymer degradation occurs via hydrolytic degradation, 
providing additional support for our structural assignments19–22. The compound that corresponds 
to the ion m/z 243 (Figure 4.22d) was a compound specifically expected to be released during 
degradation due to the melt-phase polycondensation using thiomalic acid, 1,8-octanediol and 
maleic acid. The polycondensation took place at 140 °C for 38 min under nitrogen to obtain a 
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viscous polymer allowing for disulfide bond formation. To reduce the amount of disulfide bond 
formation, the polymer was dissolved in absolute ethanol by sonication and treated with DL-
dithiothreitol and triethylamine2. Interestingly, the degradation process showed sulfide bridges that 
resemble thioethers (Figure 4.17 a-c, e-f). The thioether bonds are likely due to a thermally induced 
thiol-ene click reaction between the thiomalic acid and maleic acid units during the 
polycondensation that would not be removed by treating with DL-dithiothreitol23. A second source 
of thioether bond formation is likely to occur during the release of the nitric oxide moiety in the 
nitrosated PTMO. It has been previously reported that NO-release from S-nitrosothiols (RSNOs) 
such as S-nitrosated glutathione (GSNO) can lead to the formation of glutathione disulfide 
(GSSG)24. Additionally, the degradation of a tertiary S-nitrosothiol-based polyphosphazene 
polymer released disulfide degradation products during the hydrolytic degradation3. Specific to 
our PTMO-NO, nitrosation of the polymer takes place on the free thiol from the thiomalic acid 
monomer unit (Figure 4.15). As PTMO-NO is degraded thermally over time, the NO is released 
leaving behind a sulfur radical (RS•) that undergoes a thiol-ene click reaction between the RS• 
group and the double bond on the maleic acid units to form the thioether bonds rather than disulfide 
bridges25. 
4.5 Conclusions 
The work presented here shows the importance of incorporating LC-MS and LC-MS/MS 
to aid in the identification of the degradation products from a device to be used for biomedical 
applications. Initially, we found direct injection MS helpful for preliminary identification of 
degradation products. The identification of the degradation products from the POPs polymers was 
done successfully and they matched some of the predicted results. Regarding the polyester 
polymers, our results both confirm the expected hydrolytic degradation19–22 and also illustrate 
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thioether bridge formation in lieu of commonly-seen disulfide bonds that result when NO is 
released from RSNOs. Additionally, the use of both LC-MS and LC-MS/MS facilitate the 
characterization of structural isomers and their corresponding structures. The identification of all 
the degradation products as esters (dimers and beyond) rather than the starting monomers was 
encouraging. The absence of the diacid monomers citric acid, maleic acid and thiomalic acid 
suggests a small impact in the localized acidity as the biopolymers degrade and further encourages 
the use of these polyesters for biomedical applications.  
 Our LC-MS methodology should serve as an example for elucidating the components of a 
device intended for biomedical applications. With our method, it is possible to track the 
degradation products of the device as it degrades over the entirety of the biodegradation study. 
With appropriate internal standards, as part of a future study, this methodology can be used to 
quantify each degradation product. 
 While there is currently no indication that the molecules identified are toxic, this work 
highlights the use of LC-MS and LC-MS/MS for degradation analysis to separate, elucidate and 
potentially quantify the degradation products of biomedically relevant polymers that can be used 
as devices. This opens the door for future studies regarding the toxicity of this compounds, 
complementing the implementation of the standards ISO 10993-1 and ISO 10993-9 when 
performing biological evaluation of medical devices as they will continue to be developed for the 
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 Practical applications of MOFs continue to expand as new MOFs are developed with 
desired properties. While most of the literature focused on the gas sorportion and catalytic 
properties of MOFs, new interest has emerged as for their use as stationary phases in 
chromatographic separations. The resulting properties of a particular MOF is partially reliant on 
the type of ligands and metals used to construct the secondary building unit (SBU).  In particular, 
chiral ligands can be synthesized resulting in MOFs with chiral behavior. In an international 
collaborative effort, a copper based, chiral MOF was used to pack an empty HPLC column and 
perform chiral chromatography. The goal of this project was to develop a system that performs 
similarly and/or exceeds the chromatographic efficiency of current commercial chiral columns. 
The primary objective was to efficiently pack an empty HPLC column with a MOF as a chiral 
stationary phase and test for chiral resolution capabilities. Exploring a chiral stationary phase based 
on a MOF system was a viable route since the pharmaceutical field has yet to find a way to fully 
and efficiently resolve the separation of enantiomeric drugs. In this process, the research question 
asked was:  Could a water-stable MOF be employed as a stationary phase for the separation of 
enantiomeric compounds? This project involved developing a process for packing columns using 
MOFs as a stationary phase material and developing the mobile phase gradients to achieve baseline 
resolved separation of chiral mixtures.  The majority of the work involved our efforts to match or 
improve upon chiral resolution from commercially available chiral columns (as we present in this 
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chapter). Prof. Jose Ramon Galán-Mascarós’ group developed, synthesized and provided the chiral 
MOF. Heather N. Rubin performed the initial packing of the HPLC column. Jesus B. Tapia 
developed the methodology used and collected all chromatographic data and performed all the 
additional packings necessary for acceptable column performance. The work presented in this 
chapter was originally published in the Journal of the American Chemical Society (Corella-Ochoa, 
M. N.; Tapia, J. B.; Rubin, H. N.; Lillo, V.; Gonzalez-Cobos, J.; Núñez Rico, J. L.; Balestra, S. R. 
G.; Almora-Barrios, N.; Lledos, M.; Guell-Bara, A.; Cabezas-Giménez, J.; Escudero-Adán, E. C.; 
Vidal-Ferran, A.; Calero, S.; Reynolds, M. M.; Marti-Gastaldo, C.; Galan-Mascaros, J. R. 
Homochiral metal-organic frameworks for enantioselective separations in liquid chromatography. 
JACS. 2019, 141 (36), 14306–14316). The work was adapted with permission from the American 
Chemical Society (Copyright 2019). Prof. Melissa Reynolds acted as the advisor on this project.   
5.2 Introduction 
Perhaps the most remarkable example of the need of efficient chiral resolution is the drug 
thalidomide. As Allen states, “no other drug has a name that evokes such emotions as that of 
thalidomide”, because its infamous and unexpected teratogenicity is the main reason for the current 
stringent regulations concerning drug development and use1. Thalidomide, first synthesized in 
1954 by the CIBA pharmaceutical company, and prescribed as a sedative, tranquilizer and 
antiemetic for morning sickness, quickly became popular due to its effectiveness and lack of acute 
toxicity1,2. Several years after the negative effects of thalidomide were determined, Blaschke and 
colleagues3 reported that only the S-enantiomer of the drug is teratogenic. The discovery of 
enantiomer-specific toxicity emphasizes the importance of chiral chromatography to quickly, 
efficiently and reproducibly isolate enantiomers during drug synthesis processes. Despite the high 
importance and need of chiral separations for the pharmaceutical industry, chiral resolution 
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remains an expensive, time consuming and complex scientific challenge. To address the current 
challenges in chiral chromatographic resolution, metal-organic frameworks are becoming 
compounds of interest for chiral chromatography.  
Metal-organic frameworks (MOFs) are defined by IUPAC as “coordination networks with 
organic ligands containing potential voids”4. MOFs are crystalline materials prepared by the 
combination of metal ions with customizable ligands to construct porous structures. The multitude 
of metal ions and organic linkers that can be used to prepare MOFs offers high flexibility to 
synthesize tailor-made MOFs. Due to their high customizability, MOFs have been presented as 
excellent candidates for gas storage5, catalysis6 and drug delivery7.  
 The ability to design MOFs with customizable metal ions and ligands allows for the 
development of MOFs with highly specific and unique pore size, shape and chemical functions. 
This has led to the design of MOFs for efficient and selective separation of gases, hydrocarbons 
or aromatic compounds8. Additionally, their potential as gas storage, led to their application as 
potential carriers of therapeutic gases such as NO9,10. Additionally, copper-based MOFs have been 
studied for their use as catalysts for the release of NO from RSNOs in physiological conditions11. 
 The ability to design MOFs with specific properties, allowed for the development of MOFs 
containing chiral linkers. The use of MOFs with highly specialized properties for the separation of 
gases and hydrocarbons led to studies in which MOFs were developed with enenatiopure linkers. 
The design of chiral MOFs is gaining high interest for the development of new chiral stationary 
phases (CSPs) capable of separating chiral compounds12. Examples of chiral MOFs from 
enantiopure organic linkers such as camphoric acid, tartaric acid, amino acids, or oligopeptides 
have been previously reported for their use for chiral separation13,14. Unfortunately, small 
molecules such as camphoric acid and tartaric acid can limit the porosity of the resulting 
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frameworks, which can restrict the size and concentration of analyte concentrations13. 
Oligopeptides may be better designs for enantiomeric recognition since they can offer higher 
surface areas and tunable enantiomeric recognition by appropriate choice of the peptide 
sequence15,16. Oligopeptides based chiral MOFs however, suffer from difficulties in large scale, 
affordable production of enantiopure MOFs, and decreased stability with multiple solvent systems 
and increase pressure required for chromatography17.    
 To address the challenges of using MOFs as CSPs, Prof. Galán-Mascarós’ group 
synthetically modified amino acids rather than oligopeptides. Oligopeptides are more expensive 
to synthesize and display low chemical stability and poor robustness that can result in loss of 
structural integrity, usually uncontrolled collapse of the structure upon solvent removal17. Their 
approach was to use inexpensive, readily accessible, tunable amino acids that can be modified at 
the C/N-positions. Based on previously reported strategies18, the N-term was transformed into a 
4H-1,2,4-triazole motif. The transformation led to the synthesis of the ligand (S)-3-(1H-imidazol-
5-yl)-2-(4H-1,2,4-triazol-4-yl)propanoic acid (S-HTA) derived from L-histidine (Figure 5.1). 
 
Figure 5.1 Structure of the S-HTA ligand.  
  The S-HTA ligand was reacted with a copper salt in water to produce the crystalline 
framework TAMOF-1 (triazole acid metal-organic framework). TAMOF-1 was sent to Prof. 
Reynolds’ group as an enantiopure MOF with permanent porosity, ca. 1200 m2 g-1, with good 
stability in water and organic solvents to test for its chiral resolution capabilities. To do so, 
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TAMOF-1 was successfully packed into HPLC columns to test chiral resolution of multiple chiral 
compounds. The versatility of the columns was shown by the successful resolution of trans-2,3-
diphenyloxirane (or trans-stilbene oxide), a compound used for calibration of commercial chiral 
HPLC columns, in multiple solvent systems.  
5.3 Experimental 
5.3.1 Materials 
 All reagents were of commercial grade and used without further purification. HPLC-grade 
methanol, ethanol, isopropanol, hexanes and acetonitrile were obtained from VWR (Solon, OH, 
USA). trans-2,3-diphenyloxirane (98%), furoin (≥98%), benzoin (98%,), 1-phenylethan-1-ol 
(98%) were obtained from Sigma-Aldrich (St. Louis, MO, USA). A stainless-steel empty HPLC 
column (100 × 4.6 mm) was obtained from Restek (Bellefonte, PA, USA). TAMOF-1 was 
obtained from Prof. Jose Ramon Galán-Mascarós at the Institute of Chemical Research of 
Catalonia (ICIQ), The Barcelona Institute of Science and Technology (BIST).  
5.3.2 Methods 
5.3.2.1 Column Packing 
 To pack the empty HPLC column (100 mm × 4.6 mm I.D.) with TAMOF-1, 737 mg were 
initially added via dry packing and the column was pressurized using 100% acetonitrile at a high 
flow rate (approx. 10 mL/min, approx. 1450 psi). After 10 h pressurization with acetonitrile, the 
column was opened and an additional amount of TAMOF-1 had to be added (due to packing of the 
material) and the eluent changed to 100% isopropanol (higher viscosity). This process of adding 
TAMOF-1 and packing was repeated until a total of 1550 mg were added to the column (fully 
packed). After the column was fully packed, it was pressurized with 100% isopropanol at a high 
moderate flow rate (2 mL/min, approx. 5000 psi) for 12 h to further ensure TAMOF-1 was indeed 
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fully packed and the column did not require any additional MOF. Before any data collection, the 
column was conditioned with the appropriate solvent system at a flow rate of 0.15 mL/min for 3 h 
before chromatographic experiments (approximately 15 column volumes).  
5.3.2.2 Calculation of the chromatographic parameters 
 The selected parameters to asses separation efficiency of the selected enantiomers were the 
retention factor (k), separation factor (α), and resolution (RS). These parameters were calculated 
using the following equations:  𝑘 = 𝑡𝑅1−𝑡𝑀𝑡𝑀                                                      (eq. 1) 𝛼 = 𝑡𝑅2−𝑡𝑀𝑡𝑅1−𝑡𝑀                                            (eq. 2) 𝑅𝑆 = 2(𝑡𝑅2−𝑡𝑅1)𝑤1+𝑤2                                 (eq. 3) 
where tM is the column void volume, tR1 and tR2 are the retention times for peaks 1 and 2 and w1 
and w2 are the peak widths of each peak.  
5.3.2.3 HPLC system 
 The HPLC system used to perform all chiral chromatographic separations consisted of a 
Varian 9002 HPLC pump and a Varian 9050 UV/Vis detector equipped with a Rheodyne 7725i 
20-μL manual injector and an Eldex CH-150 column oven kept at 35 °C. To compare the 
efficiency of our TAMOF-1 column to commercial columns, CHIRALPAK AD, CHIRALCEL 
OJ and CHIRALCEL OD (250 × 4.6 mm) columns were used.  
5.4 Results 
5.4.1 Initial column packing 
 After the initial 737 mg MOF packing of the column, a series of baselines was collected as 
a first check for backpressure and to determine if more MOF needed to potentially be added. Over 
time, it was determined that tracking the baseline was not a good indicator of whether more MOF 
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needed to be added. Instead, the focus was placed on adding MOF, pressurizing it with solvent for 
12h and reopening the column to perform a visual inspection. This proved to be a more effective 
method of packing the column until a total of 1550 mg of TAMOF-1 were added to the column. 
 The fully packed column was then conditioned with the appropriate solvent to be used for 
the chiral separations using at least 15 column volumes. To assess the potential of the TAMOF-1 
column, racemic trans-2,3-diphenyloxirane (also called trans-stilbene oxide, a mixture of (2S,3S)-
2,3-diphenyloxirane and (2R,3R)-2,3-diphenyloxirane) was selected. trans-2,3-diphenyloxirane is 
commonly used to determine the commercial chiral HPLC column’s system suitability.  
5.4.2 Chromatographic resolution of trans-2,3-diphenyloxirane 
 To test the versatility of the TAMOF-1 HPLC column, resolution of the racemic trans-2,3-
diphenyloxirane was tested using multiple solvent systems. The solvents tested were 95:5 
hexanes/isopropanol, commonly used with commercial chiral HPLC columns, 100% isopropanol, 
100% methanol and 100% acetonitrile. The results shown in Figure 5.2 show that the racemic 
trans-2,3-diphenyloxirane can be baseline resolved using three out of the four solvents tested.  
 
Figure 5.2 Resolution of trans-2,3-diphenyloxirane using the 100 mm × 4.6 mm I.D. TAMOF-1 
packed column. (A) 100% isopropanol, (B) 100% methanol, (C) 95:5 hexanes/isopropanol and (D) 
100% acetonitrile each at a flow rate of 0.15 mL/min. 
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 The chromatographic efficiency to resolve trans-2,3-diphenyloxirane using the TAMOF-
1 column in each solvent system was calculated and is shown in Table 5.1.  
Table 5.1 Chromatographic efficiency of the resolution of trans-2,3-diphenyloxirane using the 
TAMOF-1 column in different solvent systemsa 
Mobile phase 
 
Rs α tR1 (min) tR2 (min) 
Isopropanol 
 
1.73 2.92 8.71 17.38 
Methanol 
 
̶ b 1.21 13.74 15.82 
Acetonitrile 
 
2.55 6.38 6.70 20.12 
95:5 hexanes/ 
isopropanol 
1.37 3.06 12.12 28.47 
aFlow rate = 0.15 mL/min, detection wavelength set to 254 nm. bNo baseline resolution achieved 
To compare the results obtained from the TAMOF-1 column, trans-2,3-diphenyloxirane 
was also resolved using the commercial columns CHIRALPAK-AD, CHIRALCEL OD, AND 
CHIRALCEL-OJ as shown in Figure 5.3.  
 
Figure 5.3 Resolution of trans-2,3-diphenyloxirane with the commercial columns (A) 
CHIRALPAK-AD, (B) CHIRALCEL-OJ, and CHIRALCEL-OD. The mobile phase and flow rate 
were selected to be the same as the analysis using the TAMOF-1 column (95:5 




 The optimal chromatographic conditions, separation times and resolutions of trans-2,3-
diphenyloxirane with the TAMOF-1 column and each of the commercial chiral columns are shown 
in Table 5.2. While each column is capable of resolving trans-2,3-diphenyloxirane, the limitation 
of these columns is their ability to only be operational using normal phase conditions, such as 95:5 
hexanes/isopropanol in this case. The TAMOF-1 column yields competitive resolution using the 
same parameters (Figure 5.2c and Table 5.2). 
Table 5.2 Comparison of the resolution of trans-2,3-diphenyloxirane by the TAMOF-1 column 
versus CHIRALPAK AD, CHIRALCEL OD, and CHIRALCEL OJ commercial columnsa  
 TAMOF-1 ADb ODc OJd 
Dimensions (mm) 100  4.6 250  4.6 250  4.6 250  4.6 
(S,S) time (min) 12.1 32.3 37.6 55.3 
(R,R) time (min) 28.5 59.6 69.2 68.4 
Resolution (RS) 1.37 4.98 5.75 2.63 
% area (S,S) 50.4 49.5 50.8 49.8 
% area (R,R) 49.6 50.5 49.2 50.2 
Total time (min) 40 75 80 80 
aMobile phase 95:5 hexanes/isopropanol (v/v) at 0.15 mL/min, detection wavelength set to 254 
nm. bCHIRALPAK AD. cCHIRALCEL OD. dCHIRALCEL OD.  
 
 The data suggests that the TAMOF-1 packed HPLC column yields highly efficient chiral 
resolutions that may exceed commercial column performance using similar conditions and 
particularly due to elution system versatility. The broader peaks obtained with TAMOF-1 could 
be attributed to in-house packing of the HPLC column as well as heterogeneous particle size 
between 0.2 and 10 µm as reported by Prof. Galán-Mascarós DLS data.   
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5.4.3 Application of TAMOF-1 column to other chiral compounds 
 Additional chiral compounds were selected to further study the potential of the TAMOF-1 
column. The compounds 1-phenylethanol, benzoin and furoin were selected since they had been 
resolved previously by different chiral MOF columns19. With the TAMOF-1 column, some 
resolution was only achieved using mobile phase compositions consisting of hexanes and ethanol 
(Figures 5.4 – 5.7). In Figure 5.4 it is shown that using 100% ethanol does not resolve trans-2,3-
diphenyloxirane, but some resolution of 1-phenylethanol, benzoin and furoin was observed, 
suggesting the potential for resolution by modification of the solvent composition.  
 
Figure 5.4 Chiral chromatography of (A) trans-2,3-diphenyloxirane, (B) 1-phenylethanol, (c) 
benzoin and (d) furoin using the TAMOF-1 column with 100% ethanol at 0.15 mL/min. trans-2,3-
diphenyloxirane was retained as a single peak while 1-phenylethanol, benzoin and furoin showed 
some resolution but were not successfully baseline resolved.  
 
 Mobile phase compositions of 99:1 ethanol/hexanes, 95:5 ethanol/hexanes and 50:50 
ethanol/hexanes were subsequently studied (Figures 5.5 – 5.7) in attempts to improve resolution 
of each analyte. Solvent compositions of 99:1 ethanol/hexanes (Figure 5.5) and 95:5 
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ethanol/hexanes (Figure 5.6) did not show improvements in resolution compared to each other and 
100% ethanol (Figure 5.4). In the case of 50:50 ethanol/hexanes (Figure 5.7), 1-phenylethanol and 
benzoin appear to have worsened resolution, however, furoin appears to be baseline resolved 
(calculations shown in Table 5.3).  
Table 5.3 Chromatographic efficiency of the resolution of furoin using the TAMOF-1 columna 
Mobile phase 
 
Rs α tR1 (min) tR2 (min) 
50:50 ethanol/ 
hexanes 
1.12 1.57 67.29 103.36 
aFlow rate = 0.15 mL/min, detection wavelength set to 254 nm. 
 
Figure 5.5 Chiral chromatography of (A) 1-phenylethanol, (B) benzoin and (C) furoin using the 
TAMOF-1 column with 99:1 ethanol/hexanes at 0.15 mL/min. All analytes showed some 





Figure 5.6 Chiral chromatography of (A) 1-phenylethanol, (B) benzoin and (C) furoin using the 
TAMOF-1 column with 95:5 ethanol/hexanes at 0.15 mL/min. All analytes showed some 
resolution but were not successfully baseline resolved.  
 
 
Figure 5.7 Chiral chromatography of (A) 1-phenylethanol, (B) benzoin and (C) furoin using the 
TAMOF-1 column with 50:50 ethanol/hexanes at 0.15 mL/min. 1-phenylethanol and benzoin 





 Functionalization of the amino acid L-histidine with a 4H-1,2,4-triazole moiety, by 
transforming its -NH2 group, yielded the enantiopure ligand S-HTA that assembled with copper in 
water to build a porous homochiral metal-organic framework, TAMOF-1. Upon packing of 
TAMOF-1 into an HPLC column, the chiral MOF was shown to work as a highly versatile chiral 
stationary phase (CSP) capable of enantiomeric resolution of chiral molecules using either polar 
(acetonitrile, alcohols) or nonpolar (hexanes) solvent conditions. This strongly suggests that 
TAMOF-1 packed columns can operate under both normal and reversed conditions for chiral 
resolution. The competitive resolution of trans-2,3-diphenyloxirane with TAMOF-1, along with 
its compatibility with multiple solvent systems, makes it highly desirable as a CSP for industrial 
size applications. In addition to the TAMOF-1’s capability of resolution in either polar or nonpolar 
solvent conditions, our 100-mm column performed better than commercially available columns 
when resolving identical compounds. Success in applicability of TAMOF-1 as a CSP should pave 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
 This dissertation has made significant contributions by the application of mass 
spectrometry to a variety of biomedical application driven discoveries. The fundamental studies 
regarding improvements in ionization of polysaccharides sets a foundation for future research to 
continue finding means to ionize and successfully characterize polysaccharides using mass 
spectrometry. The experiments described showed, for the first time, protein like ionization of 
derivatized dextran (EDA-dextran) of low molecular weight. The experiments suggest that under 
the right derivatization conditions, the potential for ionization by means of multiple charges can 
be successfully achieved and in theory applied to polysaccharides of up to 40 kDa. 
 Additionally, using the in-house developed methodology, the formation of oxidized 
glutathione (GSSG) was confirmed as a reaction byproduct from the catalytic release of NO from 
S-nitrosoglutathione using chitosan-MOF composites. The same methodology used to confirm the 
formation of GSSG, was also used simultaneously to determine whether the chitosan support 
system degraded over time as well as any potential decomposition of the MOF. This led the way 
to the development of yet another set of mass spectrometric methodology to successfully determine 
the degradation products from two polymeric systems intended for biomedical applications as part 
of our in-house pre-validated risk assessments.  
 The studies regarding potential cell viability interferences are a very important 
collaborative project completed within my graduate career. The findings strongly advise all fields 
that rely on commercial cell viability studies to perform their due diligence to account for potential 
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interferences within their experiments to minimize false positives/negatives that could lead to 
catastrophic consequences.  
 Finally, in an international collaborative effort, a chiral MOF (TAMOF-1) was used to 
perform chiral chromatographic separations in a variety of solvent systems that include both 
normal and reversed phase conditions. The work performed with the TAMOF-1 HPLC column 
should pave the way for the affordable, industrial use of a MOF-based chiral stationary phase for 
chiral chromatography needs in this still very expensive field.  
6.2 Future Directions 
6.2.1 Improvements for ionization of dextran and applications to larger polysaccharides 
With the growing interest in polymeric materials from natural origin, particularly regarding 
biomedical applications, it is important to tackle the challenge of accurate analysis using analytical 
techniques such as mass spectrometry. While it continues to be difficult to ionize neutral 
polysaccharides and successfully analyze them, Chapter 2 described a derivatization that 
successfully attached free terminal amines. The attachment of free terminal amines allowed for 
ionization of EDA-dextran similar to protein ionization as was shown in Figure 2.11, reproduced 
here as Figure 6.1. 
Future work should focus on increasing the number of ethylenediamine attachments to 
dextran, and any other polysaccharides of interest. Ideally, at least 1 successful attachment per 
glucose is recommended. With this goal in mind, as an example, a dextran polymer composed of 
500 glucose residues would have a mass of approximately 81 kDa. If there is one ethylenediamine 
attachment per glucose, the mass increase would be to 124 kDa. However, if this hypothetical 
derivatized dextran only attains 10% charging (50 protonations), the m/z will effectively move the 
mass of this dextran to approximately 2488 Da. This m/z would make the measurement of an 81 
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kDa starting polysaccharide possible with the instrument used for the dextran work since the high-
resolution mass ranges form 0 – 3200 m/z.  
 
Figure 6.1 Reproduced figure from chapter 2 (Figure 2.11) showing the protein-like ionization of 
EDA-dextran. The same four glucose EDA-dextran chain was ionized by 2, 3 and 4 protonations.  
 
6.2.2 Mass spectrometry application for degradation profiling of polymeric devices 
Polymeric devices for biomedical applications continue to be developed to match required 
moduli for tissue engineering, wound healing meshes and extracorporeal systems. It was 
demonstrated that current mass spectrometry instrumentation is capable of accurate LC-MS and 
LC-MS/MS separation and elucidation of biodegradation products as discussed in Chapter 3 
regarding chitosan-MOF composites and in Chapter 4 during the investigation of 
poly(phosphazene) and polyester polymers. It is recommended to actively screen commercially 
obtained and newly developed polymers for their degradation products and potentially unwanted 
leachates. Follow-up work for the degradation of chitosan composites, poly(phosphazene) and 
polyester based polymers should include the quantification of each degradation product, especially 




























































































6.2.3 Continuous use of mass spectrometry for analysis of reaction products  
The continuous development of new methodology to test for reaction byproducts is of 
utmost importance to confirm the intended purpose of newly developed materials/devices. In a 
similar manner, the discoveries made in Chapter 3 regarding potential interferences affecting cell 
viability studies, it is strongly recommended to keep track of the effects of the therapeutics of 
interest on the selected assay. Perhaps an internal library of interfering compounds can be started 
within the lab, focused on therapeutics specific to the Reynolds group. Eventually, any potential 
false positives/negatives can be confirmed/rejected using the methods described in Chapter 3 that 
showed the successful use of mass spectrometry for this purpose. Once a robust library is obtained, 
when enough information is collected, it would be worthy of publication and potentially included 
as a point of reference when cell viability assays are purchased.  
6.2.4 Chiral chromatography using chiral metal-organic frameworks 
With the essentially unlimited designs of MOFs possible, chiral MOFs will certainly 
continue to be designed and synthesized for their use as CSPs. As shown in the work presented in 
Chapter 5 (JACS, 2019, 141 (36), 14306–14316), taking advantage of enantiopure, naturally 
occurring building blocks such as amino acids for MOF ligand synthesis led to the highly 
specialized chiral MOF TAMOF-1. It is worth highlighting that TAMOF-1 was operational using 
a variety of solvents that ranged from normal to reversed phase leading to efficient resolution of 
trans-2,3-diphenyloxirane, greatly increasing the versatility of TAMOF-1 as a CSP. The limited 
resolution of additional chiral compounds of interest such as 1-phenylethanol, benzoin and furoin 
showed the potential of the TAMOF-1 CSP to resolve different chiral compounds, however, there 
is room for improvement. As stated in Chapter 5, heterogeneous particle size may be responsible 
for broad peaks and may also influence the poor resolution of the additional tested chiral 
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compounds. The work presented regarding chiral resolution using TAMOF-1 should pave the way 
for further studies regarding homogeneous particle size, different column dimensions, and other 
mixtures of solvents. The Varian HPLC system used for all the work in Chapter 5 did not allow 
for gradient elution, thereby limiting any improved resolution by implementation of gradients. 
Initial work regarding different column dimensions is shown in Figure 6.2 in which a longer 
column was packed (250  4.6 mm ID) with 3.79-g of TAMOF-1. The preliminary tests of the 
column were performed by separating trans-2,3-diphenyloxirane using a mobile phase of 100% 
acetonitrile at 1.0 mL/min. Additionally, TAMOF-1 should be tested using typical HPLC additives 
such as formic acid, ammonium formate, acetic acid, ammonium acetate and trifluoroacetic acid 
for stability under those conditions. Once stability is established, check for resolution of all the 
compounds already resolved with the new mobile phase conditions. A suggested series of steps is 
shown in table 6.1. 
 
Figure 6.2 250  4.6 mm ID column packed with TAMOF-1. trans-2,3-diphenyloxirane was 







Table 6.1 Suggested starting additive compatibility testing with TAMOF-1 
Mobile phase additive 
 
Solvent compatibility Suggested addition 
Formic acid/acetic acid 
 
Acetonitrile 0.01% - 0.1% (v/v) 
Formic acid/acetic acid 
 
Methanol 0.01% - 0.1% (v/v) 
Formic acid/acetic acid 
 
Isopropanol 0.01% - 0.1% (v/v) 
Ammonium formate/ 
Ammonium acetate 
Acetonitrile 1mM - 10 mM 
Ammonium formate/ 
Ammonium acetate 
Methanol 1mM - 10 mM 
Ammonium formate/ 
Ammonium acetate 
Isopropanol 1mM - 10 mM 
Trifluoroacetic acid 
 
Hexanes/isopropanol 0.01% - 0.1% (v/v) 
Trifluoroacetic acid 
 


















Supporting Information for Chapter 4 
 
A1. Additional Figures 
 
Figure A1.1 LC-MS triplicate runs of PTMO-NO degradation after 1 week.  
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Figure A1.5 Fragmentation pattern of ion m/z 265. (a) MS/MS spectrum; (b) m/z 265 parent ion; 
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Figure A1.6 Fragmentation pattern of ion m/z 265. (a) MS/MS spectrum; (b) m/z 265 parent ion; 






















Figure A1.7 Fragmentation pattern for the first m/z 393 ion. (a) MS/MS spectrum; (b) m/z 393 
parent ion; (c) fragment ions from parent ion. Fragment ions confirmed using the CFM-ID 













Figure A1.8 Fragmentation pattern for the second m/z 393 ion. (a) MS/MS spectrum; (b) m/z 
393 parent ion; (c) fragment ions from parent ion. Fragment ions confirmed using the CFM-ID 









Figure A1.9 Identity of the m/z 243 ion. Previously identified2. (a) MS spectrum. (b) Structure of 


























Figure A1.10 Fragmentation pattern for the first m/z 521 ion. A) MS/MS spectrum; (b) m/z 521 
parent ion; (c) fragment ions from parent ion. Fragment ions confirmed using the CFM-ID 












Figure A1.11 Fragmentation pattern for the second m/z 521 ion. A) MS/MS spectrum; (b) m/z 
521 parent ion; (c) fragment ions from parent ion. Fragment ions confirmed using the CFM-ID 
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To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





CAS  Chemical Abstracts Service 
CDI  1,1’-Carbonyldiimidazole 
Da  Dalton 
DMSO  Dimethyl Sulfoxide 
EDA  Ethylenediamine 
ESI  Electrospray Ionization 
LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
NaCl  Sodium Chloride 
RT  Room Temperature 
TOF  Time-of-Flight 
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B6. Materials and Equipment 
 
B6.1  Agilent 1260 Infinity HPLC System 
B6.2  Agilent 6224 TOF Mass Spectrometer 
B6.3  Agilent dual ESI ion source 
B6.4  Analytical Column: NA 
B6.5  Guard Cartridge: NA 
B6.6  Analytical Balance: Ohaus Discovery DV215CD 
B6.7  1-mL Syringes 
B6.8  Agilent Captiva Econofilter 0.2-µm PTFE Syringe Filters 
B6.9 Millipore Direct-Q Water Purification System 
B6.10  20-mL Amber Vials 
B6.11  2-mL Agilent LC-MS Amber Vials 
B6.12  Spectra/Por dialysis membranes (MW cutoff 100-500 Da) 
B6.13  -20 °C freezer 





B7.1  Methanol, LC-MS grade, CAS# 67-18-6 
B7.2  Water, LC-MS grade, CAS# 7732-18-5 
B7.3  Derivatized dextran, obtain from interested parties, or Dextran T1, CAS# 9004-54-0 
B7.4  Water, Millipore Direct-Q grade 
B7.5  1,1’-Carbonyldiimidazole, CAS# 530-62-1 
B7.6  Dimethyl Sulfoxide, CAS# 67-68-5 
B7.7  Sodium Chloride, CAS# 7647-14-5 





B8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
 
B8.1.1 Mobile Phase A: 0.1% acetic acid in water  
 
 B8.1.1.1 Dilute 1.0-mL of acetic acid to 1-L with LC-MS water and mix thoroughly 
 
B8.1.2 Mobile Phase B: 0.1% acetic acid in methanol 
 




B8.1.3 Transfer the desired volume of each mobile phase to the appropriate LC-MS solvent 
reservoir(s). Appropriately update solvent volumes on the instrument if necessary.  
 
B8.2 Preparation of Derivatized Dextran Samples (following previously established procedures1,2) 
 
 B8.2.1 Derivatization of Dextran 
 
B8.2.1.1 Prepare CDI solution by dissolving 0.2-g of CDI in 2-mL DMSO 
 
B8.2.1.2 Weigh out 0.5-g of dextran and transfer into 25-mL round bottom flask 
 
B8.2.1.3 Add 6-mL DMSO to round bottom flask with dextran and dissolve dextran 
 
B8.2.1.4 Place the 25-mL round bottom flask containing dextran in DMSO in an 
oil bath at 60 °C allowing for dextran to completely dissolve and reach 60 °C 
 
B8.2.1.5 Once at 60 °C, add the CDI solution from B8.2.1.1 to the dextran solution 
and still at 60 °C for 15 min 
 
B8.2.1.6 After 15 min, add 1-mL ethylenediamine to the dextran-CDI mixture and 
allow to react for 18 h at 60 °C  
 
 B8.2.2 Dextran Derivatization Cleanup 
 
  B8.2.2.1 After the reaction is complete (B8.2.1.6), allow mixture to reach RT 
 
B8.2.2.2 Precipitate derivatized dextran from solution by adding excess methanol. 
Approximately 100-mL will initiate precipitation 
   
B8.2.2.3 Filter the precipitate by vacuum filtration and wash with methanol to 
remove leftover DMSO and any other impurities soluble in methanol 
 
B8.2.2.4 Once the precipitate is dry, re-dissolve in Millipore water for dialysis. Try 
to keep the volume under 20-mL to maximize the dilution/cleanup by dialysis 
  
B8.2.3 Dialysis (Use in-house dialysis apparatus to speed-up dialysis) 
  
B8.2.3.1 Prepare a 0.5% w/v NaCl solution by dissolving 5-g NaCl for every 1-L 
of solution prepared 
 
B8.2.3.2 Prepare 0.01% v/v acetic acid solution by diluting 100-µL acetic acid for 
every 1-L of solution prepared 
 
B8.2.3.3 Transfer the re-dissolved derivatized dextran (from B8.2.2.4) to a dialysis 
bag and seal the bag 
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B8.2.3.4 Dialyze the derivatized dextran (from B8.2.3.3) in approximately 10-L of 
0.5% NaCl solution prepared as stated in B8.2.3.1 at RT for 24 hr 
 
B8.2.3.5 Dialyze the derivatized dextran (from B8.2.3.3) in approximately 20-L of 
0.01% acetic acid solution prepared as stated in B8.2.3.2 at RT for 24 hr 
   
 B8.2.4 Freeze dry product 
 
B8.2.4.1 Transfer they dialyzed derivatized dextran from B8.2.3.5 to a freeze-dry 
compatible vessel 
 
B8.2.4.2 If time allows, allow product to freeze overnight in the -20 °C freezer, OR: 
 
B8.2.4.3 Freeze sample carefully using liquid nitrogen  
 
B8.2.4.4 Freeze dry sample using the Labcono Freeze Dryer until all the water has 
been removed 
 
Note: This may take as little as 24 hr or as long as 7 days depending on the volume 
of water that needs to be removed. Lower volume is always recommended; 
however, this is highly dependent on the dialysis steps (section 8.2.3) 
 
B8.2.4.5 Transfer dried sample from 8.2.4.4 to an appropriate storage vial/bottle 
and store at -20 °C until LC-MS analysis 
 
 B8.2.5 Derivatized dextran sample preparation 
  
B8.2.5.1 Prepare derivatized dextran samples at a concentration of 1-mg/mL in 
0.1% acetic acid in water solution 
 
B8.2.5.2 Transfer at least 1-mL of B8.2.5.1 into a 1-mL Agilent LC-MS vial using 
a 1-mL syringe and filtering through an Agilent Captiva Econofilter 0.2-µm PTFE 
Syringe Filter 
 
B8.3 Analysis Method 
 
Follow Table B.1 for instrument method conditions. See appendix H for appropriate 
instrument setup and use. 
 
 B8.3.1 Inject reagent blank in positive polarity 
 
B8.3.2 Inject each sample in triplicate with instrument in positive polarity 
 
 B8.3.3 Load next sample sequence if needed repeating B8.3.1 – B8.3.2 or: 
 
 B8.3.4 Repeat B8.3.1 
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 B8.3.5 Put instrument on Stand-by  
 
Table B.1 LC-MS Method Parameters 
HPLC Settings 
Column Type NA 
Guard Column NA 
Column Temperature 35 °C 
Sample Tray Temperature RT 
Injection Volume 0.1 µL 
Needle Wash Methanol in Rinse Vial, Position 1 
Flow Rate 0.15 mL/min 
Stop Time 2 min 
Post Time NA 
Method Type Isocratic Direct Injection 
MP A 0.1 % acetic acid in water 
MP B 0.1 % acetic acid in methanol 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source Dual ESI 
0 90 10 Ionization Polarity Positive 
2 90 10 Capillary Voltage 4000 V 
End Analysis Fragmentor Voltage 80 V  
 Skimmer Voltage 75 V 
Drying Gas Flow Rate 12.5 l/min (N2) 
Drying Gas Temperature 250 °C (N2) 
Nebulizer Pressure 45 psi 
 
 
B9. Data Analysis 
 
B9.1 Perform the necessary MW calculations for the potential derivatized dextran chains 
 
B9.1.1 Use the MW of each expected dextran oligo or polysaccharide and design it as “M” 
 
B9.1.2 To account for the number of ethylenediamine attachments use the formula [M + 
86x] where x is the number of ethylenediamine attachments 
 
B9.1.3 To account for the number of protonations use the formula [M + 86y + yH]+ where 
y is the number of protonations 
 
B9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
B9.2.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 




B9.2.2 Extract “Background Spectrum” from data collected (extract from the baseline, not 
the unretained chromatographic peak) 
 
B9.2.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
B9.2.4 Search for the predicted masses (found following the steps in section B9.1) 
 
B9.2.5 Use the Agilent isotope distribution calculator to aid in the positive identification 
of the derivatized dextran chains 
 
B9.2.6 In the processed data files (sections B9.2.1 – B9.2.3), visually inspect for multiple 
charging events by searching for isotopic distributions that are less than ~1 Da apart1. A 
difference of ~0.5 Da denotes two charges, a difference of ~0.33 Da denotes three charges, 
a difference of ~0.25 Da denotes 4 charges and so on 
 
B9.2.7 To deconvolute the multiply charged ions use the following series of equations: 
 
 B9.2.7.1 Using two adjacent peaks suspected of multiple charging use: 
  
  𝑧 = (𝑚 𝑧⁄ )1−𝑥(𝑚 𝑧⁄ )2−(𝑚 𝑧⁄ )1       Eq. B.1 
  
Where m/z1 and m/z2 are two adjacent ion peaks, x is the mass of the adduct (usually 
1.0073 for proton adducts) and z is the calculated charge of m/z2 
 
B9.2.7.2 Once the charge is calculated, calculate the deconvoluted mass: 
 
   𝑀 = 𝑧((𝑚 𝑧⁄ )2 − 𝑥)      Eq. B.2 
   
BWhere M is the deconvoluted mass, z is the number of charges (calculated in 
9.2.7.1) and x is the mass of the adduct (usually 1.0073 for proton adducts) 
 
 
B10. Data Reporting  
 
B10.1 Export data as csv file 
 
B10.2 Use Origin or Igor to plot data files 
 
B10.3 Appropriately label peaks of interest 
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A direct flow injection with an LC-MS system is used for the identification of the products from 
nitric oxide (NO) release from S-nitrosoglutathione (GSNO), screening for hydrolytic degradation 






This test method provides instructions for the preparation and analysis of the collected media after 
GSNO is subjected to chitosan-MOF composites. The goals are to (1) clearly identify the 
byproduct from GSNO releasing NO; (2) screen for the degradation of the chitosan support system 
as it is exposed to GSNO in solution; (3) screen for the potential of the copper MOF degrading 





To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





ACN  Acetonitrile 
APCI  Atmospheric Pressure Chemical Ionization 
CAS  Chemical Abstracts Service 
Cu-BTTri H3[(Cu4Cl)3-(BTTri)8] 
ESI  Electrospray Ionization 
GSNO  S-nitrosoglutathione  




LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MMI  Mixed-Mode Ionization 
MOF  Metal-organic framework 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
NO  Nitric Oxide 
RT  Room Temperature 
TOF  Time-of-Flight 
 
 
C6. Materials and Equipment 
 
C6.1  Agilent 1260 Infinity HPLC System 
C6.2  Agilent 6224 TOF Mass Spectrometer 
C6.3  Agilent MMI ion source 
C6.4  Analytical Column: NA 
C6.5  Guard Cartridge: NA 
C6.6  Analytical Balance: Ohaus Discovery DV15CD 
C6.7  1-mL Syringes 
C6.8  Agilent Captiva Econofilter 0.2-µm PTFE Syringe Filters 
C6.9  Millipore Direct-Q Water Purification System 
C6.10  Aluminum Foil 
C6.11  20-mL Amber Vials 
C6.12  2-mL Agilent LC-MS Amber Vials 




C7.1  Acetonitrile, LC-MS grade, CAS# 75-05-8 
C7.2  Water, LC-MS grade, CAS# 7732-18-5 
C7.3  Chitosan-MOF composites, obtain from interested parties  
C7.4  Water, Millipore Direct-Q grade 





C8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
 
C8.1.1 Mobile Phase A: 0.1% formic acid in water 
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C8.1.1.1 Dilute 1.0-mL of formic acid to 1-L with LC-MS water and mix 
thoroughly 
 
C8.1.2 Mobile Phase B: 0.1% formic acid in acetonitrile 
 
 C8.1.2.1 Dilute 1.0-mL of formic acid to 1-L with LC-MS acetonitrile 
 
C8.1.3 Transfer the desired volume of mobile phase to the appropriate LC-MS solvent 
reservoir. Appropriately update solvent volumes on the instrument if necessary  
 
C8.2 Preparation of chitosan-MOF + GSNO experiments (per Megan J. Neufeld’s method1) 
 
 C8.2.1 Incubation Process 
 
C8.2.1.1 Weigh out 20 mg of provided or synthesized chitosan-Cu-BTTri 
composite and place in 20-mL amber vial  
 
C8.2.1.2 Add the desired volume of a 1 mM solution of GSNO (at least 5-mL) and 
seal the vial 
 
C8.2.1.3 Cover vial with aluminum foil to minimize exposure to light 
 
C8.2.1.4 Incubate samples (minimum of three samples, repeat steps C8.2.1.1 – 
C8.2.1.3 as needed) at 37 °C for the desired length of time 
 
Note: The disappearance of the characteristic red/pink color of GSNO in solution 
is usually a good indicator of when to stop the incubation process 
 
 C8.2.2 Sampling 
 
  C8.2.2.1 Remove vials from incubator  
 
  C8.2.2.2 Allow vials to reach RT 
   
  C8.2.2.3 Obtain a 1-mL sample aliquot using a 1-mL syringe 
 
C8.2.2.4 Filter sample through an Agilent 0.2-µm filter into an Agilent 2-mL LC-
MS vial and seal the vial 
 
C8.2.2.5 Appropriately dispose of the remaining incubation media 
  
C8.3 Analysis Method 
 
Follow Table C.1 for instrument method conditions. See appendix H for appropriate 




 C8.3.1 Inject reagent blank 
 
C8.3.2 Inject each sample in triplicate 
 
 C8.3.3 Load next sample sequence if needed repeating C8.3.1 – C8.3.2 or: 
 
 C8.3.4 Repeat C8.3.1 
 
 C8.3.5 Put instrument on Stand-by  
 
Table C.1 LC-MS Method Parameters 
HPLC Settings 
Column Type NA 
Guard Column NA 
Column Temperature 35 °C 
Sample Tray Temperature RT 
Injection Volume 0.1 µL 
Needle Wash Acetonitrile in Rinse Vial, Position 1 
Flow Rate 0.22 mL/min 
Stop Time 2 min 
Post Time NA 
Method Type Isocratic Direct Injection 
MP A 0.1% formic acid in water 
MP B 0.1% formic acid in acetonitrile 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source MMI 
0 80 20 Ionization Mode ESI 
2 80 20 Ion Polarity Positive 
End Analysis Capillary Voltage 3000 V 
 Fragmentor Voltage 200 V  
Skimmer Voltage 60 V 
Charging Voltage NA 
Drying Gas Flow Rate 10 l/min (N2) 
Drying Gas Temperature 310 °C (N2) 
Nebulizer Pressure 45 psi 
 
 
C9. Data Analysis 
 
C9.1 Perform the necessary MW calculations for the analytes of interest 
 
C9.1.1 GSNO: C10H16N4O7S; exact mass: 336.0740; m/z as [M+H]+: 337.0812 
 





Note: GSNO and doubly charged GSSG have near identical mass. Make sure to check for 
the mass difference in the isotopic distribution. For an explanation on this see 2 
 
C9.1.3 Glucosamine: C6H13NO5; exact mass: 179.0794; m/z as [M+H]+: 180.0866; m/z as 
[M - H2O + H]+: 162.0761 
 
C9.1.4 N-acetylglucosamine: C8H15NO6; exact mass: 221.0899; m/z as [M+H]+: 222.0972 
 
C9.1.5 H3BTTri: C12H9N9; exact mass: 279.0981; m/z as [M+H]+: 280.1054; m/z as 
[M+2H]2+: 140.5563 
 
C9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
C9.2.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 
unretained chromatographic peak) 
 
C9.2.2 Extract “Background Spectrum” from data collected (extract from the baseline, not 
the unretained chromatographic peak) 
 
C9.2.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
C9.2.4 Search for the ions of interest (section C9.1) 
 
C9.3 Data interpretation 
 
C9.3.1 Upon completion of the reaction (section C8.2.1), search for the ions in section 
C9.1. The compounds in sections C9.1.1 – C9.1.4 are all possible, specially GSSG, 
glucosamine and N-acetylglucosamine  
 
C9.3.1 If the compound in C9.1.5 is found, report to interested parties immediately! 
The presence of H3BTTri suggests Cu-BTTri MOF decomposition and the chitosan-MOF 




C10. Data Reporting  
 
C10.1 Export data as csv file 
 
C10.2 Use Origin or Igor to plot data files 
 
C10.3 Appropriately label peaks of interest 
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A direct flow injection with an LC-MS system is used to track the conversion of resazurin to 





This test method provides instructions for the preparation and analysis of the cell viability assay 






To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





APCI  Atmospheric Pressure Chemical Ionization 
CAS  Chemical Abstracts Service 
ESI  Electrospray Ionization 
LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MMI  Mixed-Mode Ionization 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
POPs  Poly(phosphazenes) 
RT  Room Temperature 
TOF  Time-of-Flight 
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D6. Materials and Equipment 
 
D6.1  Agilent 1260 Infinity HPLC System 
D6.2  Agilent 6224 TOF Mass Spectrometer 
D6.3  Agilent MMI ion source 
D6.4  Analytical Column: NA 
D6.5  Guard Cartridge: NA 
D6.6  Analytical Balance: Ohaus Discovery DV215CD 
D6.7  1-mL Syringes 
D6.8  Agilent Captiva Econofilter 0.2-µm PTFE Syringe Filters 
D6.9  Millipore Direct-Q Water Purification System 
D6.10  Aluminum Foil 
D6.11  20-mL Amber Vials 
D6.12  2-mL Agilent LC-MS Amber Vials 





D7.1 Methanol, LC-MS grade, CAS# 67-18-6 
D7.2 Water, Millipore Direct-Q grade 





D8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
 
D8.1.1 Mobile Phase A: NA 
 
D8.1.2 Mobile Phase B: 100% Methanol 
 
D8.1.3 Transfer the desired volume of MeOH to the appropriate LC-MS solvent reservoir. 
Appropriately update solvent volumes on the instrument if necessary 
 
D8.2 Preparation of Incubation Samples 
 
 D8.2.1 Incubation Process 
 





D8.2.1.2 Combine the interference species with the CellTiter Blue dye in a 5:1 
(interference/CellTiter Blue dye) fashion in a 20-mL amber vial to obtain a 10 mM 
final concentration of interference species 
 
D8.2.1.3 Cover vial with aluminum foil to protect samples from exposure to light  
 
D8.2.1.4 Incubate a total of four samples, one for each time period (hours 1 through 
4), at 37 °C 
 
 D8.2.2 Hourly Sampling 
 
  D8.2.2.1 Remove sample vial from incubator  
 
  D8.2.2.2 Obtain a 1-mL sample aliquot using a 1-mL syringe 
   
D8.2.2.3 Filter sample through an Agilent 0.2-µm filter into an Agilent 2-mL LC-
MS amber vial and seal the vial 
 
D8.2.2.4 Appropriately dispose of the remaining incubation media 
 
D8.2.2.5 Immediately analyze sample using the MS analysis method in section 8.3 
 
D8.2.2.6 Repeat steps D8.2.2.1 – D8.2.2.5 for each subsequent sample 
  
D8.3 Analysis Method 
 
Follow Table D.1 for instrument method conditions. See appendix H for appropriate 
instrument setup and use. 
 
 D8.3.1 Inject reagent blank in negative polarity 
 
D8.3.2 Inject each sample in triplicate with instrument in negative polarity 
 
 D8.3.3 Load next sample triplicate repeating D8.3.1 – D8.3.2 or: 
 
 D8.3.4 Repeat D8.3.1 
 











Table D.1 LC-MS Method Parameters 
HPLC Settings 
Column Type NA 
Guard Column NA 
Column Temperature 35 °C 
Sample Tray Temperature RT 
Injection Volume 0.1 µL 
Needle Wash Methanol in Rinse Vial, Position 1 
Flow Rate 0.22 mL/min 
Stop Time 2 min 
Post Time NA 
Method Type Isocratic Direct Injection 
MP A NA 
MP B Methanol 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source MMI 
0 0 100 Ion Polarity Negative 
2 0 100 Capillary Voltage 2500 V 
End Analysis Fragmentor Voltage 120 V  
 Skimmer Voltage 60 V 
Charging Voltage 2000 V 
Drying Gas Flow Rate 10 l/min (N2) 
Drying Gas Temperature 310 °C (N2) 
Nebulizer Pressure 45 psi 
 
D9. Data Analysis 
 
D9.1 CellTiter Blue molecular formula, exact mass and expected m/z 
 
D9.1.1 Resazurin: C12H7NO4, exact mass 229.0375 (calculated using Agilent Isotope 
Distribution Calculator), expected m/z 228.0302 as [M-H]- (calculated using Agilent 
Isotope Distribution Calculator) 
 
D9.1.2 Resorufin: C12H7NO3, exact mass 213.0426 (calculated using Agilent Isotope 
Distribution Calculator), expected m/z 212.0353 as [M-H]- (calculated using Agilent 
Isotope Distribution Calculator) 
 
D9.1.3 Instrument default mass range set to 100 – 3200 m/z. If the MS detection of 
resazurin and resorufin are the only two of interest, set mass range to 205 – 235 m/z.  
 
D9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
D9.2.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 




D9.2.2 Extract “Background Spectrum” from data collected (extract from the baseline, not 
the unretained chromatographic peak) 
 
D9.2.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
D9.2.4 Examine for the presence of resazurin or resorufin or both (found using the 
parameters in section D9.1) 
 
D9.2.5 Use the Agilent isotope distribution calculator to aid in the positive identification 
of resazurin of resorufin or both 
 
D10. Data Reporting  
 
D10.1 Export data as csv file 
 
D10.2 Use Origin or Igor to plot data files 
 
D10.3 Appropriately label peaks of interest 
 

































(1)  Neufeld, B. H.; Tapia, J. B.; Lutzke, A.; Reynolds, M. M. Small Molecule Interferences in 
Resazurin and MTT-Based Metabolic Assays in the Absence of Cells. Anal. Chem. 2018, 


























A direct flow injection with an LC-MS system is used to track the conversion of MTT to formazan 





This test method provides instructions for the preparation and analysis of the MTT cell viability 





To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





APCI  Atmospheric Pressure Chemical Ionization 
CAS  Chemical Abstracts Service 
ESI  Electrospray Ionization 
LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MMI  Mixed-Mode Ionization 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
POPs  Poly(phosphazenes) 
RT  Room Temperature 




E6. Materials and Equipment 
 
E6.1  Agilent 1260 Infinity HPLC System 
E6.2 Agilent 6224 TOF Mass Spectrometer 
E6.3 Agilent MMI ion source 
E6.4 Analytical Column: NA 
E6.5 Guard Cartridge: NA 
E6.6 Analytical Balance: Ohaus Discovery DV215CD 
E6.7 1-mL Syringes 
E6.8 Agilent Captiva Econofilter 0.2-µm PTFE Syringe Filters 
E6.9 Millipore Direct-Q Water Purification System 
E6.10  Aluminum Foil 
E6.11  20-mL Amber Vials 
E6.12  2-mL Agilent LC-MS Amber Vials 





E7.1 Methanol, LC-MS grade, CAS# 67-18-6 
E7.2 Water, Millipore Direct-Q grade 





E8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
 
E8.1.1 Mobile Phase A: NA 
 
E8.1.2 Mobile Phase B: 100% Methanol 
 
E8.1.3 Transfer the desired volume of MeOH to the appropriate LC-MS solvent reservoir. 
Appropriately update solvent volumes on the instrument if necessary.  
 
E8.2 Preparation of Incubation Samples 
 
 E8.2.1 Incubation Process 
 





E8.2.1.2 Per Bella H. Neufeld’s MTT assay protocol1, MTT was made in PBS with 
a final concentration of 12 mM 
 
E8.2.1.3 Combine the interference species with the MTT dye (from E8.2.1.2) in a 
5:1 (interference/MTT dye) fashion in a 20-mL amber vial to obtain a 10 mM final 
concentration of interference species 
 
E8.2.1.4 Cover vial with aluminum foil to protect samples from exposure to light  
 
E8.2.1.5 Incubate a total of four samples, one for each time period (hours 1 through 
4), at 37 °C 
 
 E8.2.2 Hourly Sampling 
 
  E8.2.2.1 Remove sample vial from incubator  
 
E8.2.2.2 To minimize ion suppression due to PBS on the mass spectrometer 
(sample incubation per section E8.2.1), the incubated mixture from E8.2.1.3 was 
diluted in ethanol to 0.1% before injection into the instrument1 
 
  E8.2.2.3 Obtain a 1-mL sample aliquot using a 1-mL syringe 
   
E8.2.2.4 Filter sample through an Agilent 0.2-µm filter into an Agilent 2-mL LC-
MS amber vial and seal the vial 
 
E8.2.2.5 Appropriately dispose of the remaining incubation media 
 
E8.2.2.6 Immediately analyze sample using the MS analysis method in section 8.3 
 
E8.2.2.7 Repeat steps E8.2.2.1 – E8.2.2.6 for each subsequent sample 
  
E8.3 Analysis Method 
 
Follow Table E.1 for instrument method conditions. See appendix H for appropriate 
instrument setup and use. 
 
 E8.3.1 Inject reagent blank in negative polarity 
 
E8.3.2 Inject each sample in triplicate with instrument in negative polarity 
 
E8.3.3 Inject water blank to remove any potentially precipitated PBS in LC lines 
 
 E8.3.4 Load next sample triplicate repeating E8.3.1 – E8.3.3 or: 
 
E8.3.5 Extensively rinse instrument with a mobile phase of 95:5 LC-MS water/LC-MS 
methanol to dissolve any PBS left in the lines 
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 E8.3.6 Put instrument on Stand-by  
 
 E8.3.7 Perform an ion source cleaning 
 
E8.3.7.1 Clean spray shield, backplate and ion source surfaces with LC-MS water 
using a lint-free cloth 
 
E8.3.7.2 Clean spray shield, backplate and ion source surfaces with 1:1 LC-MS 
isopropanol/LC-MS water using a lint-free cloth 
 
E8.3.7.3 Sonicate nebulizer in 1:1 LC-MS isopropanol/LC-MS water to remove 
any precipitated impurities 
 
Table E.1 LC-MS Method Parameters 
HPLC Settings 
Column Type NA 
Guard Column NA 
Column Temperature 35 °C 
Sample Tray Temperature RT 
Injection Volume 0.1 µL 
Needle Wash Methanol in Rinse Vial, Position 1 
Flow Rate 0.22 mL/min 
Stop Time 2 min 
Post Time NA 
Method Type Isocratic Direct Injection 
MP A NA 
MP B Methanol 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source MMI 
0 0 100 Ion Polarity Negative 
2 0 100 Capillary Voltage 2500 V 
End Analysis Fragmentor Voltage 120 V  
 Skimmer Voltage 60 V 
Charging Voltage 2000 V 
Drying Gas Flow Rate 10 l/min (N2) 
Drying Gas Temperature 310 °C (N2) 












E9. Data Analysis 
 
E9.1 MTT molecular formula, exact mass and expected m/z 
 
E9.1.1 MTT: C18H16N5S, exact mass 334.1126 (calculated using Agilent Isotope 
Distribution Calculator), expected m/z 334.1121 as [M]+ (calculated using Agilent Isotope 
Distribution Calculator) 
 
E9.1.2 Formazan: C18H17N5S, exact mass 335.1205 (calculated using Agilent Isotope 
Distribution Calculator), expected m/z 336.1277 as [M+H]+ (calculated using Agilent 
Isotope Distribution Calculator) 
 
E9.1.3 Instrument default mass range set to 100 – 3200 m/z. If the MS detection of resazurin 
and resorufin are the only two of interest, set mass range to 330 – 340 m/z 
 
E9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
E9.2.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 
unretained chromatographic peak) 
 
E9.2.2 Extract “Background Spectrum” from data collected (extract from the baseline, not 
the unretained chromatographic peak) 
 
E9.2.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
E9.2.4 Examine for the presence of MTT or formazan or both (found using the parameters 
in section 9.1) 
 
E9.2.5 Use the Agilent isotope distribution calculator to aid in the positive identification 
of MTT of formazan or both 
 
 
E10. Data Reporting  
 
E10.1 Export data as csv file 
 
E10.2 Use Origin or Igor to plot data files 
 
E10.3 Appropriately label peaks of interest 
 











(1)  Neufeld, B. H.; Tapia, J. B.; Lutzke, A.; Reynolds, M. M. Small Molecule Interferences in 
Resazurin and MTT-Based Metabolic Assays in the Absence of Cells. Anal. Chem. 2018, 


























A direct flow injection with an LC-MS system is used for the identification of products from 





This test method provides instructions for the preparation and analysis of degradation products 





To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





APCI  Atmospheric Pressure Chemical Ionization 
CAS  Chemical Abstracts Service 
ESI  Electrospray Ionization 
LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MMI  Mixed-Mode Ionization 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
POPs  Poly(phosphazenes) 
RT  Room Temperature 




F6. Materials and Equipment 
 
F6.1  Agilent 1260 Infinity HPLC System 
F6.2  Agilent 6224 TOF Mass Spectrometer 
F6.3 Agilent MMI ion source 
F6.4  Analytical Column: NA 
F6.5  Guard Cartridge: NA 
F6.6  Analytical Balance: Ohaus Discovery DV215CD 
F6.7 1-mL Syringes 
F6.8  Agilent Captiva Econofilter 0.2-µm PTFE Syringe Filters 
F6.9 Millipore Direct-Q Water Purification System 
F6.10  Aluminum Foil 
F6.11  20-mL Amber Vials 
F6.12  2-mL Agilent LC-MS Amber Vials 





F7.1 Methanol, LC-MS grade, CAS# 67-18-6 
F7.2 Water, LC-MS grade, CAS# 7732-18-5 
F7.3 POPs Polymer Samples, obtain from interested parties  





F8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
 
F8.1.1 Mobile Phase A: NA 
 
F8.1.2 Mobile Phase B: 100% Methanol 
 
F8.1.3 Transfer the desired volume of mobile phase to the appropriate LC-MS solvent 
reservoir. Appropriately update solvent volumes on the instrument if necessary 
 
F8.2 Preparation of Incubation Samples 
 
 F8.2.1 Incubation Process 
 
F8.2.1.1 Weigh out 20 mg of provided or synthesized POPs polymer and transfer 
into a 20-mL amber vial 
176 
 
F8.2.1.2 Add 5-mL of Millipore water and seal the vial  
 
F8.2.1.3 Cover vial with aluminum foil to protect samples from exposure to light  
 
F8.2.1.4 Incubate samples (minimum of three samples, repeat steps F8.2.1.1 – 
F8.2.1.3 as needed) at 37 °C for the desired length of time 
 
 F8.2.2 Weekly Sampling 
 
  F8.2.2.1 Remove vials from incubator  
 
  F8.2.2.2 Allow vials to reach RT 
   
  F8.2.2.3 Obtain a 1-mL sample aliquot using a 1-mL syringe 
 
F8.2.2.4 Filter sample through an Agilent 0.2-µm filter into an Agilent 2-mL LC-
MS vial and seal the vial 
 
F8.2.2.5 Appropriately dispose of the remaining incubation media 
 
F8.2.2.6 Rinse POPs polymer sample with Millipore water  
 
F8.2.2.7 Add the rinsed POPs sample to a clean 20-mL amber vial and repeat steps 
F8.2.1.2 – F8.2.1.4 
  
F8.2.3 Single Sampling (1-week or up to 10-week single sampling) 
   
  Follow steps F8.2.2.1 – F8.2.2.5 
 
F8.3 Analysis Method 
 
Follow Table F.1 for instrument method conditions. See appendix H for appropriate 
instrument setup and use. 
 
 F8.3.1 Inject reagent blank in selected polarity (positive or negative) 
 
F8.3.2 Inject each sample in triplicate with instrument in selected polarity (positive or 
negative) 
 
 F8.3.3 Load next sample sequence if needed repeating F8.3.1 – F8.3.2 or: 
 
 F8.3.4 Repeat F8.3.1 
 





Table F.1 LC-MS Method Parameters 
HPLC Settings 
Column Type NA 
Guard Column NA 
Column Temperature 35 °C 
Sample Tray Temperature RT 
Injection Volume 0.1 µL 
Needle Wash Methanol in Rinse Vial, Position 1 
Flow Rate 0.20 mL/min 
Stop Time 2 min 
Post Time NA 
Method Type Isocratic Direct Injection 
MP A NA 
MP B Methanol 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source MMI 
0 0 100 
Ion Polarity 
Positive 
2 0 100 Negative 
End Analysis Capillary Voltage 2500 V 
 Fragmentor Voltage 120 V  
Skimmer Voltage 60 V 
Charging Voltage 2000 V 
Drying Gas Flow Rate 10 l/min (N2) 
Drying Gas Temperature 310 °C (N2) 
Nebulizer Pressure 45 psi 
 
 
F9. Data Analysis 
 
F9.1 Perform the necessary MW calculations for the predicted degradation products 
 
F9.1.1 Use ChemDraw to draw the predicted structures based on the mode of degradation 
(hydrolytic degradation in this case) 
 
F9.1.2 In ChemDraw, obtain the formula of the structure by selecting the structure of 
interest, right clicking on it, clicking analysis, and clicking “chemical formula” 
 
F9.1.3 In ChemDraw, obtain the exact mass of the structure by selecting the structure of 
interest, right clicking on it, clicking analysis, and clicking “exact mass” 
 
F9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
F9.2.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 




F9.2.2 Extract “Background Spectrum” from data collected (extract from the baseline, not 
the unretained chromatographic peak) 
 
F9.2.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
F9.2.4 Search for the predicted masses (found following the steps in section 9.1) 
 
F9.2.5 Use the Agilent isotope distribution calculator to aid in the positive identification of 
the degradation products. The isotope distribution calculator allows for calculations that 
include negative and positive charging of the ion of interest. Additionally, different types 
of adducts, including H+, Li+, Na+, K+, NH4+, Cl-, Br-, HCOO- and CH3COO- can be 
accounted for in the calculations  
 
 
F10. Data Reporting  
 
F10.1 Export data as csv file 
 
F10.2 Use Origin or Igor to plot data files 
 
F10.3 Appropriately label peaks of interest 
 


























APPENDIX F – REFERENCES 
 
(1)  Lutzke, A.; Tapia, J. B.; Neufeld, M. J.; Reynolds, M. M. Sustained Nitric Oxide Release 
from a Tertiary S-Nitrosothiol-Based Polyphosphazene Coating. ACS Appl. Mater. 


























A direct flow injection and a LC-MS chromatographic separation with an LC-MS system is used 





This test method provides instructions for the preparation and analysis of degradation products 





To be performed by personnel who are technically qualified and trained in the use of the LC-MS 





The samples and reagents used in this procedure should be handled using good laboratory 
practices. Wear gloves and work in a fume hood. Read the Safety Data Sheets for all chemicals 





CAS  Chemical Abstracts Service 
ESI  Electrospray Ionization 
LC-MS Liquid Chromatography-Mass Spectrometry 
MeOH  Methanol 
MP  Mobile Phase 
MW  Molecular Weight 
NA  Not Applicable 
POPs  Poly(phosphazenes) 
RT  Room Temperature 






G6. Materials and Equipment 
 
G6.1  Agilent 1260 Infinity HPLC System 
G6.2 Agilent 6224 TOF Mass Spectrometer 
G6.3 Agilent dual ESI ion source 
G6.4 Analytical Column: Agilent Zorbax SB-C18, 150  4.6 mm, 3.5 µm, PN 863953-902 
G6.5 Guard Column Kit: Agilent Guard Column Hardware Kit, PN 820999-901 
G6.6 Guard Cartridge: Agilent Zorbax SB-C18, 12.5  4.6 mm, 5 µm, PN 820950-920 
G6.7 Analytical Balance: Ohaus Discovery DV215CD 
G6.8 1-mL Syringes 
G6.9 Agilent Captiva Econofilter PTFE 13-mm, 0.2-µm Syringe Filters, PN 5190-5265 
G6.10  Millipore Direct-Q Water Purification System 
G6.11  Aluminum Foil 
G6.12  20-mL Amber Vials 
G6.13  2-mL Agilent LC-MS Amber Vials 
G6.14  Incubator: Barnstead Lab-Line MaxQ 7000 
G6.15  100-mL volumetric flask 
G6.16  100-mL glass bottle 
G6.17  1000-mL volumetric flask 
G6.18  20-mL volumetric pipette 





G7.1 Methanol, LC-MS grade, CAS# 67-18-6 
G7.2 Water, LC-MS grade, CAS# 7732-18-5 
G7.3 Polyester Polymer Samples, obtain from interested parties  
G7.4 Water, Millipore Direct-Q grade 




G8.1 Preparation of Mobile Phase 
 
Note: The mobile phase solutions are stable for up to the expiration date of the reagent when no 
aqueous mobile phase is prepared when stored in glass bottles at room temperature. For aqueous 
mobile phases, 1% methanol is added to extend stability for 30 days.  
  
 G8.1.1 500 mM ammonium acetate stock (in 95:5 water/methanol) 
  
G8.1.1.1 Weigh out 3.854 g ammonium acetate and quantitatively transfer to 100 
mL volumetric flask 
 




G8.1.1.3 Add 5-mL LC-MS methanol 
 
G8.1.1.4 Dilute to 100-mL using LC-MS water and mix thoroughly 
 
G8.1.1.5 Transfer to 100-mL glass bottle and store at 4 °C 
 
G8.1.2 Mobile Phase A: 10 mM ammonium acetate in water 
 
G8.1.2.1 Transfer 20-mL of ammonium acetate stock (500 mM, section 8.1.1) using 
a 20-mL volumetric pipette into a 1000-mL volumetric flask 
 
G8.1.2.2 Transfer 10-mL of LC-MS methanol to the 1000-mL volumetric flask 
 
G8.1.2.3 Dilute to 1000-mL using LC-MS water and mix thoroughly 
 
G8.1.3 Mobile Phase B: 10 mM ammonium acetate in methanol 
  
G8.1.3.1 Transfer 20-mL of ammonium acetate stock (500 mM, section G8.1.1) 
using a 20-mL volumetric pipette into a 1000-mL volumetric flask 
 
 G8.1.3.1 Dilute to 1000-mL using LC-MS methanol and mix thoroughly 
 
G8.1.4 Transfer the desired volume of mobile phase to the appropriate LC-MS solvent 
reservoir(s). Appropriately update solvent volumes on the instrument if necessary 
 
G8.2 Preparation of Incubation Samples 
 
 G8.2.1 Incubation Process 
 
G8.2.1.1 Weigh out 100 mg of provided or synthesized POPs polymer and transfer 
into a 20-mL amber vial 
 
G8.2.1.2 Add 20-mL of Millipore water and seal the vial 
 
G8.2.1.3 Cover vial with aluminum foil to protect samples from exposure to light 
 
G8.2.1.4 Incubate samples (minimum of three samples, repeat steps G8.2.1.1 – 
G8.2.1.3 as needed) at 37 °C for the desired length of time 
 
 G8.2.2 Weekly Sampling 
 
  G8.2.2.1 Remove vials from incubator  
 
  G8.2.2.2 Allow vials to reach RT 
   
  G8.2.2.3 Obtain a 1-mL sample aliquot using a 1-mL syringe 
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G8.2.2.4 Filter sample through an Agilent 0.2-µm filter into an Agilent 2-mL LC-
MS vial and seal the vial 
 
G8.2.2.5 Appropriately dispose of the remaining incubation media 
 
G8.2.2.6 Rinse polyester polymer sample with Millipore water  
 
G8.2.2.7 Add the rinsed polyester sample to a clean 20-mL amber vial and repeat 
steps G8.2.1.2 – G8.2.1.4 
  
G8.2.2.8 Samples to be analyzed by LC-MS at a later timeframe should be stored 
in the 20-mL vials amber vials or 2-mL LC-MS amber vials at -20 °C   
 
G8.2.3 Single Sampling (1-week or up to 10-week single sampling) 
   
  Follow steps G8.2.2.1 – G8.2.2.5 
 
G8.3 Analysis Method 
 
Follow Table G.1 for instrument method conditions. See appendix H for appropriate 
instrument setup and use. 
 
 G8.3.1 Direct flow injection MS analysis 
   
G8.3.1.1 For direct flow injection MS analysis, make sure to bypass the HPLC 
column 
 
  G8.3.1.2 Inject reagent blank 
 
  G8.3.1.3 Inject each sample in triplicate 
 
  G8.3.1.4 Load next sample sequence if needed or: 
 
  G8.3.1.5 Repeat G8.3.1 
 
  G8.3.1.6 Put instrument on Stand-by  
 
 G8.3.2 LC-MS analysis 
   
  G8.3.2.1 For LC-MS analysis, make sure the flow is set to go through the column 
 
  G8.3.2.2 Follow steps in sections G8.3.1.2 – G8.3.1.5 as needed 
 
G8.3.2.3 To remove any leftover mobile phase additives, flush column at end of 




G8.3.2.4 Flush column with a high water percentage. Up to 95% water is acceptable 
depending on column specifications. For long term storage, at least 30 column 
volumes is recommended. 
 
G8.3.2.5 In a linear gradient with an increase in methanol concentration, slowly 
(less than 5%/min increase) get the column to 100% methanol. For long term 
storage, at least 30 column volumes is recommended.  
 
Table G.1 LC-MS Method Parameters 
HPLC Settings 
Column Type Zorbax SB-C18, 150  4.6 mm, 3.5 µm 
Guard Column Zorbax SB-C18, 13  4.6 mm, 5 µm 
Column Temperature 40 °C 
Sample Tray Temperature RT 
Injection Volume 
0.1 µL (direct MS injection) 
20 µL (LC-MS injection) 
Needle Wash Methanol in Rinse Vial, Position 1 
Flow Rate 
0.20 mL/min (direct MS injection) 
0.25 mL/min (LC-MS injection) 
Stop Time 
2 min (direct MS injection) 
35 min (LC-MS injection, data collection ends) 
Post Time 15 min (LC-MS injection, data not collected) 
Method Type 
Isocratic Direct Injection 
Gradient LC-MS Injection 
MP B Methanol (Isocratic, direct MS injection) 
MP A 10 mM ammonium acetate in water (Gradient) 
MP B 10 mM ammonium acetate in methanol (Gradient) 
Isocratic Injection MS Settings 
Time, min MPA, % MPB, % Ion Source Dual ESI 
0 0 100 Capillary Voltage 4000 V 
2 0 100 Fragmentor Voltage 120 V  
End Analysis Skimmer Voltage 60 V 
Gradient Injection Drying Gas Flow Rate 10 l/min (N2) 
Time, min MPA, % MPB, % Drying Gas Temperature 310 °C (N2) 
0 85 15 Nebulizer Pressure 25 psi 
30 0 100  
40 0 100 
50 85 15 
Column Re-equilibration  
 
 
G9. Data Analysis 
 




G9.1.1 Use ChemDraw to draw the predicted structures based on the mode of degradation 
(hydrolytic degradation in this case) 
 
G9.1.2 In ChemDraw, obtain the formula of the structure by selecting the structure of 
interest, right clicking on it, clicking analysis, and clicking “chemical formula” 
 
G9.1.3 In ChemDraw, obtain the exact mass of the structure by selecting the structure of 
interest, right clicking on it, clicking analysis, and clicking “exact mass” 
 
G9.2 Analyze data using MassHunter Qualitative Analysis B.07.00  
  
 G9.2.1 Analysis of direct injection MS data files 
 
G9.2.1.1 Extract “Mass Spectrum” from data collected (data file looks similar to an 
unretained chromatographic peak) 
 
G9.2.1.2 Extract “Background Spectrum” from data collected (extract from the 
baseline, not the unretained chromatographic peak) 
 
G9.2.1.3 Subtract “background spectrum” from “extracted mass spectrum” 
 
G9.2.1.4 Search for the predicted masses (found following the steps in section 9.1) 
 
G9.2.1.5 Use the Agilent isotope distribution calculator to aid in the positive 
identification of the degradation products. The isotope distribution calculator 
allows for calculations that include negative and positive charging of the ion of 
interest. Additionally, different types of adducts, including H+, Li+, Na+, K+, NH4+, 
Cl-, Br-, HCOO- and CH3COO- can be accounted for in the calculations 
  
 G9.2.2 Analysis of LC-MS data files 
  
  G9.2.2.1 Subtract blank chromatogram from sample chromatogram 
 
  G9.2.2.2 Extract “Mass Spectrum” from each chromatographic peak of interest 
 
  G9.2.2.3 Follow steps G9.2.1.4 – G9.2.1.5 to make peak assignments 
 
 
G10. Data Reporting  
 
G10.1 Export data as csv file 
 
G10.2 Use Origin or Igor to plot data files 
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M-TOF Standard Operating Procedure for FLOW INJECTIONS ONLY1 
 
Username: Obtain from TMBR group after training 
Password: Obtain from TMBR group after training 
 
Part 1: Sample Preparation 
 
1. Try to dissolve your analyte in methanol, ethanol, n-propanol, iso-propanol, acetonitrile, 
water or a mixture of this solvents that dissolves your sample (for example: 1:1 
methanol/water; 1:1 acetonitrile/water; etc.). 
2. It is acceptable to dissolve your analyte in mixtures that contain very small amounts of 
chlorinated solvents (<10% DCM, CHCl3) and <10% DMSO. Do not use normal phase 
solvents such as hexanes, cyclohexanes, heptanes, THF, DMF, etc.    
3. After your sample is prepared, filter through a 0.2-µm filter before you perform your analysis.  
4. Sample concentration should not exceed 1.0 mg/mL!! 
 
 
Part 2: System Checks 
 
1. Check solvent reservoirs to make sure the system will not run dry. The main solvent is usually 
100% LC-MS methanol in line/bottle B1.  
2. Check the rinse vial solvent level. Vial 1 should be filled up if needed with LC-MS 
methanol/water (~1:1). This may be changed to any solvent that will more appropriately 
dissolve your analyte and any potential residues (acetonitrile, acetonitrile/water, isopropanol, 
isopropanol/water, etc). 
3. Agilent MassHunter Workstation Data Acquisition must be open after you log in (Figures 
H.1 & H.2). If it’s not, get the mass spectrometry expert from the Reynolds group to check 
for any potential problems and/or an unwanted computer restart, log out or accidental 
shutdown.  
4. Make sure that the Tuning Mix bottle (bottle B on the TOF, door on bottom left corner) has 
enough tuning solution. Otherwise the instrument will not calibrate properly!  
 
 
Figure H.1 Data acquisition icon. Should always be open, if it’s not please do not proceed! 
 




Figure H.2 Data Acquisition software. Again, this software window must already be open before 
you proceed! 
 
5. On the Data Acquisition software, check current vacuum readings (Figure H.3). The normal 
readings for Rough Vac are 1.xxE+00 Torr, this can fluctuate due to room temperature and 
depending on the last Rough Vac check. The normal readings for High Vac should be 
between 8.xxE-08 and 2.xxE-07 Torr. If the High Vac is reading higher than 9.xxE-07 please 
let the mass spectrometry expert from the Reynolds group know because some major issues 
regarding the vacuum systems may be taking place.  
6. On the Data Acquisition software, once you have checked and/or filled your solvent levels 
(step 1 from Part 2: System Checks) change to the current levels so that the system does not 
stop your analyses (Figure H.4). Do this by right clicking on the solvent bottles and selecting 
Bottle Fillings... This will open the Bottle Fillings screen when you will be able to change 





Figure H.3 Vacuum readings. Make sure the Rough Vac reads 1.xxE+00 Torr and the High Vac 




Figure H.4 Solvent levels window and changes.  
 














Part 3: System Setup 
 
A. System Startup and Calibration 
 
1. Turn the system on by clicking the main power switch on the Data Acquisition software 
(Figure H.5). This power switch will turn on or off all the instrument components and 
set them ready to the last loaded/used acquisition method. 
  
 
Figure H.5 Main power buttons. This power buttons will start or turn off all the instrument 
components and get them ready to the last loaded method (Sampler, Binary Pump, Column Comp. 
and the TOF). 
 
 
2. Once the system is turned on, the Chromatogram Plot and Spectrum Plot windows will 
begin showing “data” as shown in Figure H.6. If either window does not show any real 
time data, the software has glitched out and must be restarted. Ask the mass 
spectrometry expert from the Reynolds group to perform a software restart because it is 
a multi-step process that requires a full software shutdown and startup.  
 
 
Figure H.6 Real time data. Make sure both windows have data being shown in real time. If either 
window stays blank, do not proceed, a full software restart is required.  
 
3. Once the instrument is turned on, and data is being shown in real time, find the Context 
menu (Figure H.7). It should read Context: Acquisition. Click on the drop down menu 
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and select Tune. After changing to Tune, a new window will show up to Tune the 
instrument (Figure H.8). 
 
 




Figure H.8 Window that shows the Tune/Calibration contexts.  
 
4. In the Tune context, under the tab labeled Tune & Calibration select both negative and 
positive with Mass Calibration/Check selected. Once all three are selected, click the Start 
TOF Mass Calibration button (Figure H.9).  
5. Once “Start TOF Mass Calibration” is clicked, you will be asked if you are sure you 
want to tune the instrument (Figure H.10). Click yes to proceed.  
After you click yes, the instrument will proceed to be calibrated. A series of ions will 
show up that encompass the entire range of the mass spectrometer. Calibration will first 
take place in positive mode and then in negative mode. The process will take 
approximately 5 minutes.  
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6. Once calibration is complete, two PDF documents will show up with the details of the 
calibration.  
7. Now that calibration is done, change the context back to Acquisition (top left corner, 
Figure H.7). Two questions will pop up (Figure H.10). The first one will ask if you’d 
like to Proceed to Acquisition Context. Click Yes. The second one will ask if you’d 
like to save changes to your Tune file. Click No. This will send you back to the original 
Data Acquisition windows. Now ready to collect data! 
 
 
Figure H.9 Select Positive and Negative, and Mass Calibration/Check. Then click “Start TOF 
Mass Calibration” to begin the calibration process.  
 
 
Figure H.10 Tune context exit. Once the calibration process is done and the two PDF reports are 
shown, exit the Tune context by going back to Acquisition. You will be asked if you want to 
proceed to Acquisition Context? click Yes. Then you will be asked if you want to save changes 






B. Worklist Setup  
 
1. To set up a worklist, make sure the worklist tab is selected in the bottom left menu 
(Figure H.11). This will open a spreadsheet where you will be able to write a worklist to 
run your samples.  
 
First fill out Sample ID, this can be your initials, your eID, etc. 
 
Then fill out Sample Name, this is the name of your sample. 
 
Then select the position of your sample vial, it can be anywhere from vial 2 to vial 100. 
Do not use position 1 since it is the needle rinse vial. Make sure your samples are in 
the correctly labeled vial positions, otherwise the instrument will give you an error! 
 
Then select a method, this method should be developed for your sample needs with the 
help from the mass spectrometry expert from the Reynolds group.  
 
Then write where the data file will be saved. There should already be a folder with your 
name under a folder with your PI’s name. Ask the mass spectrometry expert from the 
Reynolds group if you need assistance with this step.  
 
And finally choose an injection volume. For concentrations at 1.0 mg/mL a direct 
injection should not require more than 0.1 µL. However, if your ion counts are very 
low, you may increase the injection volume to up to 1.0 µL. 
 
 
Figure H.11 Worklist setup. Fill in Sample ID, Sample Name, Sample Position, Method, Data 
File and Injection Volume. Add samples as needed.  
 
2. Once you have a worklist that looks like the one in Figure H.12, you can click the “play” 
button after you have selected your samples. This will have the instrument begin 
collecting data. Make sure to save your worklist so that you can access it in the future! 
The recommended format is “date_initials_PI Initials”.  
 
3. If you realize you have made a mistake, click the stop button found above the “Column 
Comp.” window. This will stop the current run and the consecutive selected samples. 
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Once you restart the worklist, you may be asked if you want to override the data files, it 
is up to you if you wish to do so.  
 
 
Figure H.12 Typical worklist. All the selected samples will be ran when you press play. Make 
sure to check your sample position, method and data file closely to avoid any instrument errors.  
 
4. Once all your samples are ran, a window will pop up that says “Worklist Run Complete” 
At this point, your all the analytes that were selected have been successfully ran.  
5. You can add more samples and have the instrument run them if you have more to run. 
Otherwise, using the main power switch, press “off” to put the instrument in standby.  
6. DO NOT CLOSE THE DATA ACQUISITION SOFTWARE! IT IS MEANT TO 
STAY OPEN! IF YOU CLOSE IT BY ACCIDENT, PLEASE LET JESUS T. OR 
CHRIS A. KNOW SO THAT THEY CAN DO A PROPER SOFTWARE 
RESTART.  
7. For data analysis, please refer to the “M-TOF standard operating procedure for data 
analysis using MassHunter Qualitative Analysis” 
 
 
C. Instrument Standby 
 
1. Once your samples are done running, to put the instrument on Standby, click the “off” 
button on the “Main Power Switch” shown in Figure H.5. This will put the instrument 
on standby mode and you can lock the computer and be done. 
2. DO NOT SHUT THE COMPUTER OFF 
3. DO NOT LOG OFF USER 
4. DO NOT SWITCH ACCOUNT 
5. ONLY LOCK THE COMPUTER!! 
 
